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Abstract 
Haemorrhagic shock is a lethal condition caused by massive 
blood loss. Recent investigations in animal models have found that 
valproic acid (VPA), a well-established and widely used treatment for 
bipolar disorder and epilepsy, provides acute protection against 
haemorrhagic shock-induced mortality. Under these conditions, VPA 
prevents a decrease in glycogen synthase kinase 3β (GSK3β) Ser9 
phosphorylation, an effect suggested to relate to histone deacetylase 
(HDAC) inhibition.  
Here, the molecular signalling events during haemorrhagic shock-
like conditions were investigated using a human liver cell line (Huh7). 
Cells exposed to hypoxia, hypercapnia, and hypothermia mimic the 
signalling changes seen in haemorrhagic shock, showing reduced 
GSK3β Ser9 phosphorylation. This in vitro reduction is blocked by VPA 
at physiologically relevant concentrations as it is in vivo. VPA treatment 
also prevents apoptotic signalling, improving cell survival in this model. 
VPA-related compounds which are known activators of the 
peroxisome proliferator-activated receptor γ (PPARγ) were found to 
reproduce its protective effect independently of their HDAC inhibitory 
activity. PPARγ inhibition blocks this protection, demonstrating that 
PPARγ activity is essential for the therapeutic action of VPA in this 
model. This work therefore establishes an in vitro model for 
haemorrhagic shock signalling, identifies PPARγ regulation as a new 
molecular target in haemorrhagic shock, and provides novel candidate 
compounds for the development of life-saving treatment. 
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Introduction 
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1.1 Blood loss and haemorrhagic shock  
Haemorrhage is the significant loss of intravascular blood volume 
leading to issues with tissue perfusion and cellular hypoxia, while 
shock describes a condition in which tissue perfusion is not sufficient to 
sustain aerobic metabolism (Gutierrez et al., 2004; Rossaint et al., 
2006). During haemorrhage, loss of blood triggers local vascular 
signalling and the neuroendocrine system, which induces a systemic 
reaction (Runciman et al., 1984). As intravascular volume falls, filling 
pressure in the heart decreases, in turn reducing cardiac output 
(Dutton, 2007). Changes in sympathetic and parasympathetic flow 
increase heart rate and contractility. In response to low blood pressure, 
selective vasoconstriction preserves blood flow to organs most 
dependent upon oxygen supply, i.e. brain and heart, and reduces 
bleeding at the site of injury.  If hypoperfusion persists, lack of blood 
and nutrient flow causes necrotic cell death in affected cells, while other 
cells respond to insufficient resources with the activation of cellular 
apoptosis pathways. Massive cell death causes organ damage, multiple 
organ failure, and death (Alam et al., 2011; Angele et al., 2008; Ulukaya 
et al., 2011). 
During shock, cardiac output is insufficient to provide tissue 
perfusion adequate for sustaining aerobic metabolism (Gutierrez et al., 
2004). Though compensatory mechanisms exist, these reach their limits 
during severe blood loss, necessitating a switch from aerobic to 
anaerobic metabolism in cells (Shoemaker, 1996). In skin and muscle 
cells, anaerobic metabolism produces lactic acid, the accumulation of 
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which leads to metabolic acidosis, one member of the lethal triad 
haemorrhagic shock.  Another member, coagulopathy, is caused by liver 
damage during shock, which may continue to progress even after 
macrocirculation has been re-established, for instance due to oedema 
preventing microcirculatory recovery (Dutton, 2007). The third, 
hypothermia, is caused by a slowing of ATP metabolism alongside the 
macroeffects of blood loss (Rossaint et al., 2006). This lethal triad is 
followed by refractory cardiogenic shock, circulatory system failure, and 
patient death (Dutton, 2007). Early resuscitation is needed to prevent 
this outcome. 
Resuscitation currently relies on fluid transfusion and blood 
component reconstitution, e.g. red blood cells, platelets, and spray-
dried plasma (Alam et al., 2009; Gutierrez et al., 2004; Midwinter, 
2009). The fundamental difficulty with these approaches is that these 
substances need to be stored appropriately, have a very limited shelf-life 
and access is complicated by corresponding transport issues. 
Additionally, blood and blood components are costly, carry a risk of 
disease transmission, and most need to be cross-matched to the patient 
(Holcomb, 2007; Hodgetts et al., 2011; Kauvar et al., 2005). These 
issues are particularly problematic in austere environments, in remote 
areas, when the patient is trapped, or during military operations on 
foreign territory, emphasising the need for novel methods of treating 
terminal blood loss. One recently suggested means of preventing death 
by terminal blood loss is through the regulation of cellular apoptotic 
pathways via pharmacologic agents, e.g. valproic acid (VPA; Butt et al., 
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2009). Pharmacologic resuscitation does not purport to reverse the 
inevitable in preventing organism death, but rather attempts to extend 
the period during which sophisticated medical intervention can prevent 
irreversible shock and cardiovascular failure, thereby increasing the 
chances of survival. This pre-lethal state is investigated in this project. 
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1.1.1  Animal models of haemorrhagic shock 
The work that formed the theoretical starting point for this project 
was carried out by Alam et al. (2009) in a swine poly-trauma model of 
massive blood loss. Yorkshire swine were subjected to a femur fracture 
and 60% haemorrhage, followed by 30 min of shock and infusion of 
saline (at three times the volume of blood lost). To simulate internal 
bleeding as a delayed reaction to organ injury, swine were given a grade 
V liver injury (bilobar maceration) followed by liver packing. Animals 
were then randomised into three treatment groups: saline-only 
resuscitation (SO), fresh whole blood-based resuscitation (FWB), and 
VPA-based resuscitation (VPA). The SO group received only saline, the 
FWB group received a blood transfusion equal to the amount of blood 
lost, and the VPA group received saline containing 400mg/kg VPA. 
Animals were then monitored for four hours. As expected, survival was 
very low (25%) in the SO group and complete (100%) in the FWB group. 
Surprisingly, VPA treatment significantly increased the likelihood of 
survival (86%). In fact, the only death in the VPA group occurred during 
VPA infusion, before the animal in question had received the complete 
treatment dose. This demonstrated the marked pro-survival effect of 
VPA treatment in haemorrhagic shock with four hours, the putative 
maximum time between injury and arrival at a medical facility. 
To investigate the molecular mechanisms involved in this process, 
the researchers removed liver tissue after the end of the experiment and 
analysed protein extract by Western blot for changes in levels and 
phosphorylation of key signal relay enzymes. Under control conditions 
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treatment did not affect protein status. In contrast, VPA increased the 
activation of protein kinase B (Akt) and the inhibition of glycogen 
synthase kinase-3β (GSK3β) both indicated by increased 
phosphorylation at Ser473 and Ser9 respectively. Additionally, 
abundance of downstream proteins β-catenin and B-cell 
leukemia/lymphoma 2 (bcl-2) protein were increased in response to 
VPA. These results are in line with previous and later work by the group 
which found increased levels of β-catenin in cells and also showed an 
increase of Bcl-2 transcription within one hour (Li et al., 2008; 
Zacharias et al., 2011). The researchers concluded that VPA improved 
early survival in their model and that this was due not to improvement 
in resuscitation but to better tolerance of shock by the cells, via the 
activation of the PKB/Akt survival pathway.  
In addition to PI3K-signalling, animal models of haemorrhagic 
shock have also implicated extra-cellular regulated kinase 1/2 
(ERK1/2) signalling in this condition. Studies have shown that ERK1/2 
Thr202/Tyr204 phosphorylation is increased in the lung of Wistar-
Kyoto rats after haemorrhagic shock, and that VPA attenuates this 
increase (Fukudome et al., 2011; Patel et al., 2011). VPA also increased 
ERK1/2 phosphorylation in a rat model of intracerebral haemorrhage 
(Sinn et al., 2007). This is consistent with experiments performed in 
Sprague-Dawley rats, where administration of a specific ERK1/2 
inhibitor (PD 98059) stimulated the inflammatory response and reduced 
ERK1/2 phosphorylation in the liver (Jarrar et al., 2004). These data 
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suggest that ERK1/2 may also be involved in cellular signalling during 
haemorrhagic shock. 
Research into the nuclear changes during haemorrhagic shock 
has suggested a role for histone deacetylase (HDAC) inhibition in 
mediating pathological effects as well as therapeutic action (Shults et 
al., 2008). In this study, Wistar-Kyoto rats were subjected to 60% blood 
loss for one hour, treated, and then monitored for 24 hours. Animals 
received one of two HDAC inhibitors: VPA or suberoyanilide hydroxamic 
acid. Survival was at 75% and 83% respectively, compared to 25% in 
the control group that received no resuscitation. Acetylation of histone 
H3K9 was up-regulated in the VPA group at one and six hours, but had 
returned to below normal control levels at 24 hours. These researchers 
suggested that the histone deacetylase inhibitory effect of VPA causes 
the short-term survival advantage displayed by treated animals. Other 
research into rat models by the same group also confirmed that 
haemorrhagic shock and inflammation cause an imbalance in protein 
acetylation status (Gonzales et al., 2006; Lin et al., 2006) and that 
histone deacetylase inhibitors rectify this imbalance leading to a pro-
survival phenotype (Lin et al., 2007; Sailhamer et al., 2008) and 
hepatoprotection (Gonzales et al., 2008). In vivo work by Dash et al. 
(2010) meanwhile demonstrated that VPA has neuroprotective effects 
following traumatic brain injury in rats as well, though in this study a 
selective HDAC inhibitor (SAHA) did not replicate VPA-induced 
protection. 
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1.1.2  Modelling haemorrhagic shock in vitro  
When trying to reproduce the events of a complex, multi-organ 
event such as haemorrhagic shock, in vitro systems face severe 
challenges compared to animal models. However, these challenges must 
be overcome if cost-effective high-throughput drug screening methods 
are to be set up, as these require an in vitro model. It is widely agreed 
that the predominant cellular conditions during haemorrhagic shock 
are dominated by hypoxia (lack of adequate O2 supply) and acidosis 
(unfavourably low pH), which is a consequence of hypercapnia 
(unfavourably high CO2 levels; Butt et al., 2009; Gutierrez et al., 2004; 
Hess et al., 2008; Hierholzer et al., 2001; Li et al., 2008; Midwinter, 
2009; Rossaint et al., 2006). These conditions are caused by the lack of 
gas transport vehicle, i.e. blood. After massive blood loss (>60%) O2 
cannot be effectively transported to target tissues, leading to a drop in 
O2 levels as cells continue to function, while CO2 cannot be adequately 
removed, leading to CO2 build-up. Though many in vitro models of 
haemorrhagic shock (see above references) consider only hypoxia, the 
importance of concurrent hypercapnia has also been demonstrated 
(Hotter et al., 2004). Beyond these facts, however, literature regarding in 
vitro haemorrhagic shock modelling is scarce. It is clear that any model 
will need thorough testing and that results will need to be compared 
and verified across numerous systems.  
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1.2 Valproic acid 
Valproic acid (2-propylpentanoic acid; VPA), a branched short-
chain fatty acid, was first produced in 1882 (Burton, 1882 as cited in 
Lagace et al., 2004) and discovered to be pharmacologically active in 
1963, when it was used as a solvent for anticonvulsants and found to 
have intrinsic anti-convulsant properties. It is of therapeutic use as an 
anticonvulsant in absence, tonic-clonic, and complex partial seizures as 
well as a mood-stabiliser (Bialer et al., 2007). It has also been shown to 
be of therapeutic value in depression, migraine and schizophrenia 
(Isoherranen et al., 2003; Rosenberg, 2007). VPA has been of clinical 
interest in spinal muscular atrophy (Lunke et al., 2009), Duchenne 
Muscular Dystrophy (Gurpur et al., 2009), Parkinson’s disease (Chen et 
al., 2007; Pan et al., 2005), and Huntigton’s disease (Zadori et al., 
2009). Novel research indicates it is widely neuroprotective (Biermann et 
al., 2011; Monti et al., 2009), has potential applications in HIV and 
cancer treatment (Blaheta et al., 2002; Terbach and Williams, 2009) 
and in haemorrhagic shock during massive blood loss (Bielecka et al., 
2008) suggested to occur via its function as an inhibitor of HDAC 
activity (Göttlicher et al., 2001). Though VPA has been linked to several 
medical conditions besides haemorrhagic shock, knowledge of its 
mechanism of action in these conditions is incomplete (Fig. 1). 
23 
 
 
Figure 1.1 – Putative VPA targets and their potential roles in medical conditions. 
VPA up-regulates (arrows) or down-regulates (⊥) cellular signalling in a known (solid 
lines) or unknown (broken lines) manner. Limited data exist to correlate each VPA-
affected pathway with the medical conditions shown. Figure adapted from Terbach 
and Williams (2009). 
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1.2.1  Mechanisms of action 
1.2.1.1 Histone deacetylase inhibition 
On a molecular level, VPA has been shown to cause a gamut of 
cellular changes. One undisputed primary mechanisms of action 
identified has been the direct action of VPA acts as an HDAC inhibitor, 
a function which has been linked with its teratogenicity and potency as 
a cancer treatment (Duenas-Gonzales et al., 2008; Gotfryd et al., 2010; 
Lagace et al., 2004; Phiel et al., 2001). HDAC inhibitors are 
hypothesised to reverse gene silencing, which occurs via epigenetic 
regulation and is known to lead to cancerous changes; additionally, 
HDAC inhibitors are thought to act through transcriptional activation of 
tumour suppressor genes and induction of cell death (Marks et al., 
2000). HDAC activity is of key importance in the nucleus, where it 
indirectly regulates gene transcription. 
In the nucleus, DNA is associated with histone proteins, forming 
chromatin (Baker, 2011; Lin et al., 2007). The nucleosome, one unit of 
the repeating pattern which makes up chromatin, contains 146 base 
pairs of DNA wound around a histone octamere (two each of H2A, H2B, 
H3, and H4) stabilised by H1. DNA is inaccessible to transcription 
machinery when tightly wound in its condensed, heterochromatin form 
and accessible when decondensed into euchromatin (Fig. 3). Gene 
expression can therefore be regulated by structural changes in 
chromatin via histone modification (Li et al., 2011). All four core 
histones have lysine-rich terminal tails, which contain sites for 
methylation, phosphorylation, ubiquination, poly-ADP-ribosylation and 
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acetylation (Berger, 2002). Methylation of these lysine residues may 
promote or silence gene expression, while acetylation generally indicates 
transcriptionally active regions (Barski et al., 2007; Clayton et al., 
2006). Histone lysine acetylation is mediated by histone 
acetyltransferases (HATs), which transfer an acetyl-group from acetyl-
coenzyme A to the ε-amino group of specific lysine residues enhancing 
accessibility for transcription factors (Yang et al., 2008). HDACs achieve 
deacetylation and structural change by catalysing the hydrolytic 
removal of this group (Butt et al., 2009; Sinn et al., 2007). Transcription 
factors may also be acetylated to enhance gene transcription (Li et al., 
2011). The balance of HAT and HDAC activity has been termed 
acetylation homeostasis, highlighting the importance of acetylation in 
overall cell homeostasis (Saha et al., 2006).  
In humans, 18 HDACs have been described (Carey et al., 2006). 
They are split into four classes according to their homology to yeast 
HDACs. Class I encompasses HDACs 1-3 and 8, which are related to 
yeast Rpd3 and ubiquitously present in the nucleus (Chuang et al., 
2009; De Ruijter et al., 2003). Class II HDACs are homologous to yeast 
HDA1 and are further subdivided into class IIa (HDACs 4, 5, 7, & 9) and 
class IIb (HDACs 6, & 10) based on structural similarities. They are 
found in both nucleus and cytosol, display tissue-specific expression, 
and have been strongly implicated in neuronal function. Class III 
contains the sirtuins (SIRT1-7), NAD+-dependent metabolic sensors 
which are named after their relation to Sir2 (Gertz et al., 2010). VPA is 
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known to inhibit class I and class IIa HDACs, thereby regulating gene 
transcription (Göttlicher et al., 2001; Gurvich et al., 2004). 
Stress, such as in haemorrhagic shock, up-regulates HDAC 
activity, leading to hypoacetylation, down-regulation of gene 
transcription, and apoptosis (Lin et al., 2006). These changes are 
attenuated by HDAC inhibitor action, preventing cell death (Biermann 
et al., 2011; Gonzales et al., 2006). HDAC inhibitors have now been 
spotlighted as potential agents for short-term mortality prevention 
during massive blood loss, though their exact mechanism of action 
remains unclear. The focus must therefore lie on the interaction of 
HDACs and their inhibitors, of which VPA is one.
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Figure 1.2 – Histone 
acetylation and deacetylation 
regulates chromatin state. 
Chromatin is made up of DNA 
wrapped around histone 
proteins. One histone octamere 
and its associated 146bp of DNA 
form a nucleosome. DNA is 
inaccessible to transcription 
machinery when in its 
heterochromatin form and 
accessible when unravelled into 
euchromatin. Histones have 
terminal tails containing lysine 
residues, at which they are 
acetylated by HATs (histone 
acetyltransferases). These trans-
fer an acetyl-group from acetyl-
coA (coenzyme A) to an available 
lysine residue, thereby changing 
histone tail conformation, which 
in turn increases the distance 
from one nucleosome to the next 
and provides transcription 
machinery with DNA access. 
HDACs (histone deacetylases) 
remove these acetyl groups by 
hydrolysis, thereby causing 
chromatin to recondense. 
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In the nucleus, HDAC inhibitors like VPA are able to alter 
expression of genes involved in cell cycle control, differentiation, and 
apoptosis (Chen et al., 2009; Rosato et al., 2003; Savickiene et al., 
2006). VPA, SAHA, and TSA (trichostatin A) have been shown to up-
regulate transcription of pro-survival genes in vivo following massive 
blood loss (Alam et al., 2009; Li et al., 2011; Lin et al., 2006) and 
suppress inflammation via down-regulation of cytokine gene expression, 
thereby improving survival (Cao et al., 2008; Li et al., 2009; Zhang et 
al., 2009). However, HDAC action is not restricted to histones – indeed 
HDACs are thought to have evolved in the absence of histone proteins 
(Minucci et al., 2006). HDACs found in the cytoplasm are not part of 
histone synthesis and acetylation-dependent assembly, and those found 
in mitochondria also lack obvious substrates as there are no histones 
present. HDAC inhibitors are therefore likely affect a wide variety of 
cytosolic pathways as well, and so there might be a cytosolic target for 
the HDAC inhibitory action of VPA. 
1.2.1.2 PPARγ 
The peroxisome proliferator-activated receptors (PPARs) are 
another group of confirmed interaction partners of VPA in the nucleus. 
These nuclear receptors were identified in the 1990s and have since 
then primarily been of interest in lipid metabolism research and 
associated disorders such as diabetes and obesity (Kota et al., 2005). 
PPARs regulate gene expression by forming a heterodimer with the 
retinoid X receptor (RXR) and binding to PPAR response elements 
(PPREs) in gene promoters (Fig. 3, Abdelrahman et al., 2005). Three 
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types of PPAR have been discovered so far, encoded by separate genes: 
PPARα, PPARβ/δ and PPARγ. VPA activates PPARβ/δ and PPARγ in 
vitro, although it does not appear to be a direct ligand of PPARβ/δ 
(Lampen et al., 1999; Lampen et al., 2001), and PPARs are known to be 
part of the VPA-sensitive signalling network (Werling et al., 2001).  
PPAR activity is mainly modulated by ligand-binding, but several 
indirect regulatory mechanisms have also been discovered (Malapaka et 
al., 2012; Yau et al., 2013). The γ isoform of PPAR has been shown to 
directly interact with HDACs 3 and 4 via its zinc finger DNA binding 
domain (Franco et al., 2003), while PPAR expression has been 
demonstrated to be regulated by Wnt signalling (Bielecka and 
Obuchowicz, 2008). Additionally, PPAR action on gene expression 
depends on other chromatin modifications: PPARγ induces histone 
acetylation, but only in the absence of repressive methylation, 
indicating that PPAR activity functions as a response to the pre-existing 
gene activation/repression balance in the nucleus (Lefterova et al., 
2010). VPA may therefore also modulate PPARs indirectly, by inhibiting 
HDACs 3 and 4 or by modifying the gene expression homeostasis by 
increasing histone acetylation. Histone 3 lysine 9 (H3K9) acetylation is 
increased at PPARγ binding regions (Lefterova et al., 2010) and this 
increase has been observed in response to both acute VPA treatment in 
haemorrhagic shock (Alam et al., 2009) and in response to chronic 
treatment in bipolar disorder (Machado-Vieira et al., 2011). Conversely, 
PPARs may act on VPA, as they localise to genes involved in lipid 
metabolism (Schupp et al., 2009). 
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Figure 1.3 – Peroxisome proliferator-activated receptors (PPARs) regulate gene 
transcription. When bound by a ligand, PPARs form a heterodimer with the retinoid X 
receptor (RXR) and bind to PPAR response elements (PPREs), made up two AGGTCA 
repeats separated by a different residue, in gene promoters, thereby inducing gene 
transcription. 
 
1.2.1.3  Cytosolic effects 
In the cytosol, VPA has been shown to regulate cAMP response 
element binding protein, brain-derived neurotrophic factor, 
antiapoptotic protein bcl-2 and extracellular signal regulated 
protein/mitogen-activated protein kinases in a pro-survival manner in 
mammalian systems (Bielecka et al., 2008). VPA can also act by 
inducing heat shock protein 70 (HSP70) activity via the 
phosphoinositide 3-kinase (PI3K) pathway, leading to neuroprotective 
effects (Marinova et al., 2009). A key protein of the PI3K pathway, 
GSK3β, is also regulated by VPA (Chen et al., 1999; Werstuck et al., 
2004).  
1.2.1.3.1 Akt/PKB and GSK3β 
The majority of research into the effect of VPA on GSK3β has been 
carried out in long-term exposure studies in the brain, as both VPA and 
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GSK3β have been of particular interest in bipolar disorder. However, 
this research has yielded conflicting evidence of the effect of VPA on 
neuronal cells, illustrating model-specific differences in VPA action. 
Chen et al. (1999) reported that VPA directly inhibits GSK3β, both in an 
in vitro assay and in SH-SY5Y cells within 24h. However, Ryves et al. 
(2005) showed in vitro that while the mood stabiliser lithium inhibits 
GSK3β in neocortical cells, VPA does not. Dash et al. (2010) meanwhile 
demonstrated that VPA reduces GSK3β activity following traumatic 
brain injury in a rodent model. Further evidence indicates that VPA 
does not inhibit GSK3β directly (Hall et al., 2002), but this effect on 
GSK3β is far from universal (Williams et al., 2002). 
GSK3β is one of the two mammalian isoforms of the GSK3 
serine/threonine kinase (the other being GSK3α); a highly conserved 
433 amino acid protein with a central protein kinase catalytic domain 
(Frame et al., 2001; Grimes et al., 2001). It was originally discovered to 
phosphorylate and inactivate glycogen synthase, but is now implicated 
in a wide range of other signalling processes from neuronal plasticity 
over general gene expression to cell survival (Bielecka et al., 2008; 
Grimes et al., 2001). GSK3β is also involved in the regulation of several 
transcription factors and is a key player in apoptosis and programmed 
cell death (Grimes et al., 2001; Kaga et al., 2006). 
GSK3β activity is partially regulated by the phosphotidylinositol-
3-kinase (PI3K) cascade. Stimulation of the insulin receptor leads to 
activation of PI3K, which phosphorylates the 3'-OH position of the 
inositol ring of inositol phospholipids, producing phosphatidylinositol-
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(3)-phosphate (PIP), phosphatidylinositol-(3,4)-diphosphate (PIP2), and 
phosphatidylinositol-(3,4,5)-triphosphate (PIP3; Cantrell, 2001). This 
process is reversed by PTEN, which dephosphorylates PIP3 to PIP2 on 
the 3’ position (Tamguney et al., 2007). PIP3 enables phosphorylation of 
Akt/PKB at Ser-473 and Thr-308, thereby activating it. Akt/PKB then 
directly interacts with GSK3β, phosphorylating and inactivating it 
(Alessi et al., 1996; Van Weeren et al., 1998). Akt also promotes cell 
survival via other pathways, e.g. by directly phosphorylating and 
inhibiting BAD, a pro-apoptotic protein which binds to and inactivates 
bcl-2 (Manning et al., 2007). Additionally, the PI3K-Akt pathway up-
regulates NFκB (nuclear factor κB) survival signalling and inhibits 
JNK/p38 apoptotic signalling (Dugo et al., 2007; Kim et al., 2001). 
GSK3β, when active, targets and phosphorylates β-catenin, 
leading to its degradation (Manning et al., 2007). This signalling 
pathway is activated in heat shock and oxidative stress (Shaw et al., 
1998). Inflammation is amplified by GSK3β activity via its up-regulation 
of NFκB activity, which promotes inflammatory processes (Dugo et al., 
2007). GSK3β inhibition accordingly protects various model systems 
from damage via inflammatory processes (Jope et al., 2007). GSK3β can 
be inactivated by several kinases (e.g., Akt/protein kinase B, some 
protein kinase C isoforms, and protein kinase A) via phosphorylation of 
serine-9 (Stambolic et al., 1994; Sutherland et al., 1993). Additionally, 
threonine-43 may be phosphorylated by extracellular signal-regulated 
kinases (Ding et al., 2005), while p38 mitogen-activated protein kinase 
phosphorylates Ser-389 and Thr-390 (Thornton et al., 2008), which is 
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postulated to increase the likelihood of Ser-9 phosphorylation rather 
than directly inhibiting GSK3β action (Medina et al., 2011). On the 
other hand, Tyr-216 phosphorylation leads to an up-regulation of 
kinase activity (Kim et al., 1999; Kim et al., 2002; Sayas et al., 1999). At 
high Akt/PKB activity and corresponding low levels of GSK3β, β-catenin 
accumulates, leading to transcription of the b-cell lymphoma 2 (bcl-2) 
gene. Bcl-2 is an apoptosis regulator protein and, when activated, steers 
the cell towards a pro-survival phenotype (Dahia, 2000). 
Upstream of GSK3β, Akt/PKB has been shown to be the major 
player in insulin-triggered GSK3β regulation in the PI3K cascade (Cross 
et al., 1995; Shaw et al., 1997) and is also affected by VPA in 
haemorrhagic shock (Alam et al., 2009) which regulates the PI3K 
pathway in this condition (Hwabejire et al., 2014). Several studies have 
implicated the PI3K/Akt pathway in seizure generation and epilepsy 
(Buckmaster and Lew, 2011; Shinoda et al., 2004; Zeng et al., 2009; 
Zhang and Wong, 2012). PIP3, the active second messenger produced by 
PI3K activity, induces Akt phosphorylation and is therefore a key 
component of the PI3K pathway (Delcommenne et al., 1998; Toker and 
Cantley, 1997). VPA has been shown to modulate PIP3 turnover in the 
simple biomedical model Dictyostelium discoideum (Chang et al., 2012; 
Xu et al., 2007) which is replicated in in vitro seizure control efficacy in 
mammalian seizure models (Chang et al., 2012; Chang et al., 2013). 
Recent research indicates that seizure activity correlates with PIP3 
depletion, a change which is reversed by VPA, therefore suggesting VPA 
may act by this novel mechanism to attenuate epileptic activity (Chang 
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et al., 2014). PI3K activity is also reduced in haemorrhagic shock and 
rescued by VPA treatment (Hwabejire et al., 2014). Although no data 
has been published at present to indicate this effect is modulated by 
PIP3 levels, knowledge gained from research into the mechanisms of 
action of VPA in other disorders may provide a crucial insight into 
regulation of pathways of interest in haemorrhagic shock. 
1.2.1.3.2  ERK 1/2 
ERK 1/2 is a mitogen-activated protein kinase (MAPK) associated 
with nearly all major cell signalling processes (Martin et al., 2009).  It is 
accepted to be the major effector of the Ras oncoprotein (Mendoza et al., 
2011). Raf, the Ras GTPase-regulated kinase, phosphorylates the 
intermediate kinase (MAPKK) MEK, thereby activating it. MEK, in turn, 
phosphorylates and activates ERK, the effector kinase of the pathway. 
The pathway is activated by growth factors, polypeptide hormones, 
neurotransmitters, chemokines, and G protein-coupled receptors, or by 
direct activation of protein kinase C (PKC). Downstream cytosolic 
signalling targets include p90 ribosomal S6 kinase (RSK) and 
transcription factors. In the nucleus, ERK targets transcription factors 
that mediate gene transcription for cell survival, division, and motility 
(Dhillon et al., 2007). In haemorrhagic shock, ERK is activated, a 
process which is significantly attenuated by VPA (Fukudome et al., 
2010). Activation of ERK is also associated with a decrease in Akt 
activity (Sinha et al., 2004). However, the effect of VPA on ERK has been 
found to be independent of the HDAC inhibition effect of the drug 
(Boeckeler et al., 2006; Gotfryd et al., 2010; Ludtmann et al., 2011). The 
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regulation of ERK by VPA has also been implicated in neuroprotection 
(Creson et al., 2009; Pan et al., 2005 Yuan et al., 2001).  Finally, the 
PI3K and ERK pathways show significant cross-talk (Mendoza et al., 
2011), both inhibitory and stimulatory, so research on one of them 
must take care to not discount the other. 
1.2.1.4 VPA action on haemorrhagic shock pathways 
In swine in vivo poly-trauma models VPA has been shown to 
induce a pro-survival phenotype via up-regulation of some of the 
elements of the PI3K pathway (Alam et al., 2009, 2011; Dash et al., 
2010), though VPA has been demonstrated to induce its effects 
independent of PI3K activity, inositol recycling, and inositol synthesis 
(Chang et al., 2012). The exact mechanism of action of VPA on the PI3K 
pathway remains unproven, though one hypothesis implicates 
regulation of PIP3 by PCAF and PTEN. VPA treatment leads to increased 
levels of p-Akt, p-GSK3β, β-catenin and bcl-2 (Alam et al., 2009). Its 
target is therefore likely to be up-stream of Akt signalling. One possible 
route for Akt modulation is via the tumor suppressor protein 
phosphatase and tensin homolog (PTEN), a dual protein/lipid 
phosphatase involved in cell migration, growth and apoptosis (Dahia, 
2000; Tamguney et al., 2007). Its main substrate is PIP3, which it 
inactivates by dephosphorylating it to PIP2. PTEN is acetylated and 
inactivated by p300/CBP-associated factor (PCAF), a histone 
acetyltransferase (Okumura et al., 2006). PCAF is inhibited by HDAC3, 
which is inhibited by VPA (Goettlicher et al., 2001). Thus, a potential 
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mode of action for VPA in lethal blood loss could be cytosolic HDAC 
inhibition and PIP3 regulation. 
1.2.2  Side-effects 
As VPA has a broad spectrum of action and shows tissue-
specificity, VPA treatment can result in numerous side-effects in 
humans. These include weight gain, changes in cholesterol and fast 
glucose levels, dermatologic issues like stomatitis, cutaneous 
leukoclastic vasculitis, and psoriasiform eruption, and neurological 
effects like encephalopathy, parkinsonism and, rarely, exacerbation of 
existing epileptic symptoms (Chateauvieux et al., 2010). Children are 
particularly susceptive to liver-dependent coagulopathies, with 
symptoms like thrombocytopenia, platelet dysfunction, Von Willebrand 
disease, Factor XIII deficiency, hypofibrinogenemia, and vitamin K-
dependent factor deficiency (Gerstner et al., 2006). In addition, 
degradation products of VPA have been shown to be hepatotoxic 
(Kassahun et al., 1991; Bryant et al., 1996). Hepatotoxicity 
(microvesicular steatosis or abnormal cellular lipid retention) is thought 
to be caused by VPA metabolites with a terminal double-bond (4-ene-
VPA and 2,4-diene-VPA), which are transformed to chemically reactive 
intermediates and consequently affect fatty acid metabolism via an acyl-
coenzyme A (CoA) thioester formation, leading to CoA depletion and the 
observed toxicity (Bialer et al., 2007; Grillo et al., 2001; Neuman et al., 
2001). This effect has been reproduced in several model systems, 
including Huh7 cells and Dictyostelium discoideum (Elphick et al., 
2012).  
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Though several off-target effects of VPA are explored in the 
literature, teratogenicity is the most noted side-effect. Major birth 
defects such as spina bifida are seen three times as often in the child if 
the mother is undergoing VPA treatment, producing a heightened risk of 
6.2-7.6% compared to the 2.9-3.6% increase in risk for other anti-
epileptic treatments (Genton et al., 2006; Harden et al., 2008; Ornoy, 
2009). Children born to mothers undergoing VPA treatment also show 
an increased likelihood of developmental problems, including autism 
spectrum disorder and lowered IQ (Ornoy, 2009). Several effects of VPA 
have been implicated as the reason for its teratogenicity, including 
regulation of the folic acid cycle (Alonso-Alperte et al., 1999; Ubeda-
Martin et al., 1998), increased oxidative stress (Ornoy, 2009), regulation 
of peroxisome proliferator-activated receptor δ (PPARs; Werling et al., 
2001), and the presence of a tertiary carbon bound to a carboxylic 
group, a hydrogen atom, and two alkyl chains (Nau et al., 1991; Nau et 
al., 1992). However, research particularly supports histone deacetylase 
inhibition as the key teratogenic process (Bialer et al., 2007; Eikel et al., 
2006; Elphick et al., 2012). Treatment of mice with the potent HDAC 
inhibitor trichostatin A (TSA) mimicked birth defects seen in response to 
VPA (Menegola et al., 2005). A Structure-function study of 20 VPA 
derivatives showed that only teratogenic molecules induced histone 
hypoacetylation and that HDAC inhibitory activity quantitatively 
correlated to teratogenic potential (Eikel et al., 2006). If VPA does indeed 
exert its therapeutic effects in haemorrhagic shock via histone 
deacetylase inhibition, analogues with more pronounced inhibitory 
activity may be more beneficial in treating severe blood loss. 
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1.2.3  Congeners 
VPA is unusual in that over a hundred congeners, analogues, and 
derivatives have been investigated as therapeutic treatments for a 
variety of conditions, in part in an effort to discover more potent 
therapeutic treatments and in part to determine and potentially 
eliminate the structural basis for some of the many side-effects of VPA 
(Bialer and Yagen, 2007; Galit et al., 2007; Liu et al., 1992; Perrino et 
al., 2008; Redecker et al., 2000; Rekatas et al., 1996; Terbach and 
Williams, 2009; Winkler et al., 2005). Less than 3% of VPA is excreted 
unchanged in urine, indicating that VPA undergoes extensive 
biotransformation, which mainly takes place in the liver (Silva et al., 
2008). The two major metabolic pathways of VPA are glucuronidation 
and β-oxidation in the mitochondria, accounting for 50% and 40% of 
dose respectively, while a third pathway, cytochrome P450 (CYP-
mediated oxidation, accounts for approximately 10% (Argikar and 
Remmel, 2009; Ghodke-Puranik et al., 2013; Tan et al., 2010). VPA 
biotransformation gives rise to more than 50 known metabolites (Abbott 
and Anari, 1999), some of which exert therapeutic or toxic effects 
distinct from those of VPA itself (Silva et al., 2008).  
VPA derivatives with a terminal double bond (4-ene-VPA, 2,4-
diene-VPA), for instance, are more hepatotoxic than the parent drug 
(Nanau and Neuman, 2013). This led to the development of 
tetramethylcyclopropanecarboxylic acid (TMCA), a cyclopropyl analogue 
of VPA, which cannot be biotransformed to terminal double bond 
metabolites (Bialer and Yagen, 2007). Although TMCA does not show 
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anti-convulsant activity, its amide derivatives do, leading to a new class 
of potential anti-epileptic compounds, some of which show increased 
therapeutic potency compared to VPA (Isoherranen et al., 2003; Okada 
et al., 2006; Rogawski, 2006; Sobol et al., 2004). 
The mechanism of action of VPA is not comprehensively 
understood, but investigations of the effects of congeners and 
derivatives have succeeded in clarifying some aspects of the structure-
function relationships at play. For instance, early studies showed that 
VPA as a branched acid with eight carbons had the optimal structure to 
produce a balance of anti-epileptic potency and sedative effects 
compared to a wide variety of branched monocarboxylic acids 
(Isoherranen et al., 2003; Keane et al., 1983; Morre et al., 1984). Both 
the anti-cancer activity and the teratogenicity of VPA have been found 
to depend on its action as a histone deacetylase inhibitor (Blaheta and 
Cinatl, 2002). It has been proposed that branching at the α-position 
with a side chain longer than a methyl group is required for 
teratogenicity (Narotsky et al., 1994; Okada et al., 2004), while length of 
the side chain correlates with teratogenic potential (Bojic et al., 1998). 
As there are well-established animal models for teratogenicity, existing 
research on this topic may inform future research into anti-cancer 
congeners of VPA and facilitate novel discoveries. 
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Figure 1.4 – VPA is metabolised in the liver.  A small selection of the metabolic pathway of VPA is shown. VPA is metabolised by three pathways: 
glucuronidation, which produces VPA-glucoronide, cytochrome P450-mediated oxidation, which produces 4-ene-VPA (a cause of hepatotoxicity), and 
mitochondrial β-oxidation. VPA crosses the mitochondrial membrane, where the formation of VPA-CoA (VPA-co-enzme A) is catalysed. One possible 
oxidation pathway leads to the production of thiol conjugates of VPA, which act to detoxify the liver. 4-ene-VPA may also be metabolised by some 
stages of this pathway. Figure adapted from Ghodke-Puranik et al. (2013). 
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1.3 Model systems 
1.3.1  Hepatocellular 
1.3.1.1  Huh7 
The human hepatoma cell line Huh7, an immortal cell line of 
epithelial-like tumourigenic cells, was established by Nakabayashi et al. 
(1982) from well-differentiated carcinoma cells from a liver tumour in a 
57-year-old Japanese male. The cell line retains hepatocellular 
differentiated functions and gene expression which is thought to be 
stable in culture. Huh7 cells have been found to be closer to in vivo 
human liver cells than other cell lines, e.g. HepG2 cells (Meex et al., 
2011). Valproic acid has been found to inhibit human hepatocellular 
cancer cell growth in Huh7 and in vivo, down-regulating anti-tumour 
Notch-1 signalling (Machado-Vieira et al., 2011). The PI3K pathway and 
GSK3β have also been studied in Huh7 cells, though not in context 
relevant to this project (Chen et al., 2012; Johnston et al., 2011; 
Muraoka et al., 2012). Due to the similarity of Huh7 to human liver 
tissue, this cell line was selected as the primary model system for this 
study. 
1.3.1.2  HepG2 
 The cells of the HepG2 cell line, which were derived from the well-
differentiated liver carcinoma of a 15-year-old Caucasian male from 
Argentina, show an epithelial morphology compatible with that of 
parenchymal hepatocytes and are widely used for cancer research (Aden 
et al., 1979; Constantini et al., 2013; Meex et al., 2013). Though HepG2 
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cells have not been used to study ischaemic conditions, some research 
exists on the effects of VPA in this cell line. VPA decreases HepG2 cell 
viability and induces a hepatotoxic response (Ji et al., 2010). It also 
causes the dysfunction of mitochondrial respiration and increases the 
abundance of radical oxygen species (Komulainen et al., 2015). HepG2 
cells were chosen as a secondary hepatic cell line to provide a cellular 
environment comparable to Huh7, as this would allow comparison of 
molecular signalling responses and further inform any discoveries 
made. 
1.3.2  Neuronal 
1.3.2.1  SH-SY5Y 
 SH-SY5Y, a human neuroblastoma cell line, is a third sequential 
sub-clone derived in 1978 from the cell line SK-N-SH, which was first 
established in 1970 from a large neuroblastoma found in the chest of a 
4-year-old girl (Biedler et al., 1973; Biedler et al., 1978). SH-SY5Y has 
previously been used to investigate molecular signalling in ischaemic 
conditions and in order to explore neuroprotective effects of anti-
ischaemic agents (Seetapun et al., 2013). VPA has been shown to 
prevent cell death in SH-SY5Y (Daniel et al., 2005) and mediate anti-
apoptotic action via HSP70 induction (Pan et al., 2005). In addition, VPA 
has been reported to inhibit GSK3β in this cell line (Chen et al., 1999), 
though this result is controversial (Ryves et al., 2005). This cell line was 
selected to investigate haemorrhagic shock signalling in a neuron-like 
environment. 
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1.3.2.2  Neuro-2a 
The mouse neuroblastoma cell line Neuro-2a (N2a) was 
established by Klebe & Ruddle (1969; as cited at bioinformatics.istge.it/ 
cldb/cl3684.html) from a spontaneous tumour of a strain A albino 
mouse. Work on the PI3K pathway, as well as some on HDAC 
inhibition, has been done in this model system (Castino et al., 2008; 
Graham et al., 2006; Politis et al., 2008). As several animal models of 
haemorrhagic shock have used rodents, N2a was selected for this 
investigation to provide a signalling environment similar to that found 
in in vivo models.  
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1.4 Project Aims 
This project aims to establish an in vitro model system for the 
testing of drugs for combating negative effects of haemorrhagic shock, 
modelled by both hypoxia and hypercapnia, in the short term. The 
starting point for this research project is the drug that has shown most 
promising efficacy in vivo: valproic acid.  
Hypothesis: Molecular events during haemorrhagic can be 
modelled in a human cell line in a manner sufficient for signalling 
research and as a first step to high-throughput drug discovery. 
Four project aims are selected in an effort to disprove this hypothesis: 
I. Develop a cell line model of haemorrhagic shock which 
reproduces the regulation of GSK3β Ser9 phosphorylation seen 
in vivo. 
II. Verify whether VPA regulates in vitro signalling up- and 
downstream of GSK3β in the same manner as observed in vivo. 
III. Determine the efficacy of VPA congeners in this model to inform 
further signalling investigations and provide candidates for 
drug discovery. 
IV. Elucidate the mechanism through which VPA acts to regulate 
GSK3β in the in vitro model system. 
Reaching these aims is likely to advance the research effort in relation 
to both haemorrhagic shock and VPA.  
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2 
Materials and Methods 
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2.1 Cell line culture 
 Huh7 were supplied by Japanese Collection of Research 
Bioresources Cell Bank (#JCRB0403, Japan), HepG2  and SH-SY5Y 
were supplied by ATCC (#HB-8065 and #CRL-2266 respectively, United 
Kingdom), HEK293 and Neuro-2a were kindly supplied by Dr Murdoch 
and Dr Foster respectively (both Centre for Biomedical Sciences, Royal 
Holloway University of London). 
2.1.1  Long-term Storage 
Cells were washed with PBS and rapidly detached with 0.05% w/v 
Trypsin (Invitrogen Life Technologies #15400-054). A haemocytometer 
was used to ascertain cell number. Cells were re-suspended in freezing 
medium (Sigma #C6164) at 1-2x105 cells/ml and allowed to freeze 
gradually over 24h at -80°C prior to transferral to liquid nitrogen 
(gaseous phase). 
2.1.2  Culture 
Frozen cells were rapidly thawed in a water bath at 37°C, re-
suspended in 10ml culture medium (for Huh7, HepG2, and HEK293: 
DMEM high glucose from Sigma #D5796; for SH-SY5Y and N2a: DMEM 
F-12 Ham from Sigma #D6421) and pelleted (3min, 265xg). The 
supernatant was removed and the pellet re-suspended in 10ml complete 
cell culture medium: DMEM high glucose or DMEM F-12 Ham 
containing 10% foetal bovine serum (FBS; Invitrogen Life Technologies 
Ltd. #10082-147), 1X Penicillin / Streptomycin (Sigma #P4333) and 
non-essential amino acids (Sigma #M7145). Cells were incubated in 
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vented flasks (37°C, 5% CO2) and passaged at 70-80% confluency. Cells 
were detached for passaging using a solution of 0.05% Trypsin in PBS 
(Severn Biotech #20-7460-01) and brief incubation at 37°C (1-2min 
Huh7, HepG2, N2a, HEK293; 30sec SH-SY5Y) followed by re-
suspension in serum-containing DMEM for passaging. Cells of all types 
were used experimentally up to passage 15.  
2.1.3  Treatment 
Cells were seeded into 6-well plates at 5x104 (HEK293), 1x105 
(SH-SY5Y, N2a), or 2x105 (Huh7, HepG2) cells/well and allowed to 
recover for 48h in normoxic conditions (5% CO2, 37°C). Serum 
starvation was carried out for 12h prior to treatment with non-
complemented serum-free DMEM. Treatment compounds were added 
directly into culture medium. Cells were treated for 4h either under 
standard (37°C, 5% CO2) conditions or in stress conditions (2% O2, 10% 
CO2, 32°C) with a vehicle control (DMSO unless otherwise indicated) or 
compound of interest: 2-ene-VPA (MolPort), 2POA (Sigma), Ciglitazone 
(Tocris), DA (Sigma), GSK3787 (Tocris), GW6471 (Tocris), OA (Sigma), 
SA (Sigma), T0070907 (Tocris), VPA (Sigma, vehicle dH2O), VPD 
(Katwijk Chemie, The Netherlands). Final concentration of DMSO did 
not exceed 0.01%. After treatment, cells were rinsed once with ice-cold 
PBS and scraped directly in RIPA buffer (Sigma) containing proteinase 
and phosphatase inhibitors (Roche #04693159001 and #04906845001). 
Protein extract was immediately stored at -20°C.  
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2.2 Primary cell culture 
2.2.1  Rat cortical neuron culture 
 Primary cortical rat neurons were prepared by Dr Ursu (Centre for 
Biomedical Sciences, Royal Holloway University of London). All animal 
experiments were performed according to Home Office regulations in 
appliance with the Animals Scientific Act 1986. Briefly, E18 embryos 
from Sprague-Dawley rats were dissected and brains were removed. 
Cortical neurons were dissociated and suspended in DMEM (as before) 
supplemented with 1X penicillin/streptomycin (as before), 1X Glutamax 
(Sigma), and 5% FBS (as before) at a density of 2.5x105 cells/ml. Cells 
were then seeded into poly-d-lysine-treated (0.1mg/ml; Sigma in 0.1 M 
Borate buffer) 6-well plates at a density of 5x105 cells/well (2ml/well). 
Cells were allowed to recover for 24h (37°C, 5% CO2) and DMEM was 
replaced with Neurobasal medium (Gibco #21103-049) containing 1X 
penicillin/streptomycin, 1X B27 supplement (Gibco #17504044) and 1X 
GlutaMax (Life Technologies #35050-061) and cells were further 
maintained at 37°C and 5% CO2. Cultures were supplemented with 
0.5ml Neurobasal medium (as before) on a weekly basis from the 7th day 
of in vitro culture, until maturation at 18th - 21st day in vitro. On day 21, 
cells were treated with compound of interest or vehicle control added 
directly into medium for 4h in standard (37°C, 5% CO2) or stress 
conditions (2% O2, 10% CO2, 32°C). After treatment, cells were rinsed 
once with ice-cold PBS and scraped directly in RIPA buffer containing 
proteinase and phosphatase inhibitors (all as before). Protein extract 
was stored at -20°C. 
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2.2.2  Human hepatocellular culture 
 Cryopreserved pooled human hepatocytes were supplied by Life 
Technologies (HMCS10, Lot HUE117). Cells were thawed and 
transferred to culture medium according to supplier’s instructions. All 
reagents used were provided by Life Technologies. Cells were rapidly 
thawed in a water bath at 37°C, re-suspended in Thawing Medium 
(#CM7500) supplemented with hepatocyte maintenance supplement 
pack (#CM4000), and pelleted (200xg, 10min). Supernatant was 
discarded, cell viability was determined by trypan blue exclusion (Hay, 
2002), and cells were suspended in incubation medium (#A1217601) at 
a rate of 1x106 viable cells/ml. After a brief recovery (incubation at 
37°C, 5% CO2 for 30min), cells were treated for 4h either under 
standard conditions or in stress conditions (2% O2, 10% CO2, 32°C) 
with vehicle control or compound of interest. After treatment, cells were 
pelleted, washed once in ice-cold PBS, and lysed in RIPA buffer (Sigma) 
containing proteinase and phosphatase inhibitors (Roche 
#04693159001 and #04906845001). Protein extract was immediately 
stored at -20°C.  
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2.3 Primary tissue slices 
2.3.1  Rat whole brain slices 
Rat whole brain slices were provided by Dr Chang (Centre for 
Biomedical Sciences, Royal Holloway University of London). Briefly, 
male Sprague-Dawley rats were kept under controlled environmental 
conditions (24–25°C; 50–60% humidity; 12h light/dark cycle) with free 
access to food and tap water. Rats were killed using pentobarbital; the 
brain was removed and placed in ice-cold sucrose solution (NaCl 87mM, 
KCl 2.5mM, MgCl2 7mM, CaCl2 0.5mM, NaH2PO4 1.25mM, sucrose 
75mM, glucose 25mM, equilibrated with 95% O2 / 5% CO2). Transverse 
slices (350µm) were prepared with an Epilepsia Leica Vibratome (Leica 
VT1200S) and were then stored in an interface chamber containing 
artificial cerebrospinal fluid solution (ACSF; NaCl 119mM, KCl 2.5mM, 
MgSO4 4mM, CaCl2 4mM, NaHCO3 26.2mM, NaH2PO4 1mM, glucose 
11mM) gassed continuously with a 95% O2 / 5% CO2 gas mixture and 
kept at 37°C in a water bath. Treatment was added directly to ACSF 
(Fig. 1) and allowed to diffuse for five minutes prior to brain slice 
transfer. After 4h slices were homogenised manually in PBS. The cell 
suspension was pelleted (3min at 1,500xg), the pellet re-suspended in 
RIPA buffer containing proteinase and phosphatase inhibitors 
(750µl/slice) and centrifuged a second time (3min at 10,000xg) to pellet 
cell debris. The supernatant was removed and stored at -20°C. 
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Figure 2.1 – Brain slice treatment set-up. The brain slices rest on a mesh embedded 
in a tube, open at both ends, which is placed inside a beaker containing oxygenated 
artificial cerebrospinal fluid (ASCF). The carrier tube is either suspended from the 
beaker at a slightly elevated point or rests on a jagged edge, allowing ASCF to perfuse 
freely around the tissue. The ASCF is continuously gassed with 95% O2 / 5% CO2 
throughout the experiment. 
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2.3.2  Mouse liver slices 
For the pilot liver slice experiment, mice were sacrificed by 
cervical dislocation, the liver immediately excised and the gallbladder 
removed. The liver was rapidly moved to ice-cold Earle’s balanced salt 
solution (EBSS; Sigma #E7510) containing D-glucose (25mM; Sigma) 
which had been gassed for 1h with a 95% O2 / 5% CO2 gas mixture. 
Cylindrical tissue cores (8mm diameter) were prepared using a hand-
held coring tool. Cores were placed into the core mount of a Krumdieck 
tissue slicer (Alabama Research and Development Corporation) and 
250µm slices prepared according to equipment instructions. Slices were 
transferred to pre-incubated (30min at 37°C, 5% CO2) 12-well plates 
containing RPMI 1640 culture medium (1.5ml/well; Invitrogen 
#31870082) supplemented with 5% FBS (as before) as well as the 
following (all supplied by Sigma): 0.5mM L-methionine (#M5308), 1µM 
insulin (#I9278), 0.1mM hydrocortisone-21-hemisuccinate (#H2270) 
and gentamicin 50µg/ml (#G1397). Slice-containing plates were placed 
on a gyratory shaker (90rpm) to insure adequate media circulation and 
incubated inside a humidified incubator (37°C, 5% CO2). After a brief 
pre-incubation (30min), slices were moved to new, pre-incubated plates 
containing 1.5ml/well RPMI with treatment compounds or vehicle 
controls. After treatment (4h), plates were removed and immediately 
stored on ice. Slices were briefly rinsed in ice-cold PBS before being 
transferred to ice-cold 500µl RIPA+PP buffer and homogenised 
manually. Tissue suspensions were centrifuged briefly at high speed 
and the supernatant stored at -20°C. 
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2.4 Western Blotting 
Extracted protein was boiled (10min at 95°C) in 1X loading buffer 
(5X: 160mM Tris pH 6.8, 240mM Glycerol, 50mM SDS, 1.8M β-
mercaptoethanol, Bromophenol blue) and loaded into a 12.5% 
acrylamide/bisacrylamide (Sigma #A3699) gel. Protein was separated by 
SDS-PAGE (150V, 1h) alongside a pre-stained size marker (Fermentas 
#26619) and transferred to PVDF membrane (Merck Millipore 
#IPFL00010) via Western Blot (200mA, 1h). All following 
incubation/washing steps were performed on a bench rocker. 
Membranes were blocked in blocking buffer containing 5% BSA V 
(Sigma #A2153) in TBST (Severn Biotech) for 1h. Antibody was added 
directly to blocking buffer (1:1000) and membranes were incubated at 
4°C overnight. All primary antibodies provided by Cell Signaling 
Technology: GSK3β (#12456), Ser9 pGSK3β (#5558), Akt (#9272), 
Ser473 pAkt (#4060), PPARγ (#2443), PTEN (#9188), 
Ser380/Thr382/383 pPTEN (#9549), β-catenin (#8480), acetylated 
lysine (#9441), β-actin (#4970), β-tubulin (#2128). Membranes were 
washed in TBST (3x5min) and incubated with secondary antibody 
(1:15,000; Li-Cor #926-32211 Goat anti-Rabbit) in Odyssey Blocking 
Buffer (Li-Cor #927-50000) for 1h at room temperature, followed by 
another washing step in TBST (3x5min) and rinse with TBS. 
Membranes were visualised and quantified using the Odyssey Sa 
system (Li-Cor). The prestained protein size marker was used to verify 
target protein size. 
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2.5 Commercial assays 
2.5.1  Histone deacetylase (HDAC) assay 
HDAC inhibition assays were performed using a fluorimetric in 
vitro histone deacetylase assay (Merck Millipore #17-372) and according 
to instructions using HeLa cell enzyme extract (Enzo #BML-KI140-0100) 
at a 1:10 dilution. During assay incubation, the enzymatic activity from 
HeLa cell extract deacetylates a substrate unless inhibited by the 
compound of interest. Deacetylation of substrate allows a fluorescent 
compound (the activator) to bind, leading to an amplified signal with 
increasing deacetylation. Inhibitor-containing reactions are compared to 
a vehicle control sample. 
2.5.2  Bicinchoninic acid (BCA) Assay 
 Protein abundance was measured using the Pierce BCA assay, 
which was supplied by Life Technologies (#23225) and carried out 
according to manufacturer’s instructions. 
2.5.3  Lactate dehydrogenase (LDH) activity assay 
LDH release was measured using LDH Cytotoxicity Assay (Pierce 
#88953) and according to the manufacturer’s instructions. 
2.5.4  Viability, cytotoxicity, and apoptosis assay 
Huh7 cells were analysed for cell viability, cytotoxicity, and 
apoptosis using ApoTox Glo (Promega #G6320) according to 
manufacturer instructions.  
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2.6 siRNA knock-down 
Specific PPARγ siRNAs and negative control siRNA (Qiagen 
#GS5468 and #SI03650325 respectively) were used in conjunction with 
Lipofectamine RNAiMAX (Inivtrogen) according to manufacturer 
protocols. Cells were seeded into 6-well plates and cultured to 70% 
confluence (48h, 37°C, 5% CO2). Cells were transfected in 250µl 
unsupplemented culture medium (DMEM high glucose, as before) with 
all four PPARγ siRNAs or the negative control siRNA for 6h, after which 
750µl DMEM containing 10% FBS was added to each well. Cells were 
rested overnight (16h), at which point medium was replaced with fresh 
DMEM (containing 10% FBS) and cultured for a further 24h prior to 
experiments. 
 
2.7 Reverse transcription quantitative RT-PCR 
Huh7 cells were trypsinised after treatment and re-suspended in 
200µl PBS / well for RNA extraction. RNA was extracted using High 
Pure RNA Isolation kit (Roche #11828665001) and according to the 
manufacturer’s instructions. RNA was then purified using DNA free (Life 
Technologies #AM1906) and coding DNA (cDNA) was synthesised using 
First Strand cDNA Synthesis (Life Technologies #K1612). Real-time 
amplification with SYBR Green (BioRad #172-5120) was performed 
using a Rotor-Gene 6000 (Qiagen). Levels of transcription were 
quantified using the method proposed by Livak and Schmittgen (2001; 
2-∆∆CT). 
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2.8 Cell fixing and staining 
Huh7 cells were seeded at 8x104 cells/well into 6-well plates 
containing poly-d-lysine-coated (0.1mg/ml; Sigma in 0.1 M Borate 
buffer) coverslips. Cells were allowed to recover for 24h prior to the 
experiment, after which culture medium was aspirated, coverslips were 
rinsed with PBS, and cells were fixed in 4% paraformaldehyde (20min). 
Cells were then permeabilised with 0.2% Triton in PBS (3min) and 
blocked in 10% FBS in PBS (15min). Fixed cells were incubated with 
PPARγ antibody (1:100) at 4°C overnight, followed by incubation with 
fluorescent secondary antibody (1:1000, 30min) in the dark. Finally, 
cells were stained with diamidino-2-phenylindole (DAPI; Life 
Technologies #62248). Coverslips were mounted onto microscope slides 
using Fluoromount (Sigma #F4680) and allowed to dry overnight prior 
to analysis. 
 
2.9 Software 
Statistical analysis and graphing were performed using Prism 5 
(GraphPad Software). Microscopic images were captured using Image 
Pro Plus 6.3 (Media Cybernetics). Cell fluorescence was analysed using 
Image J (Rasband, 1997). 
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2.10 Statistical analysis 
Data were analysed using one-way ANOVA, two-way ANOVA, or 
Student’s t-test as appropriate after confirmation of normal distribution 
with Kolmogorov-Smirnov test. Results were further analysed using 
post-hoc Tukey test where appropriate. Probability (p) values larger 
than 0.05 were considered insignificant (n.s.), 0.01–0.05 significant (*), 
0.001–0.01 very significant (**), and <0.001 highly significant (***). 
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3 
Investigating the effect of VPA 
on molecular signalling in 
standard culture conditions 
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3.1 Introduction 
VPA is known to modulate glycogen synthase kinase-3β (GSK3β) 
and extracellular regulated kinase 1/2 (ERK1/2) signalling in vivo. VPA 
increases GSK3β phosphoylation during haemorrhagic shock in liver 
tissue (Alam et al., 2009; Alam et al., 2011; Hwabijre et al., 2014) and is 
neuroprotective in the brain by regulating ERK1/2 signalling 
(Fukudome et al., 2010; Kochanek et al., 2012; Pramod et al., 2010). 
These effects are tissue-specific (Gotfryd et al., 2010) and occur within 
four hours (Alam et al., 2009). A broad approach encompassing these 
factors in experimental design was therefore necessary to establish an 
in vitro model. 
Four cell lines, two primary cell types, and two types of primary 
tissue were selected to investigate their response to VPA treatment. Two 
human hepatocarcinoma cell lines (Huh7 and HepG2) were chosen to 
model changes in GSK3β phosphorylation and two neuroblastoma cell 
lines, Neuro2a (mouse) and SH-SY5Y (human) to model those in 
ERK1/2 phosphorylation. The use of two independent cell lines per 
tissue was necessary to control for line-dependent signalling differences 
for which VPA is known (Gotfryd et al., 2010). Primary cells and tissue 
were utilised as they more accurately reflect in vivo conditions 
compared to immortalised cell lines. As ERK1/2 and GSK3β are the 
protein of interest in neuronal and hepatic tissues  respectively, the 
study of VPA effects on ERK1/2 in liver- and GSK3β in brain-derived 
cells and tissue served as a control for pathway-specific activation. The 
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extent of cell and tissue types used provided a substantial range of 
environments for new discovery. 
In cell culture, serum-starvation is used as a standard 
methodology to prepare cells for experimental procedure. However, the 
removal of serum from cell culture medium has recently been 
highlighted as a stressor in itself (Pirkmajer and Chibalin, 2011). 
Therefore, to ensure the use of appropriate cell culture techniques, all 
cell lines were treated in both serum-starved and serum-supplemented 
conditions in order to discover whether serum state affects the response 
of ERK1/2 and GSK3β phosphorylation to VPA. Experimental results 
were interpreted with the aim of establishing the correct model 
environment. 
The experiments described in this chapter were performed to 
discover the effect of VPA at a range of concentrations on the 
phosphorylation state of two proteins (GSK3β and ERK1/2) in four cell 
lines (Huh7, HepG2, Neuro2a, and SH-SY5Y) and primary cells and 
tissue within four hours. This approach studied the effect of VPA on two 
known protein targets while taking into account some complexities of 
the tissue-dependent VPA mechanism of action and providing a suitable 
framework for result interpretation. 
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3.2 Results 
3.2.1  Neuronal tissue 
3.2.1.1 Effect of VPA on neuroblastoma-derived cell lines  
3.2.1.1.1 GSK3β phosphorylation 
In a pilot experiment, Neuro2a cells were serum-starved and 
treated with VPA at two physiologically relevant (0.5 and 1mM) and one 
clinically excessive (3mM) concentration (Levy & Shen, 1995) for four 
hours. GSK3β phosphorylation levels were calculated as phosphorylated 
protein to total protein ratio and compared to an untreated control (Fig. 
1). No change in GSK3β phosphorylation was observed in response to 
VPA treatment at any concentration in Neuro2a cells (p>0.05), nor did 
treatment affect the level of total GSK3β.  
To examine the effect of VPA on a second neuroblastoma-derived 
cell line, SH-SY5Y cells were treated with VPA. In order to discover the 
effect of serum starvation on protein phosphorylation in response to 
VPA, cells received fresh media with or without serum 16h before 
treatment. GSK3β phosphorylation was quantified as a phosphorylated 
protein to total protein ratio and compared to an untreated control (Fig. 
2). VPA did not affect pGSK3β levels in SH-SY5Y cells, a result 
unaffected by the presence or absence of serum in culture media 
(p>0.05). Total levels of GSK3β were also not affected in cells regardless 
of serum state. The analysis indicates that VPA does not modulate 
GSK3β phosphorylation in SH-SY5Y cells in standard cell culture 
conditions over four hours of treatment. 
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Figure 3.1 – Effect of VPA treatment on GSK3β 
phosphorylation in Neuro2a. Neuro2a cells were 
cultured under standard conditions (37°C, 5% CO2) 
receiving fresh serum-free medium 16h prior to the 
start of treatment. Cells were treated with VPA at 
indicated concentrations or vehicle control (dH2O) for 
four hours. Protein extract was probed with 
phosphorylated GSK3β (pGSK3β; Ser9) and total 
GSK3β (tGSK3β) antibodies and visualised with 
fluorescent secondary antibody. Levels of pGSK3β 
were calculated as ratio to tGSK3β and are shown as 
mean ± SEM.  Data (n=4, technical duplicates) were 
statistically analysed (ANOVA and Tukey test) and * 
indicate significance: * p<0.05, ** p<0.01, *** 
p<0.001. 
 
 
 
 
Figure 3.2 – Effect of VPA treatment on GSK3β phosphorylation in SH-SY5Y. SH-
SY5Y cells were cultured under standard conditions (37°C, 5% CO2) receiving fresh 
media with or without serum 16h prior to the start of treatment. Cells were treated 
with VPA at indicated concentrations or vehicle control (dH2O) for four hours in (A) 
serum-supplemented or (B) serum-free medium.  Protein extract was probed with 
phosphorylated GSK3β (pGSK3β; Ser9) and total GSK3β (tGSK3β) antibodies and 
visualised with fluorescent secondary antibody. Levels of pGSK3β were calculated as 
ratio to tGSK3β and are shown as mean ± SEM.  Data (n=3, technical duplicates) were 
statistically analysed (ANOVA and Tukey test) and * indicate significance: * p<0.05, ** 
p<0.01, *** p<0.001.  
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3.2.1.1.2 ERK1/2 phosphorylation 
SH-SY5Y cells were treated with VPA to discover any effect on 
ERK1/2 phosphorylation. After four hours, protein was extracted and 
pERK1/2 (Thr202/Tyr204) levels quantified (Fig. 3) as a ratio of 
phosphorylated protein to total protein and compared to an untreated 
control. VPA did not have a significant effect on ERK1/2 
phosphorylation in SH-SY5Y cells regardless of serum state (p>0.05), 
nor did the amount of total ERK1/2 change. The data therefore suggest 
that VPA does not affect ERK1/2 phosphorylation in SH-SY5Y in 
standard cell culture conditions during short-term treatment. 
 
 
Figure 3.3 – Effect of VPA treatment on ERK1/2 phosphorylation in SH-SY5Y. 
SH-SY5Y cells were cultured under standard conditions (37°C, 5% CO2) receiving fresh 
media with or without serum 16h prior to the start of treatment. Cells were treated 
with VPA at indicated concentrations or vehicle control (dH2O) for four hours in (A) 
serum-supplemented or (B) serum-free medium. Protein extract was probed with 
phosphorylated ERK1/2 (pERK1/2; Thr202/Tyr204) and total ERK1/2 (tERK1/2) 
antibodies and visualised with fluorescent secondary antibody. Levels of pGSK3β were 
calculated as ratio to tGSK3β and are shown as mean ± SEM. Data (n=3, technical 
duplicates) were statistically analysed (ANOVA and Tukey test) and * indicate 
significance: * p<0.05, ** p<0.01, *** p<0.001. 
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3.2.1.2 Effect of VPA on primary neuronal cells and tissue 
Primary tissue more accurately represents in vivo tissue 
compared to cell lines. To elucidate potential differences in GSK3β and 
ERK1/2 phosphorylation between cell lines and primary tissue, pilot 
studies were performed on isolated rat neuronal tissue. Rat cortical 
cells and whole brain tissue slices were exposed to VPA for four hours 
and protein phosphorylation quantified. VPA effects on protein 
phosphorylation in primary tissue served as a comparison to that seen 
in cell lines. 
Rat cortical neurons were extracted, cultured for six days, and then 
treated with VPA. Due to small extract volume, only phosphorylated and 
total GSK3β levels were visualised and quantified (Fig. 4). VPA did not 
significantly change Ser9 phosphorylation of GSK3β (p>0.05) and did 
not affect total GSK3β levels. These data suggest that VPA does not 
affect GSK3β signalling via phosphorylation in primary rat cortical 
neurons. 
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Figure 3.4 – Effect of VPA treatment on 
GSK3β phosphorylation in primary murine 
cortical neurons. Cortical neurons extracted 
from E18 murine embryos were provided in 
monolayer culture six days post-extraction. 
Cells were treated in standard conditions (37°C, 
5% CO2) with VPA at indicated concentrations 
or vehicle control (dH2O) for four hours. Protein 
extract was probed with phosphorylated GSK3β 
(pGSK3β; Ser9) and total GSK3β (tGSK3β) 
antibodies and visualised with fluorescent 
secondary antibody. Levels of pGSK3β were 
calculated as ratio to tGSK3β and are shown as 
mean ± SEM.  Data (n=6, technical duplicates) 
were statistically analysed (ANOVA and Tukey 
test) and * indicate significance: * p<0.05, ** 
p<0.01, *** p<0.001. 
 
Whole rat brain slices (350µm thick) were prepared as described 
previously (Chang et al., 2010) and stored for treatment in an interface 
chamber containing artificial cerebrospinal fluid (aCSF) solution. VPA 
was added directly to the aCSF and slices were treated for four hours 
and then homogenised manually. Protein was extracted for visualisation 
and analysis of GSK3β (Ser9) and ERK1/2 (Thr202/Tyr204) 
phosphorylation levels (Fig. 5). VPA does not significantly affect GSK3β 
(Fig. 5A) or ERK1/2 (Fig. 5B) phosphorylation in rat whole brain slices 
(p>0.05). VPA treatment also had no effect on total protein levels. The 
data therefore indicate that VPA does not affect GSK3β and ERK1/2 
signalling through phosphorylation in ex vivo brain slice tissue. 
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Figure 3.5 – Effect of VPA treatment on GSK3β and ERK1/2 phosphorylation in 
rat brain slices. Rat brains were removed and sliced using a Leica Vibratome slicer. 
Slices treated with VPA at indicated concentrations in an interface chamber containing 
artificial cerebral spinal fluid for four hours. Protein extract was probed with (A) 
phosphorylated GSK3β (pGSK3β; Ser9) or total GSK3β (tGSK3β) antibody, or (B) 
phosphorylated ERK1/2 (pERK1/2; Thr202/Tyr204) or total ERK1/2 (tERK1/2) 
antibody and visualised with fluorescent secondary antibody.  Levels of pGSK3β and 
pERK1/2 were calculated as ratio to tGSK3β and are shown as mean ± SEM. Data 
(n=6 for GSK3β; n=4 for ERK1/2; technical duplicates) were analysed (ANOVA and 
Tukey test) and are shown as mean ± SEM and * indicate significance: * p<0.05, ** 
p<0.01, *** p<0.001. 
3.2.2  Hepatic tissue 
3.2.2.1 Effect of VPA on hepatocarcinoma-derived cell lines 
3.2.2.1.1 GSK3β phosphorylation 
VPA affects GSK3β phosphorylation in liver during haemorrhagic 
shock (Alam et al., 2009). Therefore, liver-derived cell lines were utilised 
to discover the effect of VPA on GSK3β phosphorylation in vitro. Two 
human cell lines, Huh7 and HepG2, were selected to enable comparison 
of any signalling changes observed in response to VPA between two cell 
lines from hepatic source tissue. Cells were treated with VPA for four 
hours in serum-free and serum-supplemented media to analyse the 
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effect of serum state on GSK3β (Ser9) phosphorylation in response to 
VPA. Effects on Ser9 phosphorylation were quantified as a 
phosphorylated protein to total protein ratio and compared to an 
untreated control.   
In Huh7 cells treated in serum-supplemented media, VPA did not 
significantly affect pGSK3β levels (Fig. 6A). In serum-starved Huh7, VPA 
increased GSK3β phosphorylation (to 121±8% compared to untreated 
cells) at 3mM (Fig. 6B), but this change was not significant (p>0.05). In 
HepG2, VPA did not significantly affect GSK3β phosphorylation in either 
serum-starved or serum-supplemented cells even at high 
concentrations (Fig. 7). VPA did not modulate total protein level in either 
cell line. The results therefore indicate that VPA does not affect GSK3β 
phosphorylation in Huh7 or HepG2 in standard cell culture conditions. 
Figure 3.6 – Effect of VPA treatment on GSK3β phosphorylation in Huh7. Huh7 
cells were cultured under standard conditions (37°C, 5% CO2) receiving fresh media 
16h prior to the start of treatment. Cells were treated with VPA at indicated 
concentrations or vehicle control (dH2O) for four hours in (A) serum-supplemented or 
(B) serum-free medium.  Protein extract was probed with phosphorylated GSK3β 
(pGSK3β; Ser9) and total GSK3β (tGSK3β) antibodies and visualised with fluorescent 
secondary antibody. Levels of pGSK3β were calculated as ratio to tGSK3β and are 
shown as mean ± SEM.  Data (n=6, technical triplicates) were statistically analysed 
(ANOVA and Tukey test) and * indicate significance: * p<0.05, ** p<0.01, *** p<0.001. 
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Figure 3.7  – Effect of VPA treatment on GSK3β phosphorylation in HepG2. 
HepG2 cells were cultured under standard conditions (37°C, 5% CO2) receiving fresh 
media 16h prior to the start of treatment. Cells were treated with VPA or vehicle 
control (dH2O) for four hours in (A) serum-supplemented or (B) serum-free medium.  
Protein extract was probed with phosphorylated GSK3β (pGSK3β; Ser9) and total 
GSK3β (tGSK3β) antibodies and visualised with fluorescent secondary antibody. 
Levels of pGSK3β were calculated as ratio to tGSK3β and are shown as mean ± SEM.  
Data (n=6, technical triplicates) were statistically analysed (ANOVA and Tukey test) 
and * indicate significance: * p<0.05, ** p<0.01, *** p<0.001. 
 
3.2.2.1.2 ERK1/2 phosphorylation 
Though ERK1/2 phosphorylation has been shown to be 
modulated in vivo during haemorrhagic shock, this regulation has not 
been observed in liver (Fukudome et al., 2010). To discover potential 
differences in pathway activation between GSK3β and ERK1/2, the 
same two hepatocarcinoma-derived cell lines were exposed to VPA and 
analysed for ERK1/2 phosphorylation. Cells were treated in serum-
supplemented or serum-free media to discover the effect of serum state 
on ERK1/2 phosphorylation in response to VPA. Effects on protein 
phosphorylation were then compared to those seen on GSK3β. 
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Huh7 cells were treated with VPA and pERK1/2 (Thr202/Tyr204) 
levels were quantified as a phosphorylated protein to total protein ratio 
and compared to an untreated control (Fig. 8). ERK1/2 phosphorylation 
in Huh7 cells did not differ significantly between treated and untreated 
cells, regardless of serum state (p>0.05). To examine the effect of VPA in 
a distinct liver-derived cell line, HepG2 cells were treated with VPA and 
ERK1/2 phosphorylation (Thr202/Tyr204) was quantified (Fig. 9). VPA 
treatment does not have a significant effect on ERK1/2 phosphorylation 
in HepG2 cells at any concentration used, neither in serum-
supplemented nor in serum-free media (p>0.05). The data suggest that 
VPA does not affect ERK1/2 phosphorylation in Huh7 or HepG2 cells 
and that these results are not modulated by the presence or absence of 
serum. 
 
Figure 3.8 – Effect of VPA treatment on ERK1/2 phosphorylation in Huh7. Huh7 
cells were cultured under standard conditions (37°C, 5% CO2) receiving fresh media 
16h prior to the start of treatment. Cells were treated with VPA or vehicle control 
(dH2O) for four hours in (A) serum-supplemented or (B) serum-free medium.  Protein 
extract was probed with phosphorylated ERK1/2 (pERK1/2; Thr202/Tyr204) and total 
ERK1/2 (tERK1/2) antibodies and visualised with fluorescent secondary antibody. 
Levels of pERK1/2 were calculated as ratio to tERK1/2 and are shown as mean ± 
SEM.  Data (n=6, technical triplicates) were statistically analysed (ANOVA and Tukey 
test) and * indicate significance: * p<0.05, ** p<0.01, *** p<0.001. 
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Figure 3.9 – Effect of VPA treatment on ERK1/2 phosphorylation in HepG2. 
HepG2 cells were cultured under standard conditions (37°C, 5% CO2) receiving fresh 
media 16h prior to the start of treatment. Cells were treated with VPA or vehicle 
control (dH2O) for four hours in (A) serum-supplemented or (B) serum-free medium.  
Protein extract was probed with phosphorylated ERK1/2 (pERK1/2; Thr202/Tyr204) 
and total ERK1/2 (tERK1/2) antibodies and visualised with fluorescent secondary 
antibody. Levels of pERK1/2 were calculated as ratio to tERK1/2 and are shown as 
mean ± SEM.  Data (n=6, technical triplicates) were statistically analysed (ANOVA and 
Tukey test) and * indicate significance: * p<0.05, ** p<0.01, *** p<0.001. 
 
3.2.2.2 Effect of VPA on primary hepatic cells and tissue 
Cell lines reflect conditions in healthy in vivo tissue less 
accurately than primary cells used ex vivo. Therefore, pilot studies on 
primary hepatic cells tissue were performed to investigate potential 
effects of VPA on GSK3β and ERK1/2 phosphorylation. Results were 
compared to those from cell lines treated in vitro to discover any 
differences in protein phosphorylation. 
Cryopreserved rodent hepatocytes were treated with VPA in an 
approach similar to that used with cell lines. GSK3β phosphorylation 
(Ser9) was visualised, quantified, and compared to an untreated control 
(Fig. 10A). Due to a limited amount of available cells, the number of 
experimental repeats were not sufficient to determine whether VPA had 
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a significant (p<0.05) effect on GSK3β phosphorylation in primary 
hepatocytes, but preliminary data did not reproduce those found in vivo 
(Alam et al., 2009). 
A pilot experiment on hepatic tissue was performed using 
heterogeneous murine liver tissue core slices. GSK3β phosphorylation 
levels in murine liver slice protein extract were visualised and quantified 
(Fig. 10B). VPA treatment significantly (p<0.01) decreased pGSK3β 
levels by 58±10% at 3mM concentration compared to untreated control 
but did not modulate GSK3β levels at lower concentrations (p>0.05). 
These results, obtained in in non-cancerous tissue, indicate that the 
lack of signalling response to VPA seen in Huh7 and HepG2 is likely not 
specific to carcinoma-derived cells and therefore due to treatment 
conditions rather than carcinoma-specific effects of VPA. 
 
Figure 3.10 – Effect of VPA treatment on GSK3β phosphorylation in primary 
hepatic tissue (pilot). After VPA treatment (4h) protein was extracted and probed with 
phosphorylated GSK3β antibody (Ser9) or total GSK3β antibodies, visualised, and 
quantified. Data are shown as mean (bar) ± SEM (error bar). (A) Rat primary 
hepatocytes were thawed, allowed to form a monolayer and to rest overnight. After 
16h, cells were treated with VPA or vehicle control (dH2O) (n=2 technical). Due to the 
limited number of repeats, statistical analysis of the data was not possible. (B) Murine 
livers were excised and liver cores produced using a hand-held coring tool. A 
Krumdieck tissue slicer produced 250µm thick slices which were allowed to rest for 
30min prior to treatment with VPA or vehicle control (dH2O). Data (n=3 technical) were 
analysed using ANOVA and Tukey test. * indicate significance compared to 0mM VPA: 
* p<0.05, ** p<0.01, *** p<0.001. 
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3.3 Discussion 
3.3.1  Effect of VPA on protein phosphorylation in neuron 
cells 
VPA treatment has been shown to be neuroprotective in brain 
injury and during haemorrhagic shock (Dash et al., 2010; Sinn et al., 
2007; Williams et al., 2006). Acute protective cellular changes after 
traumatic brain injury and intracerebral haemorrhage in response to 
VPA have been shown to be effected by ERK1/2 signalling (Dash et al., 
2010; Sinn et al., 2007). VPA also affects GSK3β signalling in the brain, 
but studies have focused on the effects of chronic treatment (Hall et al., 
2002; Leng et al., 2008).  Neuronal cells were therefore selected to 
investigate the acute effect of VPA on ERK1/2 and GSK3β 
phosphorylation. 
Two neuroblastoma cell lines, Neuro2a (mouse) and SH-SY5Y 
(human), both of which have been shown to respond to VPA treatment, 
were used in these experiments. In SH-SY5Y, VPA has an anti-apoptotic 
effect via p53 and bcl-2 (Song et al., 2012) and decreases the 
vulnerability of cells to oxidative stress (Monti et al., 2009). VPA also 
induces bcl-2 regulation via the MAPK and PI3K pathways in SH-SY5Y 
and shows activity similar to that in cultured cortical cells (Creson et 
al., 2009). In Neuro2a however, VPA induces differentiation (Chen et al., 
2011) but does not modulate GSK3β activity (Phiel et al., 2001). 
Neuro2a was selected for experiments as in vivo studies of the effect of 
VPA in haemorrhagic shock have utilised rodent models (Kochanek et 
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al., 2012; Li et al., 2010) while SH-SY5Y was chosen due to its 
increased similarity to the human cellular environment. 
Neuro2a and SH-SY5Y were both exposed to VPA at a series of 
concentrations, both clinically relevant (0.5, 1mM) and excessive (3mM; 
Levy & Shen, 1995). A pilot experiment on Neuro2a showed no effect of 
VPA on GSK3β phosphorylation. Treatment of SH-SY5Y with VPA 
replicated the lack of response seen in Neuro2a, both in serum-free and 
serum-supplemented media. Neither GSK3β phosphorylation nor 
ERK1/2 phosphorylation were acutely modulated by VPA treatment in 
SH-SY5Y, regardless of drug concentration. These data demonstrate the 
need to modify the treatment or culturing conditions of SH-SY5Y cells to 
gain the opportunity of creating a functional model system. 
Primary neuronal tissue was utilised to investigate the effect of 
VPA on protein phosphorylation in a cellular environment more similar 
to in vivo  conditions than can be found in cell lines. Isolated rat cortical 
cells were chosen for VPA exposure to allow for use of a treatment 
protocol almost identical (save for changes in incubation medium) to 
that used with cell lines. VPA did not affect GSK3β phosphorylation and 
low protein yield precluded the analysis of ERK1/2 phosphorylation 
status in cortical neurons. These results indicated that the lack of 
significant effect on protein phosphorylation seen in SH-SY5Y was not 
specific to the cell line. 
To investigate whether the acute effect of VPA in the brain relies 
on the action of non-neuronal supporting cells, heterogenous brain 
tissue was exposed to VPA. Rat whole brain slices were dissected and 
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treated in an interface chamber at identical drug concentrations to 
those used in vitro. This exposure of primary brain tissue to VPA did not 
produce significant changes to protein phosphorylation status, neither 
of GSK3β nor in ERK1/2. These data suggest that the absence of a 
significant effect of VPA on protein phosphorylation in SH-SY5Y was not 
due to the homogenous cellular environment of the cell line cells. 
3.3.2  Effect of VPA on protein phosphorylation in hepatic 
cells 
As the main focus of haemorrhagic shock research has been on 
GSK3β signalling in the liver (Hwabejire et al., 2014) ex vivo hepatic 
tissue and hepatocarcinoma-derived cell lines were chosen as the basis 
for the primary line of experimental enquiry into modelling 
haemorrhagic shock. In vivo studies have often relied upon GSK3β 
phosphorylation at Serine 9 as a modulation marker (Alam et al., 2009; 
Li et al., 2008; Li et al., 2011) which was therefore of interest as a 
primary target. ERK1/2 phosphorylation status was investigated as a 
control to demonstrate the selective impact of VPA on GSK3β 
phosphorylation.  
Two hepatocarcinoma-derived cell lines, Huh7 and HepG2 (both 
modified from human tumours), were selected for their proven response 
to VPA treatment and prevalence of data regarding the effect of VPA on 
liver tissue during haemorrhagic shock. HepG2 has been used more 
extensively than Huh7, but the latter is beneficial for experiments due 
to evidence for its increased similarity to human tissue (Krelle et al., 
2013; Meex et al., 2011). In Huh7, VPA inhibits cell proliferation 
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(Machado et al. 2011) and in HepG2, VPA decreases cell viability 
(Neuman et al., 2013). VPA primes both Huh7 and HepG2 for TRAIL-
dependent apoptosis (Pathil et al., 2006). However, some apoptotic 
action of VPA has been shown to be balanced by VPA itself: The histone 
deacetylase (HDAC) inhibitory activity of VPA induces clusterin over-
expression which renders cancer cells resistant to HDAC inhibition-
induced apoptosis (Liu et al., 2009). In primary tissue, evidence is 
equally conflicting: VPA has been shown to sensitise primary 
hepatocytes to the death receptor agonist CD95L (Weiller et al., 2011), 
but Armeanu et al. (2005) found that primary hepatocytes tolerate VPA 
treatment well. These data further reinforce the need for cross-system 
comparisons. 
Huh7 and HepG2 were acutely treated with VPA to investigate 
potential effects on protein phosphorylation. VPA treatment had no 
significant effect on GSK3β Ser9 phosphorylation in Huh7 or HepG2, 
irrespective of the presence or absence of serum in culture media. 
ERK1/2 phosphorylation (Thr202/Tyr204) was also unaffected in Huh7 
and HepG2, regardless of treatment concentration and serum state. The 
lack of response indicates that the cellular conditions used in this 
chapter do not model those found in haemorrhagic shock. 
3.3.3  Effect of serum on VPA action 
The experiments on cell lines discussed in this chapter were 
performed on cells incubated in culture media supplemented with foetal 
bovine serum (FBS) and in media not supplemented with FBS. Cell lines 
are traditionally cultured in serum-supplemented media but are often 
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serum-starved prior to experiments to ensure homogenous cell states 
(e.g. Di Daniel et al., 2005; Gurvich et al., 2004; Jo et al., 2011; Li et al., 
2009). However, cells show reduced basal cellular activity in serum-free 
media (Codeluppi et al., 2011) and individual cell lines react differently 
to serum starvation (Levin et al., 2010). Removal of serum from culture 
media has even been shown to induce apoptosis (Wang et al., 2013). 
Pirkmajer and Chibalin (2011) warn that serum starvation, though 
widely used as a standard method in cell culture experiments, 
modulates signalling response to yield results divergent from or 
opposite to those produced in cells treated in serum-supplemented 
media, accordingly producing conflicting results and hindering data 
interpretation. Experiments were therefore performed in both serum-
free and serum-supplemented media to investigate the effect of serum 
state on VPA-dependendent changes to protein phosphorylation. 
Cell serum state did not significantly affect protein 
phosphorylation in response to VPA treatment. In neuronal cells, the 
presence or absence of serum did not modulate ERK1/2 or GSK3β 
phosphorylation levels during exposure to VPA. In hepatic cells, no 
effect of VPA on pERK1/2 or pGSK3β was observed to be dependent on 
serum supplementation. As serum starvation lacks a parallel in the 
clinical context as well as in whole organism models of haemorrhagic 
shock, future experiments on cell lines were performed in serum-
supplemented media. 
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3.3.4  Implications and conclusion 
This chapter investigated the acute effect of VPA treatment on 
GSK3β and ERK1/2 phosphorylation in neuronal and hepatic cell lines 
and primary tissue with the aim of establishing an in vitro model of 
haemorrhagic shock. However, VPA did not affect protein 
phosphorylation in the majority of model systems studied. A review of 
the literature on the short-term protective effects of VPA observed in 
vivo highlights a potential reason for these results: Though several 
studies have shown the beneficial therapeutic effects of VPA in disease, 
the relevant feature of these data is that the humans, animals, or in 
vitro models under discussion underwent pathological conditions prior 
to or during treatment with VPA (e.g. Alam et al., 2009; Hwabejire et al., 
2014; Kochanek et al., 2014; Williams et al., 2006). This is a key 
difference between these studies and the model systems exposed to VPA 
in this chapter, which were treated in standard culturing conditions.  
Unlike organ tissue during lethal blood loss, cells undergoing VPA 
treatment in the experiments discussed here were not in the process of 
responding to adverse circumstances. The absence of significant change 
to protein phosphorylation in response to VPA may be due to cells being 
cultured in standard cell culture conditions favourable to cellular 
activity and growth. Thus, a central consideration for future 
experiments must be the successful reproduction of the pathological 
circumstances found during haemorrhagic shock. Any effect of VPA on 
in these systems will specifically be due to its effect on cellular 
compensation to the adverse environment provided, as it is in vivo. The 
78 
 
response to VPA treatment in these pathological environments will 
provide a solid foundation on which to establish a successful model of 
haemorrhagic shock.  
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3.4 Summary 
 The results in this chapter demonstrate that VPA does not affect 
GSK3β or ERK1/2 phosphorylation in cell lines or ex vivo cells and 
tissue at clinically relevant concentrations. The data suggest that this is 
unlikely to be due to differential effects on immortalised cell lines and 
primary tissue or the homogeneous environment of cell lines and 
isolated primary cells. Serum-starvation, a common methodology in cell 
culture, has been demonstrated to not modulate the effect of VPA on 
GSK3β and ERK1/2 phosphorylation. Due to these data and the lack of 
a clinical parallel for this methodological step, its inclusion in future 
experiments is unwarranted. The models studied in this chapter do not 
accurately reflect the signalling changes observed in response to VPA 
treatment in vivo, thus further approaches need to be investigated with 
a focus on inducing pathological environments mimicking those found 
in terminal blood loss. 
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4 
Investigating the effect of VPA 
on molecular signalling in 
stress conditions 
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4.1 Introduction 
Haemorrhagic shock, caused by significant loss of blood, affects 
the entire organism (Kauvar and Wade, 2005). Loss of intravascular 
volume leads to decreased tissue perfusion, which affects cellular 
respiration: a lack of a gas transport vehicle (blood) leads to a decrease 
in essential components required for respiration (oxygen, nutrients) and 
an accumulation of waste product such as carbon dioxide, thereby 
increasing cellular stress (Gutierrez et al., 2004). As the effects of 
regional hypoperfusion spread, the core temperature of the organism 
falls (Kheirbek et al., 2009). Together with coagulopathies, these effects 
combine and exacerbate each other to make massive blood loss and 
haemorrhagic shock a potentially lethal condition (Findlay et al., 2007). 
Animal models of haemorrhagic shock aim to recreate the 
conditions found in human patients as closely as possible. This 
includes loss of at least 40% of total blood as in the most severe cases 
of lethal blood loss (Gutierrez et al., 2004), artificial control of core 
temperature to ensure precise reduction, and bone and internal soft 
tissue injury (Alam et al., 2009; Butt et al., 2009; Kochanek et al., 
2012). While it is necessary to accurately mimic events seen during 
lethal blood loss in vivo in animal treatment protocols in order to 
investigate model organism survival, these experiments are cost- and 
time-intensive which may prevent in-depth investigations of molecular 
signalling. 
To effectively model the impact of lethal blood loss on cellular 
signalling in vitro the individual components of this whole organism 
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condition must be distinguished and simulated on a cellular scale. 
During haemorrhagic shock, loss of blood leads to a decrease in 
available oxygen (hypoxia) and an increase in carbon dioxide 
(hypercapnia), which in turn causes a reduction of pH (acidosis; Hotter 
et al., 2004). A decrease in local or global temperature (hypothermia) 
also affects cellular gene expression and molecular signalling (Jia et al., 
2014; Kelly et al., 2005; Shore et al., 2013), for instance decreasing 
GSK3β phosphorylation in swine liver (Alam et al., 2009) and increasing 
ERK1/2 phosphorylation in rat lung (Fukudome et al., 2010). The 
presence of the components of this pathological state is therefore likely 
to be of key importance in producing a haemorrhagic shock-like 
environment in vitro.  
In the experiments described in this chapter, human cell lines 
were exposed to pathological conditions mimicking those present in 
haemorrhagic shock (hypoxia, hypercapnia, and hypothermia) and 
treated with VPA to determine the effect on cellular signalling compared 
to that seen in standard cell culture conditions (normoxia). The 
presence of conditions in isolation or in combination and with or 
without VPA treatment was characterised with regards to the effects on 
GSK3β and ERK1/2 phosphorylation. These changes in levels of 
phosphorylated protein were compared to those found in vivo to 
determine which, if any, stress conditions replicated the 
phosphorylation changes observed in animal models, thereby yielding a 
suitable in vitro model of haemorrhagic shock signalling.  
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4.2 Results 
4.2.1  Stress conditions in Huh7 
To determine the effect of pathological gas and temperature states 
on GSK3β phosphorylation in Huh7, which is reduced after 
haemorrhagic shock in vivo (Alam et al., 2009 Hwabejire et al., 2014), 
cells were exposed to hypoxia (2% O2), hypercapnia (10% CO2), and 
hypothermia (32°C). Huh7 cells were incubated for four hours in stress 
or standard (atmospheric O2, 5% CO2, 37°C) cell culture conditions with 
or without VPA at clinically relevant concentrations (0.1-1mM; Levy & 
Shen, 1995). Cell protein extract was analysed for GSK3β (Ser9) or 
ERK1/2 (Thr202/Tyr204) phosphorylation compared to total GSK3β 
and ERK1/2 levels while β-tubulin levels were established to provide a 
reference for total protein present.  
 Huh7 cells were first treated with hypoxia and hypercapnia at a 
standard cell culture temperature (37°C) to determine whether these 
conditions sufficed to modulate protein phosphorylation (Fig. 1). 
Exposure to low oxygen and high carbon dioxide for four hours did not 
significantly affect phosphorylation of GSK3β and ERK1/2 compared to 
cells cultured in standard conditions (normoxia; p>0.05). Neither 
GSK3β nor ERK1/2 phosphorylation levels were modulated by VPA 
during these conditions at any concentration tested. Levels of total 
ERK1/2 and GSK3β were also unaffected by gas stress without 
concurrent VPA treatment (p>0.05). 
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Figure 4.1 - Effect of VPA treatment on ERK1/2 and GSK3β phosphorylation in 
Huh7 undergoing hypoxia and hypercapnia. Huh7 cells were cultured under 
standard conditions (37°C, 5% CO2) receiving fresh medium 16h prior to the start of 
treatment. After VPA was added to media at indicated concentration, cells were 
transferred to adverse gas conditions (2% O2, 10% CO2) for four hours. Control cells 
were treated with vehicle control (dH2O) and concurrently incubated in standard 
conditions (normoxia; Nx). Protein extract was probed with (A) phosphorylated ERK1/2 
(pERK1/2; Thr202/Tyr204) and total ERK1/2 (tERK1/2) antibodies or (B) 
phosphorylated GSK3β (pGSK3β; Ser9) and total GSK3β (tGSK3β) antibodies, as well 
as β-tubulin antibody as loading control, and visualised with fluorescent secondary 
antibody. ERK1/2 and GSK3β fluorescence were corrected for loading differences with 
β-tubulin and phosphorylated protein levels were calculated as ratio to total protein 
and are shown as mean ± SEM.  Data (n=9, technical triplicates) were statistically 
analysed (ANOVA and Tukey test) and * indicate significance: * p<0.05, ** p<0.01, *** 
p<0.001.  
 
As adverse gas conditions did not significantly affect protein 
phosphorylation, Huh7 cells were exposed to hypoxia and hypercapnia 
in combination with hypothermia (32°C) to establish any effect on 
ERK1/2 or GSK3β phosphorylation (Fig. 2). The three combined 
stressors (HxHcHp) did not significantly affect ERK1/2 phosphorylation 
(Fig. 2A), nor total ERK1/2 levels compared to those found in cells 
cultured in standard conditions (Nx). The adverse conditions also did 
not significantly modulate total GSK3β levels, however, they 
significantly (p<0.001) reduced GSK3β Ser9 phosphorylation to 50±6% 
of untreated standard culture control (Nx; Fig. 2B). Treatment with VPA 
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reduction of pGSK3β in a dose-dependent manner, increasing 
phosphorylation levels to 91±10% of control at 0.5mM and to 128±16% 
at 0.75mM. VPA did not have this effect on GSK3β phosphorylation 
during standard cell culture conditions where treatment at 0.75mM did 
not significantly affect pGSK3β levels. These results suggest that the 
increase of GSK3β phosphorylation observed in response to VPA 
treatment during hypoxia, hypercapnia, and hypothermia is specific to 
cells treated in stress conditions similar to those observed in severe 
blood loss.  
 
 
Figure 4.2 - Effect of VPA treatment on ERK1/2 and GSK3β phosphorylation in 
Huh7 undergoing hypoxia, hypercapnia, and hypothermia. Huh7 cells were 
cultured under standard conditions (37°C, 5% CO2) receiving fresh medium 16h prior 
to the start of treatment. After VPA was added to media at indicated concentration, 
cells were transferred to adverse gas and temperature conditions (2% O2, 10% CO2, 
32°C; HxHcHp) for four hours. Control cells were treated with vehicle control (dH2O) or 
VPA as indicated and concurrently incubated in standard conditions (Normoxia; Nx). 
Protein extract was probed with (A) phosphorylated ERK1/2 (pERK1/2; 
Thr202/Tyr204) and total ERK1/2 (tERK1/2) antibodies or (B) phosphorylated GSK3β 
(pGSK3β; Ser9) and total GSK3β (tGSK3β) antibodies, as well as β-tubulin antibody as 
loading control, and visualised with fluorescent secondary antibody. ERK1/2 and 
GSK3β fluorescence were corrected for loading differences with β-tubulin and 
phosphorylated protein levels were calculated as ratio to total protein and are shown 
as mean ± SEM.  Data (n=9, technical triplicates) were statistically analysed (ANOVA 
and Tukey test) and * indicate significance: * p<0.05, ** p<0.01, *** p<0.001.  
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To determine whether the effect on GSK3β phosphorylation 
observed during combined hypoxia, hypercapnia, and hypothermia was 
dependent upon the presence of all three conditions, Huh7 cells were 
exposed to each condition separately and to all possible pairs of adverse 
conditions (Fig. 3). Cells exposed to hypoxia, hypercapnia, or 
hypothermia individually did not show a decrease in pGSK3β levels, nor 
did any two conditions combined lead to a reduction of 
phosphorylation. Therefore, these results suggest that the presence of 
all three conditions is necessary to cause the reduction in GSK3β Ser9 
phosphorylation in Huh7 cells which mimics that seen during 
haemorrhagic shock in vivo (Alam et al., 2009). 
 
Figure 4.3 – Effect of hypoxia, hypercapnia, and hypothermia on GSK3β 
phosphorylation in Huh7. Huh7 cells were cultured under standard conditions 
(37°C, 5% CO2) receiving fresh medium 16h prior to the start of treatment. Cells were 
then exposed for four hours to standard cell culture conditions or to single or 
combined stress conditions (2% O2, 10% CO2, 32°C) as indicated. Protein extract was 
probed with phosphorylated GSK3β (pGSK3β; Ser9) and total GSK3β (tGSK3β) 
antibodies, as well as β-tubulin antibody as loading control, and visualised with 
fluorescent secondary antibody. GSK3β fluorescence was corrected for loading 
differences with β-tubulin. Phosphorylated protein levels were calculated as ratio to 
total protein and are shown as mean ± SEM. Data (n=9, technical triplicates) were 
statistically analysed (ANOVA and Tukey test) and * indicate significance compared to 
Nx 0: * p<0.05, ** p<0.01, *** p<0.001. 
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4.2.2  Stress conditions in HepG2 and HEK293 
To establish whether other cell lines may provide cellular 
environments suitable for modelling haemorrhagic shock signalling two 
human cell lines, HepG2 and HEK293, were selected for further 
experiments. Signalling changes in the HepG2 line, a hepatocarcinoma-
derived cell line, would serve as a comparison to the changes observed 
in Huh7. HEK293 cells, derived from human embryonic kidney, were of 
interest as the GSK3β pathway has been shown to be activated during 
massive blood loss in kidney in a similar manner to that seen in liver 
(Zacharias et al., 2011). Both cell lines were exposed to hypoxia (2% O2), 
hypercapnia (10% CO2), and hypothermia (32°C) with or without 
concurrent VPA treatment for four hours. GSK3β phosphorylation 
(Ser9) was quantified to show any changes in phosphorylation state and 
highlight potential pathway activation.  
Figure 4.4 – Effect of VPA treatment on 
GSK3β phosphorylation in HepG2 
during hypoxia, hypercapnia, and 
hypothermia. HepG2 cells were cultured 
under standard conditions (37°C, 5% 
CO2) receiving fresh medium 16h prior to 
the start of treatment. After VPA was 
added to media at indicated 
concentration, cells were transferred to 
suboptimal gas and temperature 
conditions (2% O2, 10% CO2, 32°C; 
HxHcHp) for four hours. Control cells were 
treated with vehicle control (dH2O) or VPA 
as indicated and incubated in standard 
conditions (Normoxia; Nx) concurrently. 
Protein extract was probed with 
phosphorylated GSK3β (pGSK3β; Ser9) 
and total GSK3β (tGSK3β) antibodies. 
 
Levels of β-tubulin served as loading control. GSK3β fluorescence was corrected for 
loading differences with β-tubulin and phosphorylated protein levels were calculated as 
ratio to total protein and are shown as mean ± SEM.  Data (n=3, technical triplicates) 
were statistically analysed (ANOVA and Tukey test) and * indicate significance: * p<0.05, 
** p<0.01, *** p<0.001.  
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In HepG2 cells, the adverse gas and temperature conditions did 
not have a significant effect on GSK3β phosphorylation (Fig. 4). As in 
standard cell culture conditions, VPA did not affect pGSK3β levels in 
HepG2 exposed to the simulated haemorrhagic shock environment. 
Despite sharing source tissue with Huh7 (human hepatocarcinoma), 
HepG2 did not replicate the signalling changes seen in the first cell line 
which mimic those in vivo and was therefore excluded from further 
experiments. 
In HEK293 Hypoxia, hypercapnia, and hypothermia did not 
significantly affect pGSK3β levels (Fig. 5). However, VPA treatment 
significantly increased GSK3β Ser9 phosphorylation during stress 
conditions even at low concentrations; to 363±37% at 0.1mM (p<0.01), 
372±54% at 0.5mM (p<0.001) and 381±38% at 0.75 (p<0.001). As the 
adverse culture conditions used did not affect pGSK3β, VPA treatment 
was not corrective as seen in vivo during haemorrhagic shock. Therefore 
HEK293 was excluded from further experiments in favour of Huh7, 
which models in vivo signalling changes more accurately. 
89 
 
Figure 4.5 – Effect of VPA on GSK3β 
phosphorylation in HEK293 undergoing 
hypoxia, hypercapnia, and hypothermia. 
HEK293 cells were cultured under standard 
conditions (37°C, 5% CO2) receiving fresh 
medium 16h prior to the start of treatment. 
After VPA was added to media at indicated 
concentration, cells were transferred to 
suboptimal gas and temperature conditions 
(2% O2, 10% CO2, 32°C; HxHcHp) for four 
hours. Control cells were treated with 
vehicle control (dH2O) or VPA as indicated 
and incubated in standard conditions 
(Normoxia; Nx) concurrently. Protein extract 
was probed with phosphorylated GSK3β 
(pGSK3β; Ser9) and total GSK3β (tGSK3β) 
antibodies. 
 
Levels of β-tubulin were used as loading control, and visualised with fluorescent 
secondary antibody. GSK3β fluorescence was corrected for loading differences with β-
tubulin and phosphorylated protein levels were calculated as ratio to total protein and 
are shown as mean ± SEM.  Data (n=3, technical triplicates) were statistically analysed 
(ANOVA and Tukey test) and * indicate significance compared to Nx 0: * p<0.05, ** 
p<0.01, *** p<0.001.  
4.2.3  Stress conditions in SH-SY5Y 
To determine whether hypoxia, hypercapnia, and hypothermia 
and concurrent VPA treatment affect protein phosphorylation in 
neuronal tissue the neuroblastoma-derived cell line SH-SY5Y was 
exposed to combined stress conditions with or without VPA and 
analysed for GSK3β Ser9 and ERK1/2 Thr202/Tyr204 phosphorylation. 
Haemorrhagic shock-like conditions did not significantly decrease levels 
of pGSK3β and VPA did not affect GSK3β phosphorylation at any 
concentration (Fig. 6A). Adverse gas conditions also did not affect 
ERK1/2 phosphorylation, regardless of the presence or absence of VPA 
(Fig. 6B, C). However, while adverse incubation conditions did not 
significantly affect total ERK1/2 levels, concurrent treatment with VPA 
did (p<0.05), increasing total ERK1/2 by 75±23% at 1mM (Fig. 6D). 
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Figure 4.6 - Effect of hypoxia, hypercapnia, and hypothermia and VPA treatment 
on GSK3β and ERK1/2 in SH-SY5Y. SH-SY5Y cells were cultured under standard 
conditions (37°C, 5% CO2) receiving fresh medium 16h prior to the start of treatment. 
After VPA was added to media at indicated concentration, cells were transferred to 
suboptimal gas and temperature conditions (2% O2, 10% CO2, 32°C) for four hours. 
Control cells were treated with vehicle control (dH2O) and concurrently incubated in 
standard conditions (Normoxia; Nx). Protein extract was probed with (A) 
phosphorylated GSK3β (pGSK3β; Ser9) and total GSK3β (tGSK3β) antibodies or (B) 
phosphorylated ERK1/2 (pERK1/2; Thr202/Tyr204) and total ERK1/2 (tERK1/2) 
antibodies, as well as β-tubulin antibody as loading control. Levels of  ERK1/2 and 
GSK3β were corrected for loading differences with β-tubulin and phosphorylated 
protein levels were calculated as (A, B) ratio to total protein or (C, D) ratio to β-tubulin 
and are shown as mean ± SEM.  Data (n=9, technical triplicates) were statistically 
analysed (ANOVA and Tukey test) and * indicate significance compared to Nx 0: * 
p<0.05, ** p<0.01, *** p<0.001.  
 
To further investigate a potential change in total ERK1/2 levels in 
response to VPA treatment during pathological conditions, a reverse 
transcription quantitative real-time PCR assay was performed to 
quantify erk1/2 expression, using GAPDH levels as a control. The 
expression of erk1/2 increased significantly in cells undergoing gas and 
temperature stress, by 2.5±0.3 fold in untreated cells and by 2.8±0.4 
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fold in cells treated with 1mM VPA (Fig. 7). However, erk1/2 expression 
did not vary significantly depending on the presence of absence of VPA 
regardless of incubation conditions. The data therefore suggest that 
cells respond to stress conditions by increased erk1/2 expression but 
that VPA treatment does not have a significant effect on gene expression 
in stress or standard conditions. 
 
 
 
Figure 4.7 – Effect of VPA on ERK1/2 transcription in SH-SY5Y in hypoxia, 
hypercapnia, and hypothermia. SH-SY5Y cells were cultured under standard 
conditions (37°C, 5% CO2) receiving fresh medium 16h prior to the start of treatment. 
After VPA (1mM) or vehicle control (dH2O) was added to media, cells were transferred 
to stress conditions (2% O2, 10% CO2, 32°C; HxHcHp) for four hours. Control cells 
were treated with vehicle control (dH2O) or VPA as indicated and incubated 
concurrently in standard conditions (Normoxia; Nx). SH-SY5Y mRNA was extracted 
and cDNA produced which served as the template for quantitative real-time PCR to 
quantify erk1/2 expression (GAPDH expression was quantified as control). Data (n=3, 
technical duplicates) is presented as fold-change compared to untreated Nx samples. * 
indicate significance compared to Nx 0 unless otherwise indicated: * p<0.05, ** 
p<0.01, *** p<0.001; n.s. not significant. 
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4.3 Discussion 
In this chapter, four cell lines were exposed to haemorrhagic 
shock-like culture conditions of hypoxia (2% O2), hypercapnia (10% 
CO2), and hypothermia (32°C) in order to investigate whether any 
changes in GSK3β and ERK1/2 phosphorylation showed similarity to 
those observed in vivo during severe blood loss. Hepatic, nephric, and 
neuronal cell lines were selected in order to determine the similarity in 
signalling response to each host tissue respectively. Cells were treated 
with VPA to establish whether phosphorylation changed in the 
protective manner seen in animal models. The experiments discussed 
provide evidence for the suitability of selected cell lines as model 
systems for signalling in haemorrhagic shock. 
4.3.1  Stress conditions in Huh7  
Huh7 cells were exposed to hypoxia and hypercapnia to 
investigate any acute effects on GSK3β Ser9 and ERK1/2 
Thr202/Tyr204 phosphorylation. These gas conditions were selected as 
potential in vitro model components because one of the first effects of 
massive blood loss is tissue hypoperfusion (Peitzman et al., 1995) which 
causes cellular hypoxia (Rossaint et al., 2006) and hypercapnia 
(Johnson and Weil, 1991). Huh7 cells were cultured in severe hypoxia of 
2% oxygen (Miyamoto et al., 2015), which is approximately equal to 
2kPa, a value below the clinical threshold of 8kPa for significant [sic] 
hypoxia (Findlay et al., 2007). Carbon dioxide levels were increased 
during cell treatment to 10%, approximately equal to 10kPa, which is 
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above the in vivo clinical threshold for hypercapnia (6kPa; Findlay et al., 
2007). Under these adverse conditions total or phosphorylated GSK3β 
or ERK1/2 levels were unaffected. These results are dissimilar from 
those observed during haemorrhagic shock in vivo, where GSK3β 
phosphorylation is decreased (Alam et al., 2009; Hwabejire et al., 2014) 
and ERK1/2 phosphorylation is increased (Fukudome et al., 2010). 
Concurrent VPA treatment did not affect protein phosphorylation in 
Huh7, a result distinct from those observed in published work, where 
VPA has been shown to modulate both pGSK3β and pERK1/2 by 
increasing and reducing phosphorylation levels respectively. The data 
therefore suggest that Huh7 cells exposed to hypoxia and hypercapnia 
do not appropriately reflect the cellular conditions during haemorrhagic 
shock. 
As acute exposure of Huh7 to hypoxia and hypercapnia was not 
sufficient to produce the changes in protein phosphorylation observed 
in vivo, cells were exposed to adverse gas conditions in conjunction with 
suboptimal temperature (hypothermia). The presence of hypothermia, 
which often occurs spontaneously during or after massive blood loss, is 
associated with increased lethality in clinical practice (Shafi et al., 
2005). Cells were exposed to a temperature of 32°C which is classified 
as moderate hypothermia (Kheirbek et al., 2009) and beyond the clinical 
threshold for coagulopathy risk (Cosgriff et al., 1997) alongside the 
previously used adverse gas concentrations. Combined hypoxia, 
hypercapnia, and hypothermia significantly reduced GSK3β Ser9 
phosphorylation to 60% of normoxic levels. This reduction was reversed 
94 
 
in a dose-dependent manner during VPA treatment, to 91% of untreated 
normoxic control at a treatment concentration of 0.5mM and to 128% at 
0.75mM. These results mimic those found in vivo, where Hwabejire and 
colleagues (2014) showed that VPA dose-dependently reverses the 
decrease of GSK3β phosphorylation caused by blood loss within an 
acute time period (1-6h) in a rodent model of haemorrhagic shock. In 
this study, GSK3β phosphorylation was decreased by approximately 
65% by haemorrhagic shock, and rescued by VPA to approximately 
150% of healthy animal values. Recovery was dose-dependent, with 
higher doses of VPA resulting in increased protein phosphorylation. The 
changes in GSK3β phosphorylation observed in Huh7 therefore 
replicate those seen in vivo to a remarkable extent which suggests that 
culturing Huh7 in simultaneous hypoxia, hypercapnia, and 
hypothermia may simulate signalling changes seen in severe blood loss 
in vivo. 
Haemorrhagic shock-like conditions did not significantly affect 
ERK1/2 phosphorylation or total ERK1/2 levels in Huh7, nor did 
concurrent VPA treatment modulate these levels within four hours of 
treatment. These data contrast with a previously referenced study, in 
which Kochanek and colleagues (2012) showed that haemorrhagic 
shock increased ERK1/2 phosphorylation 2.5-fold after four hours in a 
Wistar-Kyoto rat model of shock, while VPA treatment induced a 
decrease of pERK1/2 to healthy levels. However, these researchers 
observed ERK1/2 regulation in lung and as the effects of haemorrhagic 
shock and VPA have been shown to be tissue-specific, data may vary 
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according to tissue types studied. This conclusion is supported by data 
presented by Patel et al. (2011), which demonstrates that pERK1/2 
increases more than 2-fold in Wistar-Kyoto rat liver after haemorrhagic 
shock and is attenuated by therapeutic intervention with VPA. However, 
data on pERK1/2 in Huh7 do not replicate those seen in rodent liver 
after haemorrhagic shock and was therefore not investigated further. 
To establish whether low oxygen, high carbon dioxide, and low 
temperature were sufficient, either individual or in paired treatment, to 
cause the reduction in pGSK3β observed during concurrent exposure, 
Huh7 cells were incubated in all possible adverse condition 
combinations for four hours. Only simultaneous exposure to all three 
treatments significantly reduced GSK3β Ser9 phosphorylation, while all 
other combinations had no significant effect. During lethal blood loss in 
vivo these three pathological changes cause and exacerbate each other 
in vivo (Gutierrez et al., 2004; Hotter et al., 2004; Kheirbek et al., 2009) 
and are therefore unlikely to occur individually during severe 
haemorrhage. These data suggest that this model system can be used to 
analyse cell signalling events in blood loss.  
4.3.2  Stress conditions in HepG2 and HEK293 
 To investigate whether the effect of adverse gas and temperature 
conditions on GSK3β phosphorylation in Huh7 could be replicated in 
another liver-derived cell line, HepG2 cells were exposed to these 
conditions for four hours with and without VPA treatment. In HepG2, 
neither adverse conditions nor VPA treatment significantly affected 
GSK3β phosphorylation. This difference in response to hypoxia, 
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hypercapnia, and hypothermia between Huh7 and HepG2 may be 
explained by differences in cell metabolism between cell lines. Dettmer 
and colleagues (2013) investigated metabolic regulation across a 
number of cell lines, including HepG2 and Huh7. Their analysis of 
relative amount of metabolites showed that these two cell lines differ in 
terms of kynurenine levels, which were higher in HepG2 than in Huh7. 
Kynurenine, a metabolite of tryptophan, has been of therapeutic 
interest as a GSK3β inhibitor in diabetes, cancer, affective disorders, 
and neurodegenerative diseases (Pele-Shulman et al., 2008). In the liver, 
kynurenine is produced by tryptophan-2,3-dioxygenase while 
indoleamine-2,3-dioxygenase performs this role in most other tissues 
(Stone and Darlington, 2013). It is therefore possible that the 
tryptophan-kynurenine pathway is targeted by distinctive regulatory 
mechanisms in the liver compared to other tissues, which could provide 
an explanation for the tissue-specific effect of VPA on GSK3β 
phosphorylation. A recent study indicated that the up-regulation of the 
kynurenine pathway may be a component in VPA action, as 
demonstrated by an increase in kynurenine levels in response to acute 
VPA treatment (Maciejak et al., 2013). This evidence combined 
highlights the possibility that the differences observed in pGSK3β 
between Huh7 and HepG2 in response to VPA treatment are due to 
different baseline activity of the kynurenine pathway. The difference in 
regulation may also play a part in the lack of change in pGSK3β 
observed in HepG2 in response to haemorrhagic shock-like conditions. 
Supporting evidence shows that both kynurenine and quinolinic acid (a 
kynurenine pathway metabolite) were increased in patients after 
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haemorrhage and therapeutic intervention (Heyes et al., 1995). This 
suggests that a high basal level of kynurenine in HepG2 may prevent a 
replication of the pathway response seen in vivo, which may affect 
regulation of GSK3β phosphorylation or VPA action. 
Differences in regulation of the kynurenine pathway are merely 
one potential cause for the distinct signalling responses observed in 
Huh7 and HepG2, as they also differ with regards to the presence of 
drug-metabolising enzymes as shown by Guo et al. (2010). This study 
analysed 251 enzymes in terms of their relative abundance in HepG2 
and Huh7, of which several are present in significantly different levels 
in the two cell lines under discussion. Any one of these enzymes may be 
a key component in the cellular reaction to haemorrhagic shock and/or 
VPA treatment and therefore be responsible for the signalling 
differences observed. Thorough investigation of these differences may 
therefore yield further insight into the effect of simulated blood loss on 
cellular signalling. However, as Huh7 closely replicates changes in 
pGSK3β observed in vivo, this cell line was selected for in-depth 
experimental investigation and, as the effect of adverse culture 
conditions and VPA treatment did not regulate GSK3β in HepG2 this 
manner, HepG2 cells were excluded from further modelling 
experiments. 
 In order to explore the possibility of modelling haemorrhagic 
shock signalling in a cell line derived from independent source tissue, 
the kidney-derived cell line HEK293 was exposed to haemorrhagic 
shock-like conditions and treated with VPA. Stress conditions did not 
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significantly affect pGSK3β levels, but simultaneous VPA treatment 
caused a significant increase of GSK3β phosphorylation up to 381±38% 
compared to untreated normoxic controls. Patel et al. (2012) observed a 
similar 3-fold increase in vivo in kidney in response to therapeutic 
intervention after acute injury, where pGSK3β is not affected in 
response to haemorrhagic shock. Results gained from a rat kidney, 
however, show that GSK3β is significantly reduced (by approximately 
40%) after haemorrhagic shock compared to healthy animals (Nandra et 
al., 2013). The decrease in pGSK3β in response to these conditions is 
not replicated in HEK293 cells. However, the animals used in this study 
were treated with erythropoietin for three days prior to haemorrhage, 
which may have affected signalling in a manner not seen in patients 
with severe blood loss. As GSK3β inhibitors have been shown to 
attenuate renal injury (Dugo et al., 2006) and GSK3β is highly 
phosphorylated at Ser9 and therefore inhibited in HEK293, further 
investigation into this cell line may determine whether it is suitable to 
model renal signalling during haemorrhagic shock.     
4.3.3  Stress conditions in SH-SY5Y 
 In SH-SY5Y cells exposed to hypoxia, hypercapnia, and 
hypothermia levels of pGSK3β did not change significantly. Concurrent 
treatment with VPA had no effect, regardless of concentration. Total 
GSK3β protein levels were unaffected both by adverse conditions and 
VPA treatment. In vivo studies on the effect of VPA on GSK3β pathway 
protein phosphorylation during haemorrhage and brain injury have 
focused on Akt (Sinn et al., 2007; Wang et al., 2013), therefore the 
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results described in this chapter cannot be compared directly. However, 
Akt phosphorylation is reduced in shock and increased in response to 
VPA, which may cause a concurrent increase and reduction of GSK3β 
phosphorylation respectively. No such change was observed in SH-SY5Y 
undergoing haemorrhagic shock-like conditions. This is in contrast with 
results from a study into VPA action in SH-SY5Y, which found that 
GSK3β was dose-dependently inhibited by VPA, as indicated by 
increased Ser9 phosphorylation and reduced kinase activity (Chen et 
al., 1999). Though this study was performed in standard cell culture 
conditions those data still diverge from the results discussed in this and 
the previous chapter, where VPA did not affect GSK3β regardless of 
culture environment. The differences seen between published data and 
those obtained in the experiments performed for this work show that 
the SH-SY5Y cell line did not replicate either in vivo or in vitro results. 
As the stress conditions used induce a change in GSK3β 
phosphorylation in Huh7 the lack of effect on pGSK3β in SH-SY5Y 
indicates that pathway regulation in response to adverse conditions is 
tissue specific. GSK3β Ser9 phosphorylation was therefore not further 
investigated in SH-SY5Y. 
 SH-SY5Y cells were then analysed for ERK1/2 phosphorylation 
and total protein level post-exposure to adverse conditions and VPA. 
Hypoxia, hypercapnia, and hypothermia did not significantly affect 
pERK1/2 (Thr202/Tyr204) compared to total ERK1/2 levels, but total 
ERK1/2 was significantly increased compared to β-tubulin loading 
control during VPA treatment (1mM) in haemorrhagic shock-like 
100 
 
conditions. In a related study, ERK1/2 phosphorylation was reduced in 
SH-SY5Y during simulated ischaemia and reperfusion (Zuo et al., 2006). 
However, these experiments were performed under combined glucose 
and oxygen deprivation to simulate ischaemic conditions. The presence 
of an additional stressor such as glucose deprivation may explain why 
these results differ from those discussed in this chapter. In vivo, VPA 
increases ERK1/2 phosphorylation in rat hippocampal neurons after 
traumatic brain injury (Dash et al., 2010), a result replicated in rat after 
intracerebral haemorrhage (Sinn et al., 2007). It is likely that cellular 
signalling in SH-SY5Y is modulated differently than that in mature 
whole brains and that this dissimilar regulation is the cause for the 
disparity in results. When Noël and colleagues (2015) exposed SH-SY5Y 
cells to hypothermia (30°C), they found that phosphorylated ERK1/2 
levels were reduced in response. It is possible that the combination of 
hypothermia with additional stressors prevented this change in 
pERK1/2 from occurring here. However, in all of the studies referenced 
above, total ERK1/2 levels were unaffected by stress conditions or 
therapeutic intervention. It is therefore unlikely that the data on 
ERK1/2 phosphorylation in SH-SY5Y discussed in this chapter 
replicate those seen in vivo.  
 To further investigate the effect of VPA treatment on total ERK1/2 
levels during haemorrhagic shock-like conditions, erk1/2 transcription 
levels were analysed utilising RT-PCR. Compared to untreated cells in 
standard culture, adverse conditions significantly increased erk1/2 
expression 2.5±0.3-fold. VPA treatment, however, did not significantly 
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modulate gene expression in standard or stress conditions compared to 
standard and stressed untreated cells respectively. This result contrasts 
with the previously discussed protein data, where VPA treatment does 
significantly increase ERK1/2 levels while stress conditions do not. This 
potential incongruity suggests that ERK1/2 may be post-
transcriptionally regulated in this model. The RNA-binding protein Hu 
antigen R (HuR), which regulates transport and stability of mRNAs 
containing AU-rich domains, is known to regulate both MEK-1 and 
ERK1/2 (Brennan and Steitz, 2001; Wang et al., 2010). HuR is involved 
in anti-apoptotic signalling and has been shown to mediate the cellular 
response to oxidative stress via MAPK phosphatase 1 (Abdelmohsen et 
al., 2007; Kuwano and Gorospe, 2008). This RNA-binding protein has 
also been studied in SH-SY5Y, where it regulates HSP70 in oxidative 
stress (Amadio et al., 2008). Therefore, Therefore, HuR may be involved 
in ERK1/2 signalling in haemorrhagic shock. Additionally, 
dysregulation of HuR has been implicated in a number of cancers 
(Blaxall et al., 2000; Danilin et al., 2010; Heinonen et al., 2005). 
Distinct modes of regulation of HuR in SH-SY5Y compared to the non-
immortalised cells found in vivo could potentially explain the differences 
in ERK1/2 regulation discussed in this chapter. Further investigation 
into HuR may therefore yield insight into ERK1/2 signalling in 
haemorrhagic shock-like conditions in SH-SY5Y. However, as the cell 
line did not accurately mimic the cellular response to severe blood loss 
in animal models, it was excluded from further experiments. 
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4.4 Summary 
In this chapter, exposure of cell lines to haemorrhagic shock-like 
conditions of hypoxia, hypercapnia, and hypothermia produced cell 
line-dependent responses in total protein level and protein 
phosphorylation. These three stress conditions combined induced a 
significant reduction of GSK3β phosphorylation in Huh7 which was 
dose-dependently reversed by VPA treatment. These data replicate those 
seen in animal models in vivo and accordingly suggest that the in vitro 
system discussed in this chapter accurately models the regulation of 
pGSK3β observed in haemorrhagic shock. Therefore, further 
investigations into associated signalling changes are necessary to 
establish the suitability of Huh7 as a model system for severe blood 
loss. 
Haemorrhagic shock-like conditions did not affect pGSK3β levels 
in HepG2, HEK293, or SH-SY5Y cells. However, concurrent VPA 
treatment increased pGSK3β levels 3.8-fold in HEK293 and increased 
total ERK1/2 levels in SH-SY5Y. The pGSK3β results from HEK293 
partially reproduced those seen in vivo, while further investigation of 
erk1/2 expression in SH-SY5Y suggested that post-transcriptional 
regulation may play a role in the effects observed. Signalling changes in 
these cell lines did not mimic those seen in the respective source 
tissues during haemorrhagic shock in animal models, and though 
either cell line may be used to gain insight into modulation of cell 
signalling during stress, both were excluded in favour of Huh7 which 
more accurately models in vivo signalling. 
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5 
Characterising the effect of 
haemorrhagic shock-like 
conditions and the VPA 
mechanism of action in Huh7 
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5.1 Introduction 
Haemorrhagic shock has a multitude of effects on an organism on 
a cellular level, as detrimental changes in the heart and vascular 
system leads to reduced tissue perfusion and oxygen transport which 
widely affects cellular processes (Angele et al., 2008). Lack of oxygen 
triggers anaerobic metabolism and carbon dioxide accumulates, leading 
to acidosis (Rossaint et al., 2006). This fall in pH alongside hypoxia, 
hypercapnia, and hypothermia causes cell stress, causing apoptosis 
and necrosis (Ulukaya et al., 2011). VPA prevents cell death via pro-
survival pathways in the liver after massive blood loss (Gonzales et al., 
2008; Hwabejire et al., 2014) but does not modulate acidosis (Alam et 
al., 2009). It was therefore of interest to establish how VPA affected 
these parameters in the in vitro model system under investigation. 
Haemorrhagic shock and VPA treatment affect cellular activity by 
inducing cytosolic signalling changes in affected cells in vivo. In liver 
cells after massive blood loss, GSK3β Ser9 phosphorylation is reduced 
(Alam et al., 2009), which correlates with increased activity. GSK3β, 
when active, contributes to the degradation of β-catenin (Manning et al., 
2007), the accumulation of which is associated with a pro-survival 
phenotype via induction of bcl-2 (Dahia, 2000). Akt, which inhibits 
GSK3β by phosphorylation at Ser9 (Frame et al., 2001; Buttrick and 
Wakefield, 2008), is dephosphorylated at Ser473 and thereby 
inactivated during blood loss conditions (Alessi et al., 1996; Hwabejire 
et al., 2014). Akt phosphorylation at Ser473 is mediated by PI3K, which 
in turn is inhibited by PTEN (Maehama and Dixon, 1998) and itself 
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inhibited by phosphorylation (Ross and Gericke, 2009). PTEN activity 
therefore decreases Akt activity (Stambolic et al., 1998) leading to 
increased GSK3β action which, by the degradation of β-catenin, leads to 
increased apoptosis. This process is reversed by VPA treatment in vivo 
(Hwabejire et al., 2014; Li et al., 2008; Zacharias et al., 2011). PTEN, 
Akt, and β-catenin are therefore prime targets for investigation of the 
suitability of Huh7 in adverse culture conditions as a model for 
haemorrhagic shock signalling. 
In addition to cytosolic changes VPA treatment also modulates 
nuclear histone acetylation during massive blood loss (Li et al., 2011) by 
inhibiting histone deacetylases (HDACs; Gurvich et al., 2004; Marinova 
et al., 2009; Phiel et al., 2001; Sinn et al., 2007). HDACs remove acetyl 
groups from histone amino acid residues (Thiagalingam et al., 2006), 
thereby increasing the abundance of tightly packed heterochromatin 
(De Rujiter et al., 2003) which is inaccessible to transcription 
machinery. In haemorrhagic shock, VPA treatment induces histone 3 
lysine 9 acetylation which increases the amount of loosely packed 
euchromatin available to gene transcription machinery (Butt et al., 
2009; Gonzales et al., 2008). Although there is evidence that HDAC 
inhibitors structurally unlike VPA have pro-survival effects in 
haemorrhagic shock (Lin et al., 2007; Shults et al., 2014; Zacharias et 
al., 2011), there is also evidence to suggest HDAC inhibitory activity is 
not sufficient to mimic the beneficial effects of VPA (Dash et al., 2010). 
This suggests that VPA may act through a separate mechanism to 
attenuate the effects of haemorrhagic shock. Investigation of the effect 
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of haemorrhagic shock-like conditions and concurrent VPA treatment 
on histone acetylation in Huh7 was therefore of interest in order to 
further characterise this cell line as model of massive blood loss. 
In this chapter, the mechanism of VPA in providing protection 
against haemorrhagic shock-like signalling was investigated. Changes 
in response to stress conditions and concurrent VPA treatment in 
acidosis, cell viability, necrosis and apoptosis were quantified alongside 
their effects on cytosolic signalling and their impact on nuclear histone 
acetylation. These data were obtained to further characterise Huh7 as a 
potential in vitro model for haemorrhagic show and to allow comparison 
with the changes observed in animal models of severe blood loss to 
further indicate the suitability of this Huh7-dependent system as a 
model system. 
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5.2 Results 
5.2.1  Huh7 cell state and viability 
 VPA treatment after haemorrhagic shock in vivo decreases the 
expression of genes which modulate necrosis (Dekker et al., 2014) and 
reduces the size of necrotic lesions (Sinn et al., 2007). To investigate the 
effect of VPA treatment on necrosis an assay was performed to indicate 
the production of LDH, a necrosis marker enzyme, in Huh7 cells after 
exposure to stress culture conditions (Fig. 2). Surprisingly, these 
conditions significantly reduced LDH release to 58±5% compared to 
untreated cells undergoing normoxic conditions. VPA treatment 
significantly reduced LDH release regardless of culture conditions, to 
61±9% in normoxia compared to untreated cells, and to 63±6% of 
untreated cells undergoing adverse conditions in hypoxia, hypercapnia, 
and hypothermia (37±7% of untreated normoxia control). These data 
suggest that VPA protects Huh7 cells from necrosis regardless of 
culture conditions.   
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Figure 5.1 – Effect of hypoxia, hypercapnia, and hypothermia with concurrent 
VPA treatment on LDH release in Huh7. Huh7 cells were grown under standard 
conditions (37°C, 5% CO2) receiving fresh medium 16h prior to the start of treatment. 
Cells were treated with VPA (0.75mM) or vehicle control (dH2O) and exposed for four 
hours to standard cell culture conditions (Nx) or to haemorrhagic shock-like 
conditions (HxHcHp; 2% O2, 10% CO2, 37°C) as indicated. At treatment end point, cell 
culture medium analysed. LDH presence was investigated by measuring formazan 
formation, where increase in LDH resulted in increased formazan levels and therefore 
increased light absorbance at 490nm. Data (n=5, technical triplicates) were analysed 
using ANOVA and Tukey test. * indicate significance compared to Nx 0 unless 
otherwise indicated: * p<0.05, ** p<0.01, *** p<0.001. HxHcHp significantly (p<0.001) 
reduced LDH release compared to untreated Nx control. 
Haemorrhagic shock induces apoptosis and reduces cell viability, 
changes which are partially blocked by VPA treatment in rat liver, 
porcine brain, and rat kidney (Butt et al., 2009; Dekker et al., 2014; 
Zacharias et al., 2011). To study how haemorrhagic shock-like 
conditions affect Huh7 with regards to three enzymatic measures for 
cell state, cells were exposed to these conditions and analysed for 
viability, cytoxicity, and apoptosis. Viability was measured via cleavage 
of a specific substrate that is only performed by live cells, Cytotoxicity 
was measured by amount of substrate cleaved outside of cells by 
protease leaked from dead cells, and apoptosis was quantified via 
measurement of caspase-3/7 activity (Fig. 3).  In normoxic conditions, 
VPA treatment did not affect cell viability, cytotoxicity, or apoptosis. 
Hypoxia, hypercapnia, and hypothermia did not significantly affect 
viability or cytotoxicity either, regardless of VPA treatment. However, 
these conditions significantly (p<0.01) increased apoptosis by 15±4%, 
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which concurrent VPA treatment reduced by 28±5% to a level of activity 
significantly (p<0.001) lower than that seen in untreated cells both in 
stress and in standard conditions. These results suggest that while the 
haemorrhagic shock-like model environment investigated does not affect 
cell membrane integrity within four hours, it does increase apoptotic 
signalling; an effect which is reversed if cells are simultaneously 
exposed to VPA. The data therefore provide evidence for an anti-
apoptotic effect of VPA in Huh7 cells undergoing hypoxia, hypercapnia, 
and hypothermia. 
 
Figure 5.2 – Effect of hypoxia, hypercapnia, and hypothermia with concurrent 
VPA treatment on Huh7 cell viability, cytotoxicity, and apoptosis. Huh7 cells 
were grown under standard conditions (37°C, 5% CO2) receiving fresh medium 16h 
prior to the start of treatment. Cells were then treated with VPA (0.75mM) or vehicle 
control (dH2O) and exposed for four hours to standard cell culture conditions (Nx) or to 
haemorrhagic shock-like conditions (HxHcHp; 2% O2, 10% CO2, 37°C) as indicated. 
Indicators of cell state (Viability, Cytotoxicity, and Apoptosis) were measured as in-well 
enzyme activity using a commercial assay (Promega). Briefly, substrate for the viability 
measure crosses cell membranes and is cleaved by a live-cell protease to yield 
fluorescence while substrate for the cytotoxicity measure cannot cross cell membranes 
and is cleaved to yield fluorescence by dead-cell protease leaked from dead cells which 
have lost membrane integrity. Apoptosis is investigated by addition of substrate for 
caspase-3/7 activity which luminesces when cleaved. Signal from cell state reactions 
was measured in arbitrary fluorescent units (AFU) for viability and cytotoxicity and 
arbitrary luminescence units (ALU) for apoptosis. Data (n=5, technical triplicates) were 
statistically analysed using ANOVA and Bonferroni test and compared to values from 
untreated Nx cells. * indicate significance: * p<0.05, ** p<0.01, *** p<0.001. 
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Haemorrhagic shock in vivo causes acidosis – a reduction of pH 
below 7.1 (Angele et al., 2008) – but this effect is not reversed by VPA 
treatment (Alam et al., 2009). Huh7 cells were therefore exposed to 
haemorrhagic shock-like conditions of hypoxia, hypercapnia, and 
hypothermia to investigate the effect of these conditions and concurrent 
VPA treatment on culture medium pH (Fig. 3). The haemorrhagic shock-
like conditions of hypoxia (2% O2), hypercapnia (10% CO2), and 
hypothermia (32°C) significantly reduced pH in Huh7 culture medium 
to 6.80±0.05 from 7.73±0.03 measured in standard (normoxic) 
conditions. These results suggest that VPA treatment does not 
significantly affect environmental (media) pH in standard or adverse 
culture conditions.  
 
Figure 5.3 – Effect of hypoxia, hypercapnia, and hypothermia with concurrent 
VPA treatment on Huh7 culture media pH. Huh7 cells were grown under standard 
conditions (37°C, 5% CO2) receiving fresh medium 16h prior to the start of treatment. 
Cells were treated with VPA (0.75mM) or vehicle control (dH2O) and exposed for four 
hours to standard cell culture conditions (Nx) or to haemorrhagic shock-like 
conditions (HxHcHp; 2% O2, 10% CO2, 37°C) as indicated, after which pH was 
measured in culture medium. Data (n=5, technical triplicates) are presented as mean 
± SEM and were statistically analysed (ANOVA and Tukey test). * indicate significance 
compared to Nx 0 unless otherwirse indicated: * p<0.05, ** p<0.01, *** p<0.001; n.s. 
not significant. 
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5.2.2  Cytosolic signalling in haemorrhagic shock-like 
conditions 
Since earlier experiments described in this work indicated an 
inhibiting effect of VPA on GSK3β Ser9 phosphorylation, a range of 
experiments were employed to investigate the signalling mechanism 
leading to this result. First, the effect of haemorrhagic shock-like 
conditions and concurrent VPA treatment on PTEN regulation was 
examined. PTEN indirectly regulates GSK3β, as it drives 
dephosphorylation of PIP3 to PIP2, opposing PI3K action, which induces 
Akt activity, which in turn phosphorylates GSK3β at Ser9, thereby 
inhibiting this enzyme (Frame et al., 2001; Buttrick and Wakefield, 
2008; Maehama and Dixon, 1998; Stambolic et al., 1998). As PTEN may 
be inhibited by phosphorylation itself (Rahdar et al., 2009; Ross and 
Gericke, 2009; Vazquez et al., 2001), total and phosphorylated PTEN 
abundance in protein extract from Huh7 cells was measured (Fig. 4). 
Hypoxia, hypercapnia, and hypothermia significantly increased PTEN 
levels to 140±12% compared to normoxic control, but VPA treatment did 
not affect total PTEN regardless of culture environment. However, a 
significant decrease in PTEN phosphorylation (to 69±9% of normoxia) 
caused by stress conditions was prevented by VPA (at 89±4% of 
normoxia). These results suggest that VPA blocks a drop in PTEN 
phosphorylation caused by simulated severe blood loss conditions, 
which increase total protein level, thereby potentially inducing 
heightened protein activity. 
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Figure 5.4 – Effect of hypoxia, hypercapnia, and hypothermia with concurrent 
VPA treatment on PTEN levels and phosphorylation in Huh7. Huh7 cells were 
grown under standard conditions (37°C, 5% CO2) receiving fresh medium 16h prior to 
the start of treatment. Cells were then treated with VPA or vehicle control (dH2O) and 
exposed for four hours to standard cell culture conditions (Nx) or to haemorrhagic 
shock-like conditions (HxHcHp; 2% O2, 10% CO2, 37°C) as indicated. Protein extract 
was probed with phosphorylated PTEN (pPTEN; Ser380/Thr382/Thr383) and total 
PTEN (tPTEN) antibodies. Levels of β-actin served as loading control. GSK3β 
fluorescence was corrected for loading differences with β-actin. Total protein levels 
were calculated as ratio to β-actin and phosphorylated protein levels were calculated 
as ratio to total protein compared to levels in untreated Nx. Data (n=5, technical 
triplicates) are shown as mean ± SEM and were statistically analysed using ANOVA 
and Tukey test. * indicate significance compared to Nx 0 unless otherwise indicated: * 
p<0.05, ** p<0.01, *** p<0.001. 
 
PTEN provides a critical role in regulating downstream Akt, the 
activity of which is inhibited by haemorrhagic shock via decreased 
Ser473 phosphorylation, an effect prevented by VPA treatment 
(Hwabejire et al., 2014). To determine whether Akt responded similarly 
to haemorrhagic shock-like conditions in vitro, total and phosphorylated 
Akt levels from Huh7 cells exposed to hypoxia, hypercapnia, and 
hypothermia with concurrent VPA treatment were quantified (Fig. 5). 
Exposure of Huh7 to these conditions significantly increased total levels 
of Akt to 162±19% of normoxia control with no effect of VPA treatment 
regardless of culture environment. Hypoxia, hypercapnia, and 
hypothermia significantly reduced Akt Ser473 phosphorylation to 
60±6% of normoxia control. This effect was reversed by concurrent VPA 
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treatment, which increased phosphorylation levels to 87±5% of 
untreated normoxia control (145±5% of untreated hypoxia, hypercapnia, 
and hypothermia control). These data suggest that adverse gas and 
temperature culture conditions increase Akt levels while decreasing 
phosphorylation, suggesting reduced kinase activity, and that this effect 
is reversed by simultaneous VPA treatment. 
 
 
 
 
 
 
Figure 5.5 – Effect of hypoxia, hypercapnia, and hypothermia with concurrent 
VPA treatment on Akt levels and phosphorylation in Huh7. Huh7 cells were grown 
under standard conditions (37°C, 5% CO2) receiving fresh medium 16h prior to the 
start of treatment. Cells were then treated with VPA or vehicle control (dH2O) and 
exposed for four hours to standard cell culture conditions (Nx) or to haemorrhagic 
shock-like conditions (HxHcHp; 2% O2, 10% CO2, 37°C) as indicated. Protein extract 
was probed with phosphorylated Akt (pAkt; Ser473) and total Akt (tAkt) antibodies. 
Levels of β-actin served as loading control. GSK3β fluorescence was corrected for 
loading differences with β-actin. Total protein levels were calculated as ratio to β-actin 
and phosphorylated protein levels were calculated as ratio to total protein compared to 
levels in untreated Nx. Data (n=5, technical triplicates) are shown as mean ± SEM and 
were statistically analysed using ANOVA and Tukey test. * indicate significance 
compared to Nx 0 unless otherwise indicated: * p<0.05, ** p<0.01, *** p<0.001. 
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The inhibition of GSK3β by VPA leads to an increase of β-catenin 
abundance, as active GSK3β primes β-catenin for ubiquitination and 
degradation (Liu et al., 1999). This accumulation of β-catenin is 
associated with a pro-survival phenotype after severe blood loss (Alam 
et al., 2009; Beurel and Jope, 2006). To determine whether 
haemorrhagic shock-like conditions affect β-catenin in vitro, total β-
catenin levels were investigated in Huh7 treated with VPA during stress 
conditions (Fig. 6). Hypoxia, hypercapnia, and hypothermia significantly 
reduced β-catenin levels in Huh7 to 59±7% compared to Huh7 cultured 
in standard conditions. Concurrent VPA treatment blocked this trend 
and increased total β-catenin levels to 91±5% of control. These results 
provide evidence that VPA prevents the decrease of β-catenin levels in 
Huh7 caused by a haemorrhagic shock-like culture environment. 
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Figure 5.6 – Effect of hypoxia, hypercapnia, and hypothermia with concurrent 
VPA treatment on β-catenin levels in Huh7. Huh7 cells were grown under standard 
conditions (37°C, 5% CO2) receiving fresh medium 16h prior to the start of treatment. 
Cells were then treated with VPA or vehicle control (dH2O) and exposed for four hours 
to standard cell culture conditions (Nx) or to haemorrhagic shock-like conditions 
(HxHcHp; 2% O2, 10% CO2, 37°C) as indicated. Protein extract was probed with β-
catenin and β-tubulin antibodies, the latter serving as loading control. Total protein 
levels were calculated as ratio to β-tubulin and compared to β-catenin levels in 
untreated cells in Nx. Data (n=5, technical triplicates) are shown as mean ± SEM and 
were statistically analysed using ANOVA and Tukey test. * indicate significance: * 
p<0.05, ** p<0.01, *** p<0.001. 
 
5.2.3  VPA regulates histone acetylation 
The protective pro-survival effects of VPA treatment in animal 
models of haemorrhagic shock have been attributed to histone 
deacetylase inhibition, as VPA increases H3K9 acetylation in vivo (Butt 
et al., 2009; Gonzales et al., 2008; Sinn et al., 2007; Zacharias et al., 
2011). To examine the effect of VPA on histone regulation in Huh7 
undergoing haemorrhagic shock-like conditions, cell extract was 
quantified for histone acetylation levels in the presence and absence of 
VPA (Fig. 7). In normoxia, VPA treatment significantly (p<0.01) 
increased H4 lysine acetylation in normoxic culture conditions (to 
406±39% compared to untreated control), but not H2/3 acetylation. In 
hypoxia, hypercapnia, and hypothermia, histone acetylation was 
0 0.75 0 0.75
0
50
100
150
Nx HxHcHp
VPA (mM)
β-catenin
β-tubulin
**
*
β-
c
a
te
n
in
 (
%
 N
x
)
116 
 
unchanged. VPA treatment in these stress conditions significantly 
(p<0.01) increased the level of H4 acetylation compared to untreated 
cells, to an extent not significantly different to that observed during VPA 
treatment in normoxia (395±116%). However, exposure to VPA 
significantly (p<0.001) increased H2/3 acetylation in stress conditions 
to 681±124%, a value significantly higher that seen in normoxia, both 
in the presence and absence of VPA. These data demonstrate that 
regulation of H4 acetylation by VPA independent of culture 
environment. This is in contrast to the effect of VPA on H2/3 
acetylation, which is not affected in normoxia but observed to be 
significantly increased in cells exposed to hypoxia, hypercapnia, and 
hypothermia.  
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Figure 5.7 – Effect of hypoxia, hypercapnia, and hypothermia with concurrent 
VPA treatment on histone acetylation in Huh7. Huh7 cells were grown under 
standard conditions (37°C, 5% CO2) receiving fresh medium 16h prior to the start of 
treatment. Cells were then treated with VPA or vehicle control (dH2O) and exposed for 
four hours to standard cell culture conditions (Nx) or to haemorrhagic shock-like 
conditions (HxHcHp; 2% O2, 10% CO2, 37°C) as indicated. Protein extract was probed 
with acetylated lysine and β-tubulin antibodies, the latter serving as loading control. 
Total acetylation levels were calculated as ratio to β-tubulin and compared to 
acetylation levels in untreated cells in Nx. Data (n=5, technical triplicates) are shown 
as mean ± SEM and were statistically analysed using ANOVA and Bonferroni test. * 
indicate significance compared to Nx 0 unless otherwise indicated: * p<0.05, ** 
p<0.01, *** p<0.001; n.s. not significant. 
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5.3 Discussion 
5.3.1  Huh7 cell state and viability 
In order to investigate the translational accuracy of Huh7 cells 
undergoing hypoxia, hypercapnia, and hypothermia as a model of 
haemorrhagic shock signalling, the effect of these stress conditions on 
cells was investigated in the presence or absence of VPA. In whole 
animal models, haemorrhage and shock have several negative effects on 
a cellular level. Firstly, inadequate tissue perfusion and a drop in 
oxygen levels induces anaerobic metabolism and therefore the 
accumulation of carbon dioxide, which leads to acidosis, a pathology so 
consequential it is billed as part of the lethal triad of haemorrhagic 
shock (Rossaint et al., 2006). Secondly, adverse tissue state increases 
necrosis, and thirdly, cellular stress induces apoptosis, which may 
continue after animal resuscitation and therefore have a delayed effect 
(Ulukaya et al., 2011). These parameters of cell state and viability were 
analysed in Huh7 in order to further characterise the proposed model 
system. 
Severe blood loss causes acidosis (Alam et al., 2009; Angele et al., 
2008; Hess and Holcomb, 2008), which negatively affects cell viability 
(Gores et al., 1989). VPA treatment does not affect acidosis in animal 
models (Alam et al., 2009) and therefore likely promotes cell survival by 
an independent mechanism. The pH of culture medium of Huh7 
undergoing hypoxia, hypercapnia, and hypothermia fell to below the 
clinical acidosis threshold to 6.80±0.05, mimicking conditions in vivo. 
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This decrease was not reversed by VPA treatment, which was 
comparable to the lack of impact on pH by VPA observed in whole 
animal models. This result suggests that any beneficial effects observed 
in Huh7 in response to VPA were not mediated by a change in pH, 
analogous to in vivo results. 
Cellular stress caused by hypoxia during haemorrhagic shock has 
been observed to cause necrosis in human liver (Helling, 2005; Ulukaya 
et al., 2011). VPA has been shown to protect against necrotic processes 
in a swine model of haemorrhage as indicated by a decrease in necrotic 
gene expression (Dekker et al., 2014). VPA also attenuated necrosis in a 
rat model of septic shock (Shang et al., 2010) and protected against 
perihematomal cell death in intracerebral haemorrhage (Sinn et al., 
2007). However, there are some conflicting data from an ex vivo study 
on rat hepatocytes, where VPA treatment increased lactate 
dehydrogenase (LDH) release, a marker for necrosis (Kiang et al., 2010). 
This disparity may be explained by a difference in culture environment, 
as the primary hepatocytes in this study were not exposed to stress 
conditions. Necrosis can be analysed by measuring LDH activity in 
culture medium, which is leaked from dead cells (Ulukaya et al., 2011). 
Therefore, LDH release into Huh7 culture medium was investigated 
during stress conditions. VPA reduced LDH activity in cells undergoing 
both standard and adverse culture conditions, suggesting a decrease in 
necrosis similar to that observed in vivo. However, LDH activity was also 
reduced in cells exposed to stress conditions compared to those 
incubated in normoxia. These data may be explained by the complexity 
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of the pathological model environment used. Though ischaemia and 
concurrent hypoxia cause necrosis, hypothermia and acidosis have 
been shown to protect against and delay the hypoxia-induced necrotic 
process within an acute time frame respectively (Gores et al., 1989; Hale 
et al., 1997). To understand how these processes may attenuate each 
other, the underlying mechanism of ATP metabolism must be 
discussed. 
One contributing cause of cellular effects during haemorrhagic 
shock is the process of ATP depletion caused by a change in cellular 
metabolism in response to blood loss. During haemorrhage, reduced 
tissue perfusion leads to a decrease in oxygen delivery while cellular 
oxygen uptake remains constant (Kheirbek et al., 2009). Though 
compensatory mechanisms exist, these reach their limits during severe 
blood loss, necessitating a switch from aerobic to anaerobic metabolism 
in cells (Shoemaker, 1996). As cells are in a pathological (hypoxic, 
hypovolemic) state, ATP use exceeds ATP production, leading to ATP 
depletion and cell death (Keller et al., 2002; Kheirbek et al., 2009). 
Though this process continues unless prevented by resuscitation, the 
speed of progression may be affected by intra- and extra-cellular 
conditions such as acidosis and hypothermia. Both of these conditions 
were present in Huh7 cells undergoing haemorrhagic shock-like 
conditions and may therefore have affected cell death and LDH release. 
Hypothermia may be beneficial or harmful in vivo, depending on 
timing and severity. Controlled hypothermia, as used in elective 
surgery, has long been known to be improve patient outcome and also 
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protects against a decrease in ATP levels (Kheirbek et al., 2009). 
Spontaneous hypothermia caused by a slowing of ATP metabolism 
during haemorrhagic shock, however, is associated with an increase in 
patient death (Rossaint et al., 2006). These two cases of hypothermia 
differ primarily in terms of time of onset: surgical hypothermia is 
induced prior to any potential ischaemia, while spontaneous 
hypothermia occurs after and because of haemorrhage (Kheirbek et al., 
2009; Midwinter, 2009). In the model system discussed, Huh7 were 
exposed to hypothermia alongside hypoxia and hypercapnia, which may 
have increased the protective effect of hypothermia, compared to a 
delayed onset of temperature reduction and therefore may explain the 
reduction in LDH release. Huh7 cells were also exposed to mild to 
moderate hypothermia, which is less likely to be harmful to patients in 
vivo (Kheirbek et al., 2009) and is commonly used as a protective 
technique (Hale et al., 1997; Jin et al., 2014; Miyauchi et al., 2014), 
supporting the hypothesis that hypothermia may protect Huh7 cells 
against death in this model. Therefore, both timing and severity of 
hypothermia in the Huh7 model system may provide protective cellular 
effects. However, as VPA action reduces LDH release, which indicates 
anti-necrotic action, in Huh7 and this result mimics those observed in 
vivo, the timing and severity of hypothermia induction was preserved. 
Acidosis may also protect Huh7 cells against cell death and 
therefore lead to a decrease in LDH release and activity. Intracellular 
acidosis has been shown to delay cell death after ATP depletion (Gores 
et al., 1989), but this protective effect of acidosis is time-limited and 
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does not ultimately prevent cell death. As cells are exposed to acidosis 
in the Huh7 model of haemorrhagic shock-signalling, the low pH may 
protect against necrosis in this system. As VPA does not affect culture 
medium pH, cells may benefit from this protective mechanism 
regardless of concurrent treatment, suggesting that LDH release in VPA-
treated cells may be further reduced due to this combination of 
protective environmental condition and VPA treatment. However, 
though the preventative delaying effect of acidosis on LDH release and 
therefore necrosis is relevant within the acute time period under 
investigation, the selected conditions may ultimately overcome this 
protection via apoptotic mechanisms. 
To further analyse the effect of hypoxia, hypercapnia, and 
hypothermia on cell state, marker enzyme activity in Huh7 was 
measured to investigate cell viability, cytotoxicity, and apoptosis. Cell 
viability and cytotoxicity measures depended on conserved and lost cell 
membrane integrity respectively. The substrate used in the viability 
measure may cross the cell membrane to be cleaved by a live cell 
protease, while the substrate for the cytotoxicity measure cannot and is 
therefore only cleaved by cell protease leaked from dead cells. Neither 
measure was affected by hypoxia, hypercapnia, and hypothermia with 
or without concurrent VPA treatment. Apoptosis, indicated by the 
activity of caspase-3/7, was increased during adverse culture 
conditions and decreased by simultaneous VPA treatment. Apoptosis 
may be caused by oxidative stress (Ulukaya et al., 2011), which occurs 
during haemorrhage (Angele et al., 2008), and against which VPA has 
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been demonstrated to be protective (Lee et al., 2014). The increase of 
apoptosis during haemorrhagic shock-like conditions and the 
modulating effect of concurrent VPA treatment therefore suggest that 
VPA protects against apoptosis in the Huh7 model of severe blood loss 
in a manner analogous to the pro-survival action observed in vivo. 
5.3.2  Cytosolic signalling in haemorrhagic shock-like 
conditions 
GSK3β is regulated and modulated by a number of signalling 
pathways (Jope et al., 2007; Katoh and Katoh, 2006; Phukan et al., 
2010; Wu and Pan, 2010) and several interacting enzymes have been 
implicated in the beneficial effects of VPA treatment in lethal blood loss.  
During haemorrhagic shock in vivo, GSK3β phosphorylation and Akt 
phosphorylation as well as total levels of β-catenin are reduced (Alam et 
al., 2009; Hwabejire et al., 2014; Li et al., 2008). PTEN may modulate 
these changes via activity antagonistic to PI3K, which induces Akt 
phosphorylation by PIP3 production, thereby affecting GSK3β and β-
catenin activity (Hwabejire et al., 2014; Wang et al., 2011). GSK3β 
phosphorylation in Huh7 undergoing haemorrhagic shock-like 
conditions and VPA treatment mimics the in vivo response, the 
experiments in this chapter investigated changes to PTEN, Akt, and β-
catenin to yield further insight into effects on cytosolic signalling. 
 In this chapter, the effect of hypoxia, hypercapnia, and 
hypothermia with concurrent VPA treatment on PTEN levels and 
phosphorylation in Huh7 was investigated. PTEN, like GSK3β, is 
inhibited by phosphorylation, at Ser380/Thr382/Thr383 (Rahdar et al., 
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2009; Torres and Polido, 2001; Vazquez et al., 2001). In a mouse model 
of traumatic brain injury, PTEN phosphorylation was observed to be 
decreased after ischaemia but increased after therapeutic intervention 
with Scriptaid, a HDAC inhibitor (Wag et al., 2013). In a rat model of 
haemorrhagic shock, phosphorylation of Akt and GSK3β, which are 
downstream of PTEN in this signalling pathway and indirectly regulated 
by its activity, is reduced after severe blood loss and this effect is 
attenuated by VPA treatment (Hwabejire et al., 2014). In Huh7, 
haemorrhagic shock-like conditions increased total PTEN abundance, 
but decreased PTEN phosphorylation. VPA did not significantly affect 
total PTEN abundance but did prevent the fall in pPTEN levels. 
Therefore, the combined increase of total protein level and decrease in 
protein phosphorylation suggests PTEN activity increases in Huh7 
during haemorrhagic shock-like conditions. As observed in vivo, VPA 
treatment inhibits both GSK3β and PTEN activity in Huh7 undergoing 
these conditions by increasing protein phosphorylation. These data 
provide evidence that the regulation of PTEN signalling in Huh7 in 
haemorrhagic shock-like conditions functions analogously to that 
observed during haemorrhagic shock in vivo. 
 The literature on potential direct or indirect interaction between 
VPA and PTEN is scarce. VPA has been shown to increase PTEN 
expression in human prostate and ovarian cancer (Gravina et al., 2009; 
Lin et al., 2008) and in the macrophage-like RAW 264.7 cell line, 
thereby inhibiting components of the lipopolysaccharide-induced 
inflammatory response (Jambalganiin et al., 2014). There is as yet no 
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published data on the effect of VPA on PTEN phosphorylation. However, 
VPA has widely been investigated in connection with PI3K and PIP3 
signalling, which may indirectly inform further work involving PTEN 
regulation. PI3K phosphorylates PIP2 to the PIP3, a second messenger 
for Akt (Delcommenne et al., 1998; Toker and Cantley, 1997). This 
process is balanced by PTEN activity, which dephosphorylates PIP3 to 
PIP2 (Maehama and Dixon, 1998). VPA has been shown to prevent a 
reduction in PIP3 signalling during seizures (Chang et al., 2014; Xu et 
al., 2007), and to act in the regulation of inositol phosphates in bipolar 
disorder (Williams et al., 2002; Harwood and Agam, 2003). While this 
evidence may implicate PTEN action in pathologies as diverse as 
haemorrhagic shock, epilepsy, and bipolar disorder, the published 
evidence does not provide an explanation for the mechanism through 
which VPA acts on PTEN. Therefore, further investigation is needed to 
determine how PTEN may be regulated by VPA in the Huh7 model of 
haemorrhagic shock. 
As discussed, PTEN inhibits Akt indirectly by dephosphorylateion 
of PIP3 to PIP2 (Stambolic et al., 1998) which leads to a reduction in 
GSK3β Ser9 phosphorylation. An increase in PTEN activity in stress 
conditions would therefore be expected to decrease Akt activity by 
inhibiting phosphorylation at Ser473 and concurrent activation (Alessi 
et al., 1996). To investigate whether Akt is regulated in a manner 
similar to PTEN and GSK3β during hypoxia, hypercapnia, and 
hypothermia, total and phosphorylated protein levels in Huh7 were 
analysed. These stress conditions increased total Akt levels and 
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decreased Akt phosphorylation. VPA treatment did not affect total Akt 
levels in these conditions, but it did significantly increase Akt 
phosphorylation at Ser473. The decrease in pAkt induced by hypoxia, 
hypercapnia, and hypothermia suggests a reduction of Akt activity, 
which correlates with an increase in PTEN and GSK3β activity and 
mimics results seen in haemorrhagic shock in vivo (Hwabejire et al., 
2014). These results suggest that haemorrhagic shock-like conditions 
and VPA treatment regulate GSK3β phosphorylation via Akt 
modulation.  
 Levels of β-catenin are reduced in animal models during severe 
blood loss and rescued by concurrent VPA treatment (Alam et al., 2009; 
Li et al., 2008). As β-catenin is primed for degradation by GSK3β (Hart 
et al., 1998; Kitagawa et al., 1999; Liu et al., 1999), levels of total β-
catenin were measured in Huh7 undergoing severe blood loss-like 
conditions with simultaneous VPA treatment. Exposure of cells to 
hypoxia, hypercapnia, and hypothermia induced a significant decrease 
in β-catenin levels, while concurrent VPA treatment protected against 
this change. These results mimic those observed in vivo and therefore 
suggest that β-catenin regulation in Huh7 during haemorrhagic shock-
like conditions appropriately models that seen in animal models. 
 In Huh7 undergoing haemorrhagic shock-like conditions enzyme 
activation is regulated in a manner distinct from that observed Huh7 
cells cultured in standard conditions and this regulation is further 
modulated by concurrent VPA treatment (Fig. 8). PTEN and Akt 
phosphorylation is decreased, which may contribute to the concurrent 
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decrease in GSK3β phosphorylation discussed in the previous chapter. 
These changes in signalling may contribute to the degradation of β-
catenin also observed in adverse culture conditions. VPA treatment 
reverses the balance on PTEN, Akt, and (as previously discussed) 
GSK3β phosphorylation, as well as increasing total levels of β-catenin. 
Inhibition and activation of this pathway is analogous to the pathway 
regulation observed during haemorrhagic shock and concurrent VPA 
treatment in vivo, which provides evidence for the suitability of Huh7 
undergoing hypoxia, hypercapnia, and hypothermia as a model for 
cytosolic signalling during haemorrhagic shock. 
 
 
 
 
 
 
Figure 5.8 – Summary of enzyme regulation in Huh7 undergoing haemorrhagic 
shock-like conditions with or without VPA treatment. The experiments discussed 
in this chapter show that adverse culture conditions lead to a reduction of PTEN, Akt, 
and GSK3β phosphorylation as well as total β-catenin levels in Huh7. Simultaneous 
VPA treatment reverses the balance of enzyme activity by inducing PTEN, Akt, and 
GSK3β phosphorylation and β-catenin accumulation. Regulation of this pathway 
mimics results observed during haemorrhagic shock in vivo. 
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5.3.3  VPA regulates histone acetylation 
VPA treatment increases H3K9 acetylation during haemorrhagic 
shock in vivo and much of the beneficial pro-survival effect of VPA has 
been attributed to its action as a histone deacetylase (HDAC) inhibitor 
(Butt et al., 2009; Shults et al., 2011; Zacharias et al., 2011). VPA 
inhibits both predominantly nuclear and cytosolic HDACs directly, 
which may explain the broad effect treatment has on cellular signalling 
which has allowed VPA to be therapeutically utilised in a diverse range 
of pathological conditions (de Rujiter et al., 2003; Göttlicher et al., 2001; 
Hoffmann et al., 2008; Phiel et al., 2001; Thiagalingam et al., 2003). In 
addition to indirect modulation of cellular signalling via an effect on 
gene expression, cytosolic proteins may be regulated directly by 
acetylation and de-acetylation (Abe et al., 2000; Kouzarides, 2000; Li et 
al., 2006; Wangsen et al., 2008). As it has been shown that oxidative 
stress increases class I and II HDAC activity (Niu et al., 2015), it is 
possible that VPA may attenuate this increase in activity and exert 
some pro-survival effects in haemorrhagic shock via HDAC inhibition. 
Investigation of the effect of VPA treatment on histone acetylation 
in Huh7 demonstrated that VPA affected histone acetylation in both 
standard and haemorrhagic shock-like conditions. Histone 4 acetylation 
was increased regardless of cell state, indicating that regulation of H4-
acK was not specific to adverse culture conditions. However, H2/3-acK 
was regulated in a manner dependent on cellular gas and temperature 
environment: acetylation was up-regulated by VPA only in hypoxia, 
hypercapnia, and hypothermia and not affected in normoxia conditions. 
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This result suggests that the effect of VPA on H2/3 is dependent on the 
modified cell state induced by haemorrhagic shock-like conditions. As 
VPA increased H3 acetylation in Huh7 in a manner similar to that 
observed during severe blood loss in vivo, the evidence does not indicate 
that Huh7 undergoing simulated blood loss conditions are unsuitable 
as a model for changes in cellular signalling. 
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5.4 Summary 
The experiments discussed in this chapter were performed to 
investigate the suitability of Huh7 cells exposed to hypoxia, 
hypercapnia, and hypothermia for the modelling of haemorrhagic shock 
signalling by comparing and contrasting changes in Huh7 cell state, 
protein modification, and total protein abundance to those observed in 
animal models. VPA treatment reduced necrosis and apoptosis in 
adverse cell culture conditions, suggesting a pro-survival effect. The 
decreases in PTEN and Akt phosphorylation as well as in total β-catenin 
levels induced by adverse gas and temperature conditions were rescued 
by concurrent VPA treatment, data which mimic those observed in vivo. 
VPA regulated H3 acetylation in a manner dependent on cell state 
which is analogous to changes observed in animal models. Therefore, 
the evidence discussed suggests that Huh7 undergoing hypoxia, 
hypercapnia, and hypothermia may be an appropriate in vitro model 
system for cellular signalling in haemorrhagic shock in vivo. 
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6 
Investigating the therapeutic 
mechanism of action of VPA 
congeners and derivatives 
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6.1 Introduction 
A key benefit to in vitro models of human pathologies is the 
potential use for high-throughput drug discovery. Often, structure-
function studies based on existing medical drugs discover related 
structures with improved therapeutic potency (e.g. Chang et al., 2015; 
Sobol et al., 2006). Novel treatment options may also inform signalling 
research by virtue of comparing enzymatic or ligand activity of varying 
chemical structure to pre-existing knowledge of cellular signalling 
mechanisms (e.g. Maar et al., 1997; Redecker et al., 2000). The 
previously established Huh7 model for haemorrhagic shock signalling 
was therefore utilised to investigate compounds structurally related to 
VPA for enhanced potency in this model. 
For this investigation, six branched and straight chain fatty acids 
and their derivatives were selected: 2-ene-valproic acid (2eVPA), 2-
propyloctanoic acid (arundic acid; 2POA), valpromide (VPD), decanoic 
acid (DA), sebacic acid (SA), and octanoic acid (OA). These congeners of 
VPA were selected based upon potential for HDAC inhibition, as the 
therapeutic effect of VPA in haemorrhagic shock has been attributed to 
this mechanism (Butt et al., 2009; Gonzales et al., 2008; Li et al., 2011). 
However, as HDAC inhibition has also been shown to not fully replicate 
a pro-survival effect in a model of cerebral ischaemia (Dash et al., 
2010), the divergent efficacies of the chosen molecules in other clinical 
contexts increased the likelihood of discovering an alternative 
mechanism of action. Finally, investigation of molecules structurally 
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similar to VPA was pursued in aid of discovering a novel, more potent 
therapeutic treatment for haemorrhagic shock. 
VPA may affect nuclear processes not only by inhibiting HDACs 
but also through its action on transcription machinery, for instance by 
targeting peroxisome proliferator-activated receptors, part of the nuclear 
receptor family, which are known to be a part of the VPA-sensitive 
signalling network (Blaheta and Cinatl, 2002). Having bound a ligand, 
PPARs form a heterodimer with the retinoid X receptor and activate 
gene transcription by binding to PPAR response elements in gene 
promoters (Abdelrahman et al., 2005). The subfamily of PPARs includes 
PPARα, β/δ, and γ, each with a range of ligands, target genes and 
biological roles (Burns et al., 2007; Kota et al., 2005). As PPAR activity 
has been implicated as an attenuating influence in ischaemic conditions 
(Collino et al., 2006; Collino et al., 2008; Culman et al., 2007) and VPA 
is known to act as a ligand to all three receptor isoforms (Lampen et al., 
1999; Lampen et al., 2001), PPAR involvement in Huh7 during 
haemorrhagic shock-like conditions and VPA treatment was 
investigated. 
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6.2 Results 
6.2.1  VPA congeners regulate GSK3β phosphorylation 
 Six derivatives, analogues, and congeners of VPA were selected for 
investigation in the Huh7 model of haemorrhagic shock signalling (Fig. 
1). As the pro-survival effect of VPA in haemorrhagic shock has been 
attributed to HDAC inhibition, all compounds were investigated for 
HDAC inhibitory activity using a commercial in vitro assay utilising 
nuclear HeLa extract as the source of HDAC activity (Fig. 2; ). Of all 
compounds tested, 2POA was determined to be the most potent HDAC 
inhibitor analysed with an IC50 of 0.4mM, 6-fold lower than the IC50 of 
VPA at 2.3mM. The IC50 values for SA, DA, OA, and 2eVPA activity were 
found to be within the same order of magnitude as VPA, while VPD did 
not inhibit half of HDAC activity up to 10mM. 
 
 
 
 
OA 
 
 
 
 
DA 
 
 
 
SA 
 
 
 
VPA 
 
 
 
2POA 
 
 
2eVPA 
 
 
VPD 
Figure 6.1 – Structural overview of VPA analogues, congeners, and derivatives. 
Three branched and three straight chain congeners and derivatives of VPA were 
selected for investigation in the Huh7 model of haemorrhagic shock signalling: 
decanoic acid (DA), sebacic acid (SA), octanoic acid (OA), 2-ene-VPA (2eVPA), 2-
propyloctanoic acid (2POA), and valpromide (VPD).  
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Figure 6.2 – Histone deacetylase inhibition activity of VPA and six related 
compounds. (A-G) HDAC inhibition activity of VPA, congeners, and derivatives was 
quantified employing HeLa nuclear enzyme extract as the source of HDAC activity and 
shown as fitted dose-response curves. Data (n=3, technical duplicates) are shown as 
mean ± SEM, however, error bars are not visible due to small SEM. (H) Comparison of 
HDAC inhibition IC50 values of VPA, congeners, and derivatives for three independent 
measurements at five concentrations (0.5-10mM). No IC50 for VPD was calculated as 
this compound did not inhibit half of activity at the highest concentration tested 
(10mM). Data are shown as mean ± 95% CI. 
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Since the effect of VPA in increasing GSK3β Ser9 phosphorylation 
in haemorrhagic shock has been linked to HDAC inhibition (Butt et al., 
2009; Shults et al., 2008), compounds investigated for HDAC inhibition 
were then assessed in Huh7 to determine their efficacy in up-regulating 
GSK3β Ser9 phosphorylation. Huh7 cells were exposed to haemorrhagic 
shock like conditions and treated with these six molecules at 0.25 and 
0.75mM (Fig. 3). Compounds found to have an effect at either of these 
treatment levels were then investigated at additional concentrations. In 
the absence of treatment, pGSK3β levels were reduced to 50±6% of 
normoxic levels. At 0.25mM, DA significantly increased pGSK3β levels 
to 110±22% and 2eVPA increased phosphorylation to 125±18% 
(p<0.01), compared to the increase seen after 0.75mM VPA treatment, 
which up-regulated phosphorylation to 128±16%. At 0.1mM, DA and 
2eVPA increased phosphorylation still further, to 138±16% and 
158±14% (p<0.01 and p<0.001) respectively. These two molecules did 
not significantly affect GSK3β phosphorylation at lower (0.05mM) or 
higher (0.75mM) concentrations. SA significantly increased pGSK3β at 
0.75mM to 123±15%, comparable to the increase observed in response 
to VPA, and lower concentrations (0.25, 0.1mM) did not affect Ser9 
phosphorylation. OA, 2POA, and VPD did not affect GSK3β 
phosphorylation at either 0.25mM or 0.75mM. The data therefore 
suggest that DA, and 2eVPA may be more potent than VPA under these 
conditions in increasing pGSK3β levels, while SA may replicate the 
dose-dependent increase in Ser9 phosphorylation seen after VPA 
treatment. Though DA, 2eVPA, and SA all inhibit HDAC activity as 
previously discussed, the increases in pGSK3β levels observed do not 
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correlate with higher IC50 values regarding HDAC inhibition. 
Surprisingly, the results therefore also suggest that the efficacy of 
congeners in increasing pGSK3β levels in the Huh7 model of 
haemorrhagic shock is independent of HDAC inhibitory activity. 
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Figure 6.3 – VPA derived and congenic PPARγ ligands increase GSK3β phosphorylation in Huh7 during haemorrhagic shock-like conditions 
independent of HDAC inhibitory activity. Huh7 cells were cultured under standard conditions (37°C, 5% CO2) receiving fresh medium 16h prior 
to the start of treatment. Cells were then transferred to stress conditions (2% O2, 10% CO2, 32°C) and treated with VPA congeners and derivatives at 
two concentrations for four hours. Levels of pGSK3β (Ser9) and tGSK3β were corrected for loading with β-tubulin, quantified as phosphorylated to 
total GSK3β ratio, and presented as percentage of levels in untreated cells incubated in standard conditions (Nx). Data are shown as mean ± SEM. 
Previously obtained average pGSK3β levels in Nx, HxHcHp, and HxHcHp + VPA (0.75mM) are indicated by horizontal lines for ease of interpretation. 
Data (n=3, technical triplicates) were statistically analysed (ANOVA and Tukey test) to discover any significant difference to HxHcHp. * indicate 
significance compared to HxHcHp: * p<0.05, ** p<0.01, *** p<0.001.  
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6.2.2  VPA acts via PPARγ 
VPA and the two analogues most efficacious in increasing GSK3β 
phosphorylation, 2eVPA and DA, are ligands of the transcription 
regulating peroxisome proliferator-activated receptors (PPARs; Lampen 
et al., 2001; Malapaka et al., 2012). To examine this mechanism, Huh7 
cells were simultaneously treated with selective PPARα, β/δ, and γ 
inhibitors and VPA in haemorrhagic shock-like conditions. Inhibitors of 
PPARα (GW6471; 50µM; Abu Aboud et al., 2013) and PPARβ/δ 
(GSK3787; 10µM; Palkar et al., 2010) did not attenuate the effect of VPA 
on pGSK3β. However, the PPARγ inhibitor T0070907 (50µM; An et al., 
2014), prevented the VPA-dependent increase in GSK3β 
phosphorylation; this did not change significantly compared to that 
observed in untreated cells exposed to stress conditions (Fig. 5A). To 
verify whether PPARγ activation was sufficient to increase pGSK3β 
phosphorylation in these conditions, Huh7 cells were treated with 
Ciglitazone (Lehmann et al., 1995), a specific PPARγ agonist structurally 
unrelated to VPA (Fig. 5B). Ciglitazone, like VPA, dose-dependently 
protected cell signalling against the reduction in pGSK3β levels under 
haemorrhagic shock-like conditions (122±16% at 20µM, 127±20% at 
40µM, and 164±22% at 80µM). These results support a role for 
activation of PPARγ as a therapeutic treatment for haemorrhagic shock. 
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Figure 6.4 –PPARγ inhibition prevents VPA-induced GSK3β phosphorylation which is mimicked by PPARγ agonist Ciglitazone. Huh7 cells 
were cultured under standard conditions (Nx; 37°C, 5% CO2) receiving fresh medium 16h prior to the start of treatment. Cells were then transferred 
to stress conditions (HxHcHp; 2% O2, 10% CO2, 32°C) for four hours and treated with (A) VPA (0.75mM) in combination with the PPARα (GW6471, 
50µM), β/δ (GSK3787, 10µM), and γ inhibitors (T0070907, 50µM), and with the inhibitors alone, or (B) the specific PPARγ agonist Ciglizatone. 
Levels of pGSK3β (Ser9) and tGSK3β were corrected for loading with β-tubulin, quantified as phosphorylated to total protein ratio, and are 
presented as percentage of levels in untreated cells incubated in standard conditions (Nx). Data are shown as mean ± SEM. Data (n=3, technical 
triplicates) were statistically analysed (ANOVA and Tukey test) to discover any significant difference to HxHcHp. * indicate significance: * p<0.05, ** 
p<0.01, *** p<0.001.  
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To investigate whether VPA and congener mechanism of action 
regulates gene transcription via PPARγ or a separate mechanism, Huh7 
cells were exposed to stress conditions and concurrently treated with 
VPA and the transcription inhibitor Actinomycin at 1µg/ml (Fig. 4). 
GSK3β phosphorylation was significantly reduced by 31±5% in the 
presence of Actinomycin compared to cells which were treated only with 
VPA. This result suggested that the mechanism of action of VPA in 
regulating GSK3β Ser9 phosphorylation relies to some extent on gene 
transcription. 
 
 
 
Figure 6.5 – Effect of Actinomycin on VPA-induced GSK3β Ser9 phosphorylation 
in Huh7 during hypoxia, hypercapnia, and hypothermia. Huh7 cells were cultured 
under standard conditions (37°C, 5% CO2) receiving fresh medium 16h prior to the 
start of treatment. Cells were then exposed for four hours to stress conditions (2% O2, 
10% CO2, 32°C) and simultaneously treated with VPA (0.75mM) and Actinomycin 
(1µg/ml) as indicated. Protein extract was probed with phosphorylated GSK3β 
(pGSK3β; Ser9) and total GSK3β (tGSK3β) antibodies, as well as β-tubulin antibody as 
loading control, and visualised with fluorescent secondary antibody. GSK3β 
fluorescence was corrected for loading differences with β-tubulin. Phosphorylated 
protein levels were calculated as ratio to total protein and are shown as mean ± SEM 
compared to normoxia (100%). Data (n=6, technical triplicates) were statistically 
analysed (Student’s t-test). * indicate significance: * p<0.05, ** p<0.01, *** p<0.001. 
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As pharmacological inhibitors may modulate signalling through 
off-target effects, a genetic approach to deplete PPARγ levels in VPA-
treated cells was also employed to corroborate the evidence for 
involvement of this receptor. Treatment of Huh7 cells with an equal 
combination of four individual PPARγ siRNAs (Echeverri and Perriman, 
2006) significantly reduced PPARγ protein abundance by 78±5% 
compared to untreated cells (Fig. 6A), whereas treatment with 
scrambled negative control (Ctrl) siRNA did not. Changes in pGSK3β 
levels in these cells were then assessed in haemorrhagic shock-like 
conditions, in the presence and absence of VPA (Fig. 6B). Cells treated 
with scrambled siRNA retained the VPA-dependent protection against 
pGSK3β reduction (93±5% compared to control). However, cell treated 
with PPARγ-specific siRNAs and showing a concurrent reduction in 
PPARγ abundance lost the protective effect of VPA on GSK3β Ser9 
phosphorylation in these conditions, which resulted in a further 
reduction of pGSK3β levels (35±7% compared to control). These data 
further support an essential role for PPARγ activation in protection 
against haemorrhagic shock-like signalling in Huh7. 
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Figure 6.6 – Protection against haemorrhagic shock-Like signalling depends on PPARγ activity. (A) Huh7 cells were transfected with PPARγ 
siRNA, negative control (scrambled) siRNA, or transfection vehicle (RNAiMAX) for 48h. Protein extract was probed with PPARγ and β-actin 
antibodies. PPARγ levels were quantified and corrected for loading with β-actin. (B) Huh7 cells were transfected with PPARγ or control siRNA for 48h 
and then exposed to stress conditions (HxHcHp; 2% O2, 10% CO2, 32°C) with VPA treatment (0.75mM) as indicated for four hours. Control cells were 
treated with vehicle control (dH2O). Levels of pGSK3β (Ser9) and tGSK3β were corrected for loading with β-tubulin, quantified as phosphorylated to 
total protein ratio. Protein levels are presented as percentage of levels in untreated cells incubated in standard conditions. (A, B) Data (n=3, 
technical triplicates) were statistically analysed (ANOVA and Tukey test) and are presented as mean ± SEM. * indicate significance: * p<0.05, ** 
p<0.01, *** p<0.001.  
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6.2.3  VPA treatment increases PPARγ transcription 
PPARγ may be regulated by VPA through a variety of mechanisms, 
including via an increase in total PPARγ abundance (Abdelrahman et 
al., 2004; Victor et al., 2006). To investigate this possibility, mRNA was 
extracted from Huh7 cells undergoing stress conditions and 
simultaneous VPA treatment to quantify the expression levels of the 
Pparγ gene using a reverse transcription quantitative real-time PCR 
assay, with Actin mRNA abundance serving as a control (Fig. 7). VPA 
treatment during haemorrhagic shock-like conditions significantly 
increased Pparγ expression 1.5±0.1 fold compared to untreated 
normoxic cells (p<0.05). However, stress conditions alone did not 
significantly regulate abundance of PPARγ mRNA. These results suggest 
that PPARγ may be regulated as part of VPA-induced response. 
 
Figure 6.7 – VPA increases PPARγ mRNA in haemorrhagic shock-like conditions. 
Huh7 cells were cultured under standard conditions (37°C, 5% CO2) receiving fresh 
medium 16h prior to the start of treatment. Cells were then exposed to stress (2% O2, 
10% CO2, 32°C) or standard conditions for four hours and treated with VPA (0.75mM) 
as indicated.  Control cells were treated with vehicle control (dH2O) or VPA as 
indicated and incubated concurrently in standard conditions. Huh7 mRNA was 
extracted and cDNA produced which served as the template for quantitative real-time 
PCR to quantify Pparγ expression (Actin expression was quantified as control). Data 
(n=3, technical duplicates) is presented as fold-change compared to untreated Nx 
samples. * indicate significance: * p<0.05, ** p<0.01, *** p<0.001.  
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6.2.4  PPARγ may be regulated by intracellular localisation 
PPARγ functions in both the nucleus and the cytoplasm (Seger 
and Burgermeister, 2007) and has been variously observed to reside 
mainly in the nucleus (Berger et al., 2000) or to be evenly distributed 
between nucleus and cytosol (Thuillier et al., 1998). To investigate 
whether PPARγ localisation changed in haemorrhagic shock-like 
conditions or during VPA treatment, Huh7 cells were fixed, probed with 
PPARγ antibody, and stained to show nuclei (DAPI DNA stain; Fig. 8A). 
Quantification of fluorescence showed that 48±1% of total PPARγ was 
localised in the nucleus in normoxic conditions. Stress conditions 
significantly reduced nuclear PPARγ levels to 45±1%, while concurrent 
VPA treatment significantly increased cytosolic abundance of PPARγ to 
57±1% compared to 55±1% in stress conditions alone (Fig. 8B). 
However, total levels of PPARγ were not affected (Fig. 8C). These data 
suggest that VPA have a small but significant effect on localisation of 
PPARγ as a component of the therapeutic mechanism of action observed 
in haemorrhagic shock signalling. 
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Figure 6.8 – Cellular localisation of PPARγ is affected by stress conditions and 
VPA treatment. Huh7 cells were cultured under standard conditions (Nx; 37°C, 5% 
CO2) receiving fresh medium 16h prior to the start of treatment. Two thirds of cells 
were then transferred to stress conditions (HxHcHp; 2% O2, 10% CO2, 32°C) and 
treated with VPA (0.75mM) as indicated. After treatment, cells were fixed with 
paraformaldehyde and probed with PPARγ antibody and fluorescent secondary 
antibody while cell nuclei were stained with DAPI. (A) Representative cells are shown. 
Size bar represents 10µm. (B) Cells (n=24 cells per treatment group per each of 3 
independent experiments) were quantified for PPARγ nucleic and cytosolic 
fluorescence. The data were statistically analysed (ANOVA and Bonferroni test) and are 
shown as mean ± SEM stacked to 100% observed cell fluorescence. (C) Cells were 
quantified for PPARγ total cell fluorescence. The data were statistically analysed 
(ANOVA and Tukey test) and are shown as mean ± SEM. * indicate significance: * 
p<0.05, ** p<0.01, *** p<0.001. 
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6.2.5  PPARγ ligands prevent apoptotic signalling in Huh7  
To establish whether PPARγ regulation was essential for the pro-
survival effect of VPA, Huh7 cells were cultured in stress conditions 
with concurrent VPA and specific PPARγ inhibitor (T0070907) treatment 
and caspase-3/7 activity was measured as an indicator of apoptosis 
(Fig. 9A). T0070907 treatment prevented the anti-apoptotic effect of VPA 
(0.75mM, 80±4% of control), increasing caspase-3/7 activity by 28% to 
108±4% of control and did not significantly affect apoptotic signalling in 
isolation (120±11% of control). To investigate whether PPARγ activation 
was sufficient to inhibit apoptotic signalling, Huh7 cells in 
haemorrhagic shock-like conditions were treated with the specific 
PPARγ agonist Ciglitazone (60µM) as well as 2eVPA (0.1mM) and DA 
(0.1mM). All three of these treatments significantly reduced apoptotic 
signalling to a similar extent as VPA, to 77±7%, 73±6%, and 77±4% 
respectively. These results suggest that the pro-survival effect of VPA is 
dependent on PPARγ activity and that specific PPARγ ligands 
successfully decrease Huh7 cell apoptosis. 
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Figure 6.9 – Pro-survival action of VPA depends on PPARγ activity and is replicated by PPARγ ligands. Huh7 cells were grown under standard 
conditions (37°C, 5% CO2) receiving fresh medium 16h prior to the start of treatment. Cells were then treated with (A) VPA (0.75mM), vehicle control 
(DMSO), or PPARγ inhibitor T0070907, or (B) vehicle control (DMSO) or PPARγ ligands 2-ene-VPA (2eVPA), decanoic acid (DA), or Ciglitazone. Cells 
were exposed to haemorrhagic shock-like conditions (2% O2, 10% CO2, 37°C) for four hours. Apoptosis was measured as in-well enzyme activity 
using a commercial assay (Promega). Briefly, apoptosis is investigated by addition of substrate for caspase-3/7 activity which luminesces when 
cleaved. Signal from cell state reactions was measured in arbitrary luminescence units (ALU). Data (n=3, technical triplicates) were statistically 
analysed using ANOVA and Tukey test and compared to values from untreated cells. * indicate significance: * p<0.05, ** p<0.01, *** p<0.001.  
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6.3 Discussion 
6.3.1  VPA congeners regulate GSK3β phosphorylation 
 The Huh7 model of haemorrhagic shock signalling was employed 
to determine whether a set of six molecules structurally similar to VPA 
could improve upon its ability to stimulate GSK3β Ser9 
phosphorylation. Any such improvement would supply additional clues 
to the mechanism of action of VPA in this model. The six congeners, 
analogues, and derivatives of VPA under investigation were selected 
based on structural or functional relation to VPA and medical efficacy in 
other pathological conditions. 2eVPA is a major, non-teratogenic 
metabolite of VPA with improved anti-epileptic potency, but clinical 
trials for epilepsy were discontinued because 2eVPA is partially bio-
transformed back to VPA in vivo, which was detectable in patient serum 
from 2 hours after administration (Bialer and Yagen, 2007; Düsing, 
1992; Isoherranen et al., 2003; Palaty and Abbott, 1995). 2POA, a 
homologue of VPA, has been of interest for the treatment of stroke and 
neurodegenerative disorders, although clinical trials for stroke were 
discontinued due to lack of proven efficacy (Bialer and Yagen, 2007; 
Ishibashi et al., 2007). VPD, the less teratogenic primary amide 
analogue and prodrug of VPA, is approved as an anti-psychotic and 
anti-epileptic drug in several European countries as it is three to five 
times more potent than VPA in these pathologies (Bialer et al., 1996; 
Isoherranen et al., 2003; Radatz et al., 1998). DA, a ten carbon straight 
chain fatty acid, accumulates in patients that follow the (anti-epileptic) 
medium-chain triglyceride ketogenic diet and has been shown to reduce 
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epileptiform activity more effectively than VPA (Chang et al., 2013; 
Haidukewych et al., 1982; Sills et al., 1986). SA, the dicarboxylic form of 
DA, has been shown to improve plasma glucose levels in mouse models 
of diabetes (Kim et al., 2008; Membrez et al., 2010). OA is rapidly 
metabolized in rats in vivo and does not control epileptiform activity in 
vitro, though it has been shown to regulate ERK1/2 but not Akt in the 
PC12 cell line (Chang et al., 2015; Kamata et al., 2007; Liu and Pollack, 
1994). These six compounds target a wide variety of signalling 
pathways, which would inform further investigations should a 
compound more potent than VPA in regulating the Huh7 model of 
haemorrhagic shock be found. 
 The beneficial mechanism of action of VPA in haemorrhagic shock 
has been thought to be via HDAC inhibitory activity (Butt et al., 2009; 
Gonzales et al., 2008; Li et al., 2011), though Dash et al. (2010) found 
that HDAC inhibition alone was not sufficient to be protective in 
traumatic brain injury, as the selective HDAC inhibitor suberoylanilide 
hydroxamic acid (SAHA) failed to produce behavioural improvements in 
their rodent model. To establish the HDAC inhibitory potency of each 
compound, an in vitro HDAC assay containing HeLa cell nuclear extract 
was employed. The IC50 values of these compounds mainly fell within 
one order of magnitude of one another (0.5-10mM). However, as VPD 
did not inhibit half of HDAC activity at the highest concentration 
studied (10mM), its IC50 value could not be calculated. However, when 
Huh7 cells were treated with these analogues, efficacy in increasing 
GSK3β Ser9 phosphorylation under these conditions was found not to 
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correlate with HDAC inhibitory activity. These data suggested, as did 
the in vivo work presented by Dash and colleagues (2010), that HDAC 
inhibitory activity is not sufficient to produce a change in GSK3β 
phosphorylation. 
6.3.2  VPA acts via PPARγ 
 2eVPA and DA, two VPA analogues which significantly 
increased GSK3β phosphorylation in haemorrhagic shock-like 
conditions, are ligands of the peroxisome proliferator-activated 
receptors (PPARs; Lampen et al., 2001). To determine whether PPARs 
are involved in VPA action in the Huh7 model of haemorrhagic shock, 
cells were treated with VPA and selective PPAR inhibitors in 
haemorrhagic shock-like conditions. Only the PPARγ inhibitor 
T0070907 prevented VPA from increasing GSK3β Ser9 phosphorylation, 
while the PPARα and PPARβ/δ inhibitors GW6471 and GSK3787 had 
no effect. None of these inhibitors affected Ser9 phosphorylation in the 
absence of other treatment. These data suggest that VPA acts 
specifically via PPARγ to modulate pGSK3β levels in the model of 
haemorrhagic shock developed here. To verify whether PPARγ activation 
is sufficient to produce an increase in Ser9 phosphorylation, Huh7 cells 
were treated with the selective PPARγ agonist Ciglitazone, the 
prototypical compound of the thiazolidinedione (TZD) family, other 
members of which are licensed for treatment of diabetes mellitus 
(Consoli and Formoso, 2013; Yau et al., 2013). Ciglitazone, like VPA, 
increased GSK3β dose-dependently in haemorrhagic shock-like 
conditions, therefore providing further evidence for the involvement of 
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PPARγ in the mechanism of action of VPA and analogous molecules. To 
determine whether the VPA-induced increase of GSK3β phosphorylation 
was dependent upon gene transcription potentially mediated by PPARγ, 
Huh7 cells were co-treated with VPA and the transcription inhibitor 
Actinomycin. Actinomycin significantly inhibited the increase of 
pGSK3β levels by VPA, indicating the involvement of transcriptional 
processes in this regulation of GSK3β phosphorylation.  
The results discussed here are supported by evidence from 
published literature. The PPARs are part of the nuclear receptor 
superfamily and promote target genes when in a heterodimer with the 
retinoid X receptor (RXR), binding to PPAR response elements in DNA 
(Abdelrahman et al., 2005; Lefterova et al., 2010). These receptors have 
been implicated in anti-inflammatory signalling and are known to be 
part of a VPA-sensitive signalling network (Lampen et al., 1999; Werling 
et al., 2001). Lampen et al. (2001) showed that while VPA ligand activity 
is approximately equal for all three PPAR receptors, 2eVPA displays 
double the affinity for PPARγ than it does for α and β/δ. DA is also a 
selective agonist of PPARγ, while OA, which did not increase GSK3β 
phosphorylation in Huh7, is not (Malapaka et al., 2012; Nascimento et 
al., 2012). The DA binding site of PPARγ is different to that occupied by 
TZDs like ciglitazone, occupying only a small part of the binding pocket 
and leaving the remainder untouched (Malapaka et al., 2012). This snug 
fit may explain why shorter straight chain fatty acids (C6-C8) do not 
bind to PPARγ and why longer chain molecules (C12–C22) fit into a 
different part of the site, the same that rosiglitazone occupies. There are 
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no published data indicating SA may act as a ligand to PPARγ. Though 
the chains in both molecules contain the same number of carbon 
atoms, the structural dissimilarity between SA and DA (the presence of 
a second charged group in SA) suggests that if SA were to occupy the 
DA binding site, it would bind with lower affinity. This mechanism 
would correlate with the comparatively high concentration required to 
produce a significant increase of pGSK3β levels. Overall, the evidence 
discussed does suggest PPARγ may be involved in the cellular response 
to VPA in haemorrhagic shock-like conditions. 
To corroborate the evidence for PPARγ involvement in the 
signalling mechanism under investigation and to exclude any off-target 
effects of the pharmacological PPARγ inhibitor T0070709, a genetic 
approach utilising siRNA to deplete PPARγ levels Huh7 cells was 
employed. Treatment of with PPARγ siRNAs significantly reduced PPARγ 
protein abundance and simultaneously inhibited the effect of VPA on 
GSK3β Ser9 phosphorylation. PPARγ depletion resulted in a larger 
reduction of pGSK3β levels than that seen in stress conditions alone, 
suggesting that PPARγ may be involved in the inherent cellular response 
to adverse conditions. This conclusion is supported by evidence from a 
study on the involvement of PPARγ in stroke, where T0070709 was 
shown to increase infarct size in the presence or absence of a PPARγ 
agonist, suggesting that endogenous PPARγ ligands may mitigate the 
effects of cerebral ischemia (Victor et al., 2006). The results shown in 
this chapter in combination with the evidence from the literature 
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therefore provide strong evidence for a role of PPARγ in haemorrhagic 
shock. 
6.3.3  VPA treatment increases PPARγ transcription 
Cerebral ischaemia increases PPARγ abundance while 
simultaneously inhibiting its activity, a process which is fully reversed 
by the endogenous PPARγ agonist cyclopentenone prostaglandin 15-
deoxy-∆12,14-PGJ2 (15d-PGJ2; Victor et al., 2006). As 15d-PGJ2 also 
protects against hepatic injury in haemorrhagic shock (Abdelrahman et 
al., 2004), the possibility that stress conditions and VPA treatment in 
Huh7 may act via a modulation of PPARγ abundance was investigated. 
Huh7 Pparγ expression was analysed using reverse transcription 
quantitative real-time PCR and showed that VPA treatment significantly 
increased Pparγ expression in haemorrhagic shock-like conditions, 
while these conditions alone did not affect PPARγ abundance. This is in 
contrast with in vivo data, where ischaemic conditions increase PPARγ 
abundance which is unaffected by ligand treatments; ligands instead 
induces PPARγ activity by increasing DNA binding (Luo et al., 2006; Ou 
et al., 2006; Victor et al., 2006). Therefore, though VPA may exert 
beneficial effects in Huh7 by promoting the accumulation of PPARγ, 
there is no evidence for such a mechanism in the literature. In addition, 
PPARγ levels do not respond to haemorrhagic shock-like conditions in 
Huh7, suggesting that the attenuating action of VPA in haemorrhagic 
shock-like conditions is not likely to depend upon a change in PPARγ 
abundance alone. 
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6.3.4  PPARγ may be regulated by intracellular localisation 
Since PPARγ is found in both nucleus and cytosol and localisation 
may play a role in regulating activity, intracellular localisation of PPARγ 
was analysed in cells after undergoing stress conditions and VPA 
treatment. In these experiments, cells were fixed and incubated with 
PPARγ antibody, to show that stress conditions significantly reduced 
nuclear levels of PPARγ by 3% compared to normoxia, and concurrent 
VPA treatment significantly increased cytosolic abundance by 2% 
compared to stress conditions alone, while total abundance of PPARγ 
was unaffected. The magnitude of these changes may seem minor, but 
it was not possible to compare these changes to published results to 
ascertain their likely validity, as the literature often only contains 
primary imaging data without quantification. However, as PPARγ is 
often thought to exert its effects through  regulation of transcription 
(Culman et al., 2007; Lefterova et al., 2010) these results may highlight 
a need for an alternative explanation for a putative increase in PPARγ 
activity correlating to an accumulation in the cytosol. 
Aside from ligand activity and total abundance, PPARγ activity is 
affected by nuclear export and import (Han et al., 2002; Kawahito et al., 
2000; Shibuya et al., 2002). This mechanism has been suggested to be 
responsible for regulating nuclear activity of PPARγ, as it is known to 
recruit transcription factor co-activators when in the nucleus, thereby 
limiting access to these co-activators for other transcription factors 
(Abdelrahman et al., 2005). The full significance of cytosolic PPARγ is as 
yet unclear and the mechanisms underlying the nuclear-cytoplasmic 
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shuttling of PPARs are not well characterised, but existing evidence 
shows that localisation and therefore intracellular transport are key 
components of PPARγ regulation (Burgermeister et al., 2007; Umemoto 
et al., 2012). PPARγ movement between intracellular compartments can 
be effected by ligand activity, Umemoto and colleagues (2012) have 
shown. These researchers found that the PPARγ ligand pioglitazone 
enhances both the nuclear import and export of PPARγ, but does not 
anchor PPARγ in the nucleus. Additionally, PPARγ is often trafficked in 
conjunction with binding partners (Umemoto et al., 2012; Victor et al., 
2006). PPARγ may affect localisation of a bound protein by co-exporting 
it from the nucleus. This mechanism has been proposed to explain the 
regulation of NFκB by PPARγ, which binds p65, the transcriptionally 
active component of NFκB, and co-transports it from the nucleus into 
the cytosol, thereby inhibiting NFκB action and suppressing 
inflammation (Kelly et al., 2004). It is therefore possible that VPA, 
2eVPA, DA, SA, and Ciglitazone act to increase PPARγ shuttling in Huh7 
and that a secondary mechanism may act during haemorrhagic shock 
to, for instance, down-regulate NFκB by p65 export with PPARγ, thereby 
promoting a pro-survival effect in treated cells. 
6.3.5  PPARγ ligands prevent apoptotic signalling in Huh7 
To determine whether VPA-induced cell survival is dependent on 
PPARγ action, caspase-3/7 activity was measured in Huh7 cells 
undergoing haemorrhagic shock-like conditions co-treated with 
T0070907 and VPA. T0070907 prevented the VPA-induced decrease in 
apoptotic signalling, suggesting that PPARγ activity is necessary for the 
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pro-survival effect of VPA. To verify these results, cells were incubated 
under haemorrhagic shock-like conditions and treated with the PPARγ 
ligands 2eVPA, DA, and Ciglitazone. All three structurally diverse 
agonists significantly decreased caspase-3/7 activity, indicating 
decreased apoptotic signalling. These data correlate with published 
results, which have shown that PPARγ ligands are beneficial in 
ischaemia-reperfusion injury, inflammation, and shock, as well as 
improving recovery after ischaemic stroke (Abdelrahman et al., 2005; 
Culman et al., 2007). Rosiglitazone, an equipotent PPARγ agonist of 
ciglitazone, attenuates caspase-3 activity in rabbit heart following 
ischaemia and reperfusion (Liu et al., 2004; Tao et al., 2003). 
Pioglitazone, another PPARγ ligand from the TZD family, prevents 
ischaemia-reperfusion injury in rat intestine in a dose-dependent 
manner (Abdelrahman et al., 2005). Taken together with the data 
discussed in this chapter, these facts strongly support a role for PPARγ 
in the pro-survival effect of VPA while suggesting PPARγ ligands as a 
new class of therapeutic treatments in haemorrhagic shock. 
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6.4 Summary 
Of the six VPA congeners, derivatives, and analogues tested in 
this chapter, three were effective in reproducing the increase in GSK3β 
Ser9 phosphorylation seen after VPA treatment in Huh7 cells 
undergoing haemorrhagic shock-like conditions. The efficacy of 2-ene-
VPA, decanoic acid, and sebacic acid did not correlate with their 
potency as histone deacetylase inhibitors but was surprisingly found to 
be dependent on PPAR. Pharmacologic inhibition of all three PPAR 
isoforms showed that only the inhibition of PPARγ resulted in a block of 
the effect of VPA on GSK3β Ser9 phosphorylation in haemorrhagic 
shock-like conditions. Conversely, the specific PPARγ ligand Ciglitazone 
mimicked the dose-dependent effect of VPA on GSK3β phosphorylation. 
These data provided solid evidence for the involvement of PPARγ in the 
VPA mechanism of action in this model. 
The PPARγ ligands investigated in this work significantly reduced 
apoptotic caspase-3/7 signalling in Huh7, suggesting they exert a pro-
survival effect on Huh7 undergoing haemorrhagic shock-like conditions. 
In vivo, PPARγ agonists have been demonstrated to be beneficial in 
pathological conditions related to haemorrhage and shock. These 
results therefore provide evidence for the involvement of PPARγ in 
haemorrhagic shock-like signalling and indicate the need to investigate 
the suitability of PPARγ agonists as life-saving treatments in animal 
models of haemorrhagic shock. 
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7 
Conclusion and Outlook 
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7.1 Huh7 cells model haemorrhagic shock signalling 
 In this work, Huh7 cells undergoing hypoxia, hypercapnia, and 
hypothermia mimicked haemorrhagic shock signalling changes seen in 
animal models in vivo (Alam et al., 2009; Hwabejire et al., 2014). 
Additionally, the signalling pathway analysed in this model system 
responded to VPA in the manner observed in vivo. These results suggest 
that Huh7 cells may be useful to provide an environment for in-depth 
molecular signalling research and as a system for high-throughput drug 
studies. Further research should investigate alternative cell lines for the 
variety of tissues characterised in haemorrhagic shock and future work 
must verify the results shown in this work in animal models to confirm 
the translational accuracy of the Huh7 model system.  
 VPA treatment reduced necrosis and apoptosis in Huh7 under 
haemorrhagic shock-like conditions, suggesting a pro-survival effect. 
VPA protects swine and rats from a lethal outcome after haemorrhage 
and shock (Alam et al., 2009; Gonzales et al., 2006; Hwabejire et al., 
2014; Shults et al., 2008). As VPA is protective in both these model 
systems, Huh7 may be as a first-step investigative tool in the process of 
developing new therapeutica for in vivo use. By providing a first 
indicator of compound efficacy prior to animal testing, this system may 
significantly reduce the number of animals necessary for these 
investigations. The model established in this work may therefore 
contribute to lowering the cost and time required to develop a life-saving 
treatment for haemorrhagic shock.  
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7.2 VPA congeners show improved potency 
In a first effort to identify compounds with improved efficacy 
compared to VPA in attenuating haemorrhagic shock-like signalling, the 
Huh7 model system was treated with several congeners of VPA, some of 
which are currently being trialled for medical use (Huhges et al., 2014; 
Asano et al., 2005, as cited in Rogawski et al., 2006; Wlaź et al., 2015). 
Three compounds, decanoic acid, sebacic acid (a metabolite of DA; Kim 
et al., 2008), and 2-ene-VPA, the unsaturated metabolite of VPA 
(Ghodke-Puranik et al. 2013), mimicked the dose-dependent increase of 
GSK3β phosphorylation induced by VPA in haemorrhagic shock 
conditions. The two more potent compounds, decanoic acid and 2-ene-
VPA, were further found to inhibit apoptosis in the Huh7 model of 
haemorrhagic shock. Future work should investigate these two 
compounds in in vivo models to determine their potential as medical 
interventions in haemorrhagic shock. 
Decanoic acid is a major component of the medium-chain 
triglyceride ketogenic diet (Hughes et al., 2014). It has been shown to 
dose-dependently reduce seizures in vitro and in an in vivo mouse model 
of epilepsy (Chang et al., 2014; Wlaź et al., 2015) and is currently 
supplied as a supplement (“Betaquik”, Vitaflo International Ltd) to 
support MCT enrichment. In vitro, decanoic acid directly blocks AMPA-
receptor generated currents (Williams, personal communication). 
Decanoic acid shows improved potency over VPA in reducing apoptosis 
and blocking a reduction in GSK3β Ser9 phosphorylation in the Huh7 
model of haemorrhagic shock. Additionally, the primary decanoic acid 
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metabolite, sebacic acid, was also shown to reduce the decrease in 
GSK3β Ser9 phosphorylation. This suggests that, should decanoic acid 
be used as a treatment for haemorrhagic shock, both the compound 
itself and its metabolite would exert a pro-survival effect, potentiating 
what may be a life-saving mechanism.  
Like decanoic acid, 2-ene-VPA is more efficacious than VPA in 
blocking dysregulated signalling and reducing apoptotic activity in 
Huh7 caused by haemorrhagic shock-like conditions. 2-ene-VPA has 
previously reached stage I clinical trials as a potential second-
generation epilepsy treatment with reduced hepatotoxicity compared to 
VPA (Düsing, 1992). These trials were discontinued because 2-ene-VPA 
is partially biotransformed to VPA in vivo, minimising its non-toxic 
advantage over a chronic treatment period (Isoherranen et al., 2003). 
However, this would be of little consequence in a potentially life-saving, 
acute intervention during the treatment of haemorrhagic shock. 
Additionally, a one-dose study in healthy male volunteers found that a 
very high (800mg) dose of 2-ene-VPA was well-tolerated by all subjects, 
who did not exhibit changes in vital signs, haematological or clinical 
chemistry parameters, or sedation beyond that seen in placebo controls 
(Düsing, 1992). Therefore, should 2-ene-VPA protect against lethal 
events in animal models in the same manner as VPA, further 
development would be accelerated by existing results from this stage I 
trial, encouraging a comparatively rapid progression to a life-saving 
treatment for terminal blood loss. 
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7.3 Haemorrhagic shock-like signalling depends on PPARγ 
 One key novel discovery made in this thesis is that PPARγ activity 
is required for the VPA-induced effect on GSK3β Ser9 phosphorylation 
and apoptotic signalling in Huh7 under haemorrhagic shock-like 
conditions. This conclusion is supported by the published literature, as 
VPA is known to be a ligand of PPARγ and both decanoic acid and 2-
ene-VPA bind PPARγ preferentially compared to PPAR isoforms (Lampen 
et al., 2001; Nascimento et al., 2012). PPARs and PPARγ in particular 
have been studied as a potential therapeutic target in ischaemia, 
inflammation, and shock (Abdelrahman et al., 2005; Collino et al., 
2008). These results provide strong evidence to recommend further 
investigation into the role of PPARγ in the VPA mechanism of action in 
haemorrhagic shock. 
 The data shown in this thesis suggest that total PTEN levels are 
increased in Huh7 undergoing haemorrhagic shock-like conditions, 
while concurrent VPA treatment increases PTEN phosphorylation, 
thereby down-regulating PTEN and leading to GSK3β inhibition via Akt. 
There are several potential mechanisms in which PPARγ activity may be 
linked to these changes. PPARγ binds the transcription co-factors CBP 
and p300, transrepressing other co-factor binding partners which no 
longer have access to these two proteins (Abdelrahman et al., 2005). 
One of these binding partners is PCAF, which regulates gene 
transcription when bound to CBP and p300 (Li et al., 2006; Nakatani, 
2006). PCAF binds PTEN (Okumura et al., 2006) and acetylates lysine 
residues within the catalytic cleft, thereby altering this structure 
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essential for PIP3 binding beyond functionality (Lee et al., 1999). PIP3 
goes on to activate Akt, a process which is inhibited by PTEN 
dephosphorylating PIP3 to PIP2 (Wang et al., 2011). It may therefore be 
possible that increased PPARγ activity, caused by VPA binding, 
indirectly functions to decrease PTEN activity by preventing PCAF from 
acting through gene transcription regulation. This may increase the 
abundance of PCAF available for other catalytic activities, such as PTEN 
acetylation (Fig. 1). Analogously to histone regulation, conformational 
changes caused by PTEN acetylation predispose this protein to further 
inhibitory post-translational modification, such as the phosphorylation 
observed in Huh7. No data exist on interactions between PTEN 
acetylation and phosphorylation, so further work is needed. As PTEN 
acetylation was not examined in this work, future studies could 
investigate this potential pathway by determining PTEN acetylation in 
the Huh7 model of haemorrhagic shock. 
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Figure 7.1 – A potential mechanism for VPA-induced PTEN inhibition via PPARγ. 
VPA interacts with PPARγ, activating it and causing PPARγ to bind the transcription 
co-factors p300 and CBP, thereby transrepressing other transcription factors, such as 
PCAF. This may result in high levels of PCAF not bound to DNA, which may then 
increasingly bind to other interaction partners, such as PTEN. PCAF acetylates (Ac) 
the PIP3 binding site of PTEN, preventing the second messenger PIP3 from being bound 
and dephosphorylated to PIP2. This may lead to conformational changes which might 
predispose PTEN to further inhibition by phosphorylation, thereby increasing PIP3 
levels and downstream activity.  
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GSK3β, an enzyme of interest in several pathologies, has been 
linked to PPARγ action before. Akt and GSK3β phosphorylation were 
induced by the angiotensin II blocker Telmisartan, which thereby 
protected primary rat cerebellar granule cells against nutrient 
deprivation-induced apoptosis, an effect inhibited by a PPARγ 
antagonist (GW9662) and mimicked by the selective PPARγ ligand 
pioglitazone (Pang et al., 2014). This study therefore describes the same 
regulatory pathway proposed in this thesis for haemorrhagic shock but 
in a neuronal context. In the rat brain, VPA protects cells from the 
detrimental effects of haemorrhagic shock and intracerebral 
haemorrhage (Li et al., 2008; Sinn et al., 2007). These data suggest that 
VPA may be able to regulate GSK3β in the brain via PPARγ. This may be 
of interest for other fields of research, such as that of bipolar disorder, 
where the action of VPA on GSK3β has long been debated. 
The inhibition of GSK3β by VPA has been extensively debated for 
some time (Harwood and Agam, 2003; Phiel et al., 2001; Ryves et al., 
2005; Shimshoni et al., 2007). However, combining existing evidence 
with the discoveries made in this work may provide a different 
perspective on the matter. Ryves and colleagues (2005) reported that 
VPA did not inhibit GSK3β in cultured neocortical cells in standard cell 
culture conditions. These data do not conflict with the pathway 
regulation shown here, as the VPA-induced inhibition of GSK3β in 
Huh7 is dependent on the presence of haemorrhagic shock-like 
conditions. Instead, these results suggest that VPA may only inhibit 
GSK3β in certain dysregulating conditions, which may exist in the 
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brains of bipolar disorder patients. In support of this, Grimes and Jope 
(2001) found that GSK3β is inhibited by VPA when overexpressed in 
SH-SY5Y cells, while Werstuck and colleagues (2004) showed that some 
VPA metabolites act as potent GSK3β inhibitors in vivo. The 
inconsistency of data across the published literature on VPA-based 
modulation of GSK3β strongly suggests that VPA does not inhibit 
GSK3β directly and that any inhibitory activity is dependent on the 
cellular environment studied. 
 VPA is known to limit the extent of depressive phases in bipolar 
disorder (Cheng et al., 2005). In an exciting development, a very recent 
randomized, double-blind, placebo-controlled trial found that co-
treatment of bipolar I patients with lithium, the well-established and 
widely-used bipolar disorder treatment, and the specific PPARγ ligand 
pioglitazone significantly reduced depressive symptoms (Zeinoddini et 
al., 2015). An earlier open-label trial found a similar decrease in 
depression of bipolar disorder patients with pioglitazone treatment in 
isolation (Kemp et al., 2014). VPA has been reported to also act 
synergistically with lithium, both in bipolar disorder (Del Grande et al., 
2013) and in neuroprotection, where concurrent treatment of both 
drugs blocked glutamate excitotoxicity (Leng et al., 2008). It is therefore 
possible that VPA, in acting on GSK3β indirectly via PPARγ, supports 
lithium action to yield an improved patient outcome. 
  
168 
 
7.4 Study limitations 
 As in any scientific work, experiments and the data they produce 
are interpreted to yield the insight believed to be closest to objective 
reality, however, both practical and theoretical limitations should be 
taken into account in this process. While some limitations are 
universal, tacitly accepted as inevitable, and simultaneously presumed 
to not be present (e.g. the possibility of consistent human error in 
experimental technique), some may be rectified in future work. The 
three most relevant examples of this latter group are discussed here. 
 As the majority of this work relies on cell culture, the most 
fundamental caveats must necessarily be concerned with associated 
techniques. Highly relevant, therefore, is the recent discussion 
regarding gas concentrations in standard cell culture conditions. Most 
cell line experiments are performed in atmospheric oxygen conditions 
(19-21% O2), while few cells are ever exposed to this level in vivo (Tiede 
et al., 2012). Indeed, physiological oxygen pressure in the liver is 
generally between 74 and 104mmHg, around half that of atmospheric 
160mmHg often used in cell culture (Jungermann and Kietzmann, 
2000). As, for instance, mitochondrial radical oxygen species production 
varies with oxygen level, it is likely that standard culture conditions 
produce an altered cell state compared to that found in vivo (Tiede et al., 
2012). Such an impact on cell state would affect any cell line 
experiments, but are particularly relevant in hypoxic set-ups, as used in 
this work. Any future work would therefore benefit from a systematic 
approach to verify the use of physiologically-relevant oxygen levels. 
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The majority of experimental results discussed in this thesis are 
quantified from Western blot data on protein abundance. Though the 
linear fluorescence quantification used is much improved compared to 
traditional ECL pixel-based quantification, it continues to rely on the 
presence of “loading control” proteins with a relatively consistent level of 
abundance, regardless of experimental condition. The two 
“housekeeping” proteins selected for this thesis, β-tubulin and β-actin, 
have not been shown to be affected by VPA in short-term experiments, 
but absence of published data does not indicate a total absence of 
effect. Another technique used to ensure equal protein loading in this 
project, preliminary quantification of sample protein concentration, may 
suffer from a related error; that is, experimental conditions may 
modulate protein abundance (total or specific) and thereby skew data 
collection. To circumvent these limitations, future experiments may rely 
on newer, improved techniques, such an in-cell Western quantification. 
However, increasing precision in protein quantification is, to a certain 
extent, dependent on technological advancement, and future progress 
in data reliability is likely to correlate with the establishing of novel or 
refined experimental equipment. 
Finally, any data-reliant experimental process is reliant on the 
correct use of statistics; however, aside from misapplication of specific 
approaches, statistical tests are subject to both inherent and 
experiment-dependent limitations. In the case of this thesis, some 
results which seem to show significant differences “by eye” are not 
statistically significant. Should statistical methods be insufficient in 
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power or accuracy, they are likely to produce false negatives or 
positives. The knock-on effects of these erroneous categorisations may 
drastically change consequent interpretation and therefore affect 
further experimental decisions. Several options of compensating for 
these errors exist and careful selection of statistical methods will 
prevent a large proportion. However, a constant limitation, especially in 
laboratory-based biological investigations, is small sample size. Ideally, 
future work would be performed with sufficient time and financial 
support to allow for larger sample sizes compared to those in this 
thesis. Extensive biological and technical repetition of experiments 
relying on so variable a system as mammalian cell lines may go a long 
way to increasing the statistical accuracy of subsequent data analysis. 
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7.5 Suggestions for future work 
 The study hypothesis is confirmed. The aims of this study have 
largely been met but the discoveries discussed in this thesis may form 
the base for a far-reaching investigation into haemorrhagic shock 
signalling. Though there is a near limitless supply of options for future 
work, the following are suggested as immediately relevant and 
interesting targets. 
I. Verification of current results through further 
investigation of changes in PPARγ protein abundance in the 
Huh7 model and analysis of the activity of other PPARγ 
interaction partners, e.g. acetyl-coenzyme A. 
II. Translation of in vitro results discussed through the use of 
animal models to establish the effect of PPARγ-agonists on 
organism survival in haemorrhagic shock. 
III. Investigation of further members of the signalling cascade 
involved in the Huh7 response to hypoxia, hypercapnia, 
and hypothermia, e.g. HDAC3/4 activity (VPA targets and 
PPARγ interactors) and the involvement of the Wnt-pathway 
in β-catenin accumulation in response to VPA. 
IV. Expansion of the concepts discussed to cell lines produced 
from additional organs and signalling pathways affected in 
haemorrhagic shock, e.g. HEK293 cells, which respond to 
haemorrhagic shock-like conditions in a manner very 
similar to in vivo kidney.  
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7.6 Summary 
 This work has established an in vitro model for the dysregulated 
signalling found in haemorrhagic shock by exposing a human liver cell 
line, Huh7, to hypoxia, hypercapnia, and hypothermia. This model 
responds to VPA treatment in the manner seen in vivo. Therefore, the 
model may be of use as a high-throughput system for drug discovery, as 
compounds with potentially improved efficacy over VPA (2-ene-VPA, a 
VPA metabolite and decanoic acid, a VPA congener) have already been 
identified in this thesis. The simplicity of the Huh7 model of 
haemorrhagic shock also provides an ideal environment for studies of 
the molecular signalling of haemorrhagic shock. This work has found 
that the therapeutic action of VPA relies on PPARγ activity, a new 
revelation which may have far reaching implications for other 
pathological conditions in which VPA is effective, e.g. bipolar disorder. 
The availability of the in vitro model of haemorrhagic shock signalling 
established in this thesis is likely to accelerate therapeutic innovation in 
haemorrhagic shock research and may ultimately save human lives. 
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